 
 
RESILIENT: A Randomiz ed, Open Label Phase 3 
Study of Irinotecan Liposome Injection (ONIVYDE®) 
versus Topotecan in Patients with Small Cell Lung 
Cancer Who Have Progressed on or after Platinum -
based First -Line Therapy  
IPSEN Bioscience, Inc  
Version 1.0:  13 DEC 2016  
Version 1.1:  31 JAN 2017  
Version 2.0:  03 APR 2017  
Version 3.0:  14 NOV 2017  
Version 4.0:  14 SEP 2018  
Version 5.0:  04 DEC 2019  
Version 6.0:  15 APR 2020  
Version 7.0:  24 NOV 2020  
Version 8.0:  [ADDRESS_624217] #:  2017 -004261 -26 
ClinicalTrials.gov ID:  [STUDY_ID_REMOVED]  
Emergency Contact:   
[CONTACT_325485], 5 avenue du Canada, [ZIP_CODE] Les Ulis, [LOCATION_009]  
Mobile:  for emergency contact)  
For serious adverse event (SAE) reporting and pregnancy notification:  
E-mail:  
If email reporting is not possible:  
Fax:
Fax:
 
Sponsor:  
IPSEN BIOSCIENCE, Inc.  
[ADDRESS_624218] understand that it is strictly confidential.  
Information contained herein cannot be disclosed, submitted for publication or used for any purpose 
other than that contemplated herein without the sponsor’s prior written authorization.  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624219] OF ABBREVIATION S ................................ ................................ ..............................  9 
SYNOPSIS  ................................ ................................ ................................ ..........................  11 
1 BACKGROUND INFORMATI ON AND RATIONALE  ................................ ..... 26 
1.1 Small Cell Lung Cancer  ................................ ................................ ...........................  26 
1.2 Study Rationale  ................................ ................................ ................................ .........  27 
1.2.1  Rationale for Evaluating Irinotecan Liposome Injection in SCLC  ...... 27 
1.2.2  Rationale for Evaluating 85 mg/m2 Every 2 Weeks Monotherapy Dose 
of Irinotecan Liposome Injection  ................................ ...........................  28 
1.2.3  Rationale for Intravenous Topotecan as Control  ................................ .. 29 
1.2.4  Nonclinical Data Supporting Evaluation of Irinotecan Liposome 
Injection in Small Cell Lung Cancer  ................................ .....................  29 
[IP_ADDRESS]  Extended Exposure of SN -38 Leads to Increased Cell Death In Vitro  .... 30 
[IP_ADDRESS]  Irinotecan Liposome Injection Effectively Delivers Irinotecan and SN -38 
to SCLC Tumors In Vivo  ................................ ................................ ..........  30 
[IP_ADDRESS]  Irinotecan Liposome Injection Has Improved Anti -Tumor Activity as 
Compared to Non -liposomal Irinotecan HCl and Topotecan In Vivo  ..... 31 
1.3 Irinotecan Liposome Injection Clinical Experience  ................................ ..............  33 
1.3.1  [LOCATION_002] Food and Drug Administration Approval of ONIVYDE® 
and Determination of Irinotecan Liposome Injection Strength  ...........  33 
1.3.2  Clinical Pharmacology  ................................ ................................ ...........  34 
[IP_ADDRESS]  Association Between Exposure and Efficacy with Irinotecan Liposome 
Injection  ................................ ................................ ................................ ... 34 
[IP_ADDRESS]  Association between Exposure and Safety with Irinotecan Liposome 
Injection  ................................ ................................ ................................ ... 34 
1.3.3  Clinical Data Supporting Evaluation of Dose  ................................ ....... 34 
[IP_ADDRESS]  Clinical Data Supporting Evaluation of 85 mg/m2 Every 2 Weeks  .........  34 
[IP_ADDRESS]  Clinical Data to Justify 70 mg/m2 Every 2 Weeks in Part 2  ....................  35 
1.3.4  Clinical Data in UGT1A1*28 Homozygous Patients  ............................  35 
2 OBJECTIVES  ................................ ................................ ................................ ...........  37 
2.1 Part 1  ................................ ................................ ................................ ..........................  37 
2.1.1  Primary Objectives  ................................ ................................ ..................  37 
2.1.2  Secondary Objectives  ................................ ................................ ..............  37 
2.1.3  Exploratory Objectives  ................................ ................................ ............  37 
2.2 Part 2  ................................ ................................ ................................ ..........................  38 
2.2.1  Primary Objective  ................................ ................................ ....................  38 
2.2.2  Secondary Objectives  ................................ ................................ ..............  38 
2.2.3  Exploratory Objectives  ................................ ................................ ............  38 
3 STUDY DESIGN  ................................ ................................ ................................ ....... 38 
3.1 Overview of Study Design  ................................ ................................ ........................  38 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624220] OBER 2021  
 
Proprietary and Confidential  Page 3  
 3.1.1  Part 1  ................................ ................................ ................................ ....... 39 
3.1.2  Part 2  ................................ ................................ ................................ ....... 42 
3.2 Study Duration and Study Closure  ................................ ................................ .........  43 
3.3 Safety Review Committee and Independent Data Monitoring Committee  .........  43 
4 STUDY POPULATION  ................................ ................................ ...........................  44 
4.1 Inclusion Criteria  ................................ ................................ ................................ ...... 44 
4.2 Exclusion Criteria  ................................ ................................ ................................ ..... 45 
4.3 Patient Discontinuation  ................................ ................................ ............................  47 
4.3.1  Permanent Discontinuation of Study Treatment  ................................ ... 47 
4.3.2  Withdrawal from the Study  ................................ ................................ ..... 47 
4.3.3  Procedures following Study Drug Discontinuation or Study Withdrawal
................................ ................................ ................................ ..................  48 
4.4 Enrollment of Additional Patients (Patient Replacement)  ................................ ... 48 
4.5 Method of Assigning Patients to Treatment Groups  ................................ .............  48 
5 INVESTIGATIONAL PROD UCTS  ................................ ................................ ....... 49 
5.1 Description of Irinotecan Liposome Injection ................................ ........................  49 
5.1.1  Storage and Handling of Irinotecan Liposome Injection  .....................  49 
5.1.2  Packaging and Labelling of Irinotecan Liposome Injection  ................  49 
5.1.3  Administration of Irinotecan Liposome Injection  ................................ . 49 
[IP_ADDRESS]  Irinotecan Liposome Injection Premedication ................................ .........  50 
[IP_ADDRESS]  Toxicity of Irinotecan Liposome Injection  ................................ ...............  50 
5.2 Description of Topotecan for Injection  ................................ ................................ ... 54 
5.2.1  Storage and Handling of Topotecan  ................................ ......................  55 
[IP_ADDRESS]  US package insert/EU SmPC  ................................ ................................ ... 55 
5.2.2  Packaging and Labelling of Topotecan  ................................ .................  55 
5.2.3  Administration of Topotecan  ................................ ................................ .. 55 
5.3 Rules for Dose Modification of Irinotecan Liposome Injection and Topotecan  . 55 
5.3.1 Irinotecan Liposome Injection  ................................ ...............................  55 
5.3.2  Topotecan for Injection  ................................ ................................ ..........  56 
5.4 Concomitant and Prohibited Therapi[INVESTIGATOR_014]  ................................ ................................ . 57 
5.4.1  Concomitant and Supportive Care Therapi[INVESTIGATOR_014]  ................................ ........  57 
[IP_ADDRESS]  Antiemetic Medications  ................................ ................................ ............  57 
[IP_ADDRESS]  Myelosuppression  ................................ ................................ ....................  58 
[IP_ADDRESS]  Therapy for Diarrhea  ................................ ................................ ...............  58 
5.4.2  Prohibited Therapi[INVESTIGATOR_014]  ................................ ................................ ...............  58 
5.5 Accountability of Study Drug  ................................ ................................ ..................  59 
6 STUDY ASSESSMENTS  ................................ ................................ .........................  59 
6.1 Screening Visit  ................................ ................................ ................................ ...........  59 
6.2 Treatment/Active Follow -up Visits  ................................ ................................ .........  59 
6.2.1  Pauses in Treatment ................................ ................................ ................  60 
6.3 30-day Follow -up Visit  ................................ ................................ ..............................  60 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624221]  ................................ ................................ ................................ ..........  69 
9.4 UGT1A1*28  ................................ ................................ ................................ ...............  69 
9.5 Pharmacokinetic Sampling  ................................ ................................ ......................  70 
9.6 Biobanking  ................................ ................................ ................................ .................  70 
10 ADVERSE EVENT REPORT ING  ................................ ................................ .........  71 
10.1  Definitions  ................................ ................................ ................................ ..................  71 
10.1.1  Adverse Events  ................................ ................................ ........................  71 
10.1.2  Serious Adverse Events  ................................ ................................ ...........  71 
10.2  Assessing and Documenting Adverse Events  ................................ .........................  72 
10.3  Reporting Serious Adverse Events  ................................ ................................ ..........  73 
10.4  Determining the Severity and Relatedness of an Event  ................................ ........  73 
10.4.1  Grading the Severity of an Adverse Event  ................................ .............  73 
10.4.2  Relationship to Study Drug  ................................ ................................ .... 74 
10.4.3  Reporting and Follow -up of Pregnancy  ................................ .................  74 
11 STATISTICAL METHODS  ................................ ................................ ....................  74 
11.1  General Considerations  ................................ ................................ ............................  74 
11.2  Statistical Hypothesis and Determination of Sample Size  ................................ .... 74 
11.3  Analysis Populations  ................................ ................................ ................................ . 75 
11.4  Disposition, Demographics, and Baseline Characteristics  ................................ .... 76 
11.5  Efficacy Analysis  ................................ ................................ ................................ ....... 76 
11.5.1  Primary Efficacy Analysis (Part 2)  ................................ ........................  76 
11.5.2  Key Secondary Analyses (Part 2) ................................ ............................  76 
[IP_ADDRESS]  Progression -free Survival  ................................ ................................ ........  76 
[IP_ADDRESS]  Objective Response  ................................ ................................ ..................  77 
[IP_ADDRESS]  Change From Baseline in Dyspnea and Cough Symptoms  .....................  77 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624222] OBER 2021  
 
Proprietary and Confidential  Page 5  
 11.5.3  Exploratory Objectives Analyses  ................................ ............................  77 
[IP_ADDRESS]  Time to treatment failure  ................................ ................................ .........  77 
[IP_ADDRESS]  EORTC -QLQ outcomes  ................................ ................................ ...........  77 
[IP_ADDRESS]  Patient Global Impression of Change and Severity  ................................ . 78 
[IP_ADDRESS]  EQ-5D-5L ................................ ................................ ................................  78 
[IP_ADDRESS]  Time to CNS Progression ................................ ................................ .........  78 
[IP_ADDRESS]  Biomarkers  ................................ ................................ ...............................  78 
11.6  Safety Analysis  ................................ ................................ ................................ ..........  78 
11.7  Pharmacokinetic Analysis  ................................ ................................ ........................  79 
11.7.1  Listings and Summary Statistics of Concentrations  ..............................  79 
11.7.2  Pharmacokinetic Data Analysis  ................................ .............................  79 
11.7.3  Pharmacokinetics/Pharmacodynamics Relationship  ............................  [ADDRESS_624223] and Independent Ethics Committee Approval  ... 80 
12.6  Monitoring  ................................ ................................ ................................ .................  81 
12.7  Data Quality Assurance  ................................ ................................ ............................  81 
12.8  Confidentiality  ................................ ................................ ................................ ...........  82 
12.9  Protocol Amendments  ................................ ................................ ..............................  82 
12.10  Publication  ................................ ................................ ................................ .................  82 
12.11  Records Retention  ................................ ................................ ................................ ..... 83 
12.12  Study Termination  ................................ ................................ ................................ .... 83 
13 INVESTIGATOR SIGNATU RE PAGE  ................................ ................................  85 
14 REFERENCES  ................................ ................................ ................................ ..........  86 
15 APPENDIX  ................................ ................................ ................................ ................  90 
15.1  Appendix I: Recommendations for Management of Chemotherapy Induced 
Diarrhea  ................................ ................................ ................................ .....................  90 
15.2  Appendix II: ECOG Performance Status  ................................ ...............................  92 
15.3  Appendix III: Response Criteria for CNS Metastases  ................................ ..........  93 
15.4  Appendix IV: Temporary Measures and Procedures Related to COVID -19 
Pandemic  ................................ ................................ ................................ ....................  94 
15.5  Appendix V: Summary of Changes 03 April 2017 (Version 2.0) to 
14 November  2017 (Version 3.0)  ................................ ................................ ..............  96 
15.5.1  Appendix Va Summary of Changes 14 November 2017 (Version 3.0) to 
25 April 2018 (Version 3.1 [LOCATION_009]) ................................ ......................  125 
15.5.2  Appendix Vb Summary of Changes 14 November 2017 (Version 3.0) to 
10 May 2018 (Version 3.1 [LOCATION_013])  ................................ ...................  127 
15.6  Appendix VI: Summary of Changes 14  November  2017 (Version 3.0) to 
14 September  2018 (Version 4.0)  ................................ ................................ ...........  131 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624224] OBER 2021  
 
Proprietary and Confidential  Page 6  
 15.7  Appendix VII: Summary of Changes 14  September 2018 (Version 4.0) to 
04 December  2019 (Version  5.0) ................................ ................................ ............  158 
15.8  Appendix VIII: Summary of Changes 04  December 2019 (Version 5.0) to 
15 April  2020 (Version  6.0) ................................ ................................ ....................  181 
15.9  Appendix IX: Summary of Changes 15 April 2020 (Version 6.0) to 
24 November  2020 (Version  7.0) ................................ ................................ ............  191 
15.10  Appendix X: Summary of Changes 24  November  2020 (Version  7.0) to 07 
October 2021 (Version 8.0)  ................................ ................................ ....................  [ADDRESS_624225] OF TABLES  
Table 1: Recommended Dosea Modifications for Irinotecan Liposome Injection  .... 56 
Table 2:  Recommended Topotecan Dose Modification Scheme for Subsequent 
Cycles  ................................ ................................ ................................ ................  57 
Table 3:  Schedule of Assessments for Patients Receiving Irinotecan Liposome 
Injection  ................................ ................................ ................................ ............  63 
Table 4:  Schedule of Assessments for Patients Receiving IV Topotecan  ..................  65 
Table 5:  Part 1 PK and ECG Extraction Time Points  ................................ ................  68 
Table  6: Pharmacokinetic Sampling Plan  ................................ ................................ .... 70 
Table 7:  Type I (α) and Type II (β) Error Spending for the Planned OS Analyses  . [ADDRESS_624226] OF FIGURES  
Figure 1:  Increased SN -38 Exposure Leads to Increased Cell Death In Vitro  ..........  30 
Figure 2:  Irinotecan Liposome Injection -mediated Tumor Delivery of Irinotecan and 
SN-38 In Vivo  ................................ ................................ ................................ ... 31 
Figure 3:  Anti -tumor Activity of Irinotecan Liposome Injection, Non -liposomal 
Irinotecan and Topotecan at Clinically Relevant Doses in DMS -114 and 
NCI-H1048 SCLC Xenograft Models  ................................ ............................  32 
Figure 4:  Anti -tumor Activity of Irino tecan Liposome Injection, Non -Liposomal 
Irinotecan and Topotecan in a Preclinical Model of Second Line SCLC  .. 32 
Figure 5:  Study Schema  ................................ ................................ ................................ ... 39 
Figure 6:  Description of Treatment Stages  ................................ ................................ .... 39 
Figure  7: Treatment Cohorts: Safety Run -in ................................ ................................  40 
 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624227] OBER 2021  
 
Proprietary and Confidential  Page 7  
 SUMMARY OF CHANGES  
The current version of the protocol (Version 8.0) was released on 07 October  2021. This 
protocol Version  8.0 includes all amendments, with summaries of changes from the protocol 
Version  2.0 included in the following appendices:  
• Appendi x V: Summary of Changes 03 April 2017 (Version 2.0) to 14  November  2017  
(Version 3.0)  
- To streamline the phase II/III study design and allow sufficient statistical power 
for interim analysis  
• Appendix Va: Summary of Changes 14 November 2017 (Version 3.0) to  
25 April  2018 (Version 3.1 [LOCATION_009])  
- To incorporate country -specific request from French regulatory authority 
received during the clinical trial submission process  
• Appendix Vb: Summary of Changes 14 November 2017 (Version 3.0) to 
10 May 2018 (Version 3.1 Ge rmany)  
- To incorporate country -specific requests from German regulatory authority 
received during the clinical trial submission process  
• Appendix VI: Summary of Changes: 14  November  2017 (Version 3.0) to 
14 September  2018 (Version  4.0) 
- To incorporate country -specific requests from regulatory authorities received 
during the clinical trial submission process  
- To clarify eligibility criteria and protocol procedures  
• Appendix VII: Summary of Changes 14 September 2018 (Version 4.0) to 
04 December  2019 (Version  5.0). 
- To provide justification for dose level chosen for Part 2  
- To clarify protocol procedures  
- To update recommendations for management of chemotherapy -induced diarrhea  
- To clarify pregnancy follow -up period  
- To revise adverse event management guidelines  
- To update disease specific inclusion criteria.  
• Appendix VIII: Summary of Changes 04  December  2019 (Version  5.0) to 15  April  2020 
(Version 6.0).  
- To remove the futility interim PFS analysis as not required for decision on 
continuity of the study.  
- To clarify def inition of length of SAE reporting (expressed differently in two 
different sections)  
- To clarify the sourcing of topotecan  
- Administration change to front cover fax number  
• Appendix IX: Summary of Changes 15 April 2020 (Version 6.0) to 24 November 2020 
(Version  7.0). 
- To update the statistical analysis to allow an assessment of the interim efficacy 
signal, confirming the promising results observed during the Part 1 by [CONTACT_1583] a 
descriptive analysis of ORR for efficacy at the time of the interim analysis of  OS 
futility  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624228] OBER 2021  
 
Proprietary and Confidential  Page 8  
 - To amend the secondary and exploratory objectives for patient reported outcomes 
(PRO).  
- To include reporting requirements and detail specifics to conduct of the study 
during the COVID -19 pandemic.  
- To clarify eligibility criterion and protocol p rocedures.  
• Appendix X: Summary of Changes 24 November 2020 (Version  7.0) to 
07 October  2021 (Version  8.0). 
- To include  supplemental interim analysis of the efficacy and safety based on 
intent -to treat (ITT) population to fulfill FDA recommendation.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624229]  Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CV Coefficient of variation  
C#D#  Cycle #, Day #  
DLT  Dose -limiting toxicity  
DMC  Data Monitoring Committee  
DNA  Deoxyribonucleic acid  
DOR  Duration of response  
D5W  Dextrose 5% in water  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EMA  European Medicines Agency  
EORTC  European O rganization for Research and Treatment of Cancer  
EORTC -QLQ -C30 EORTC quality -of-life core 30 questionnaire  
EORTC -QLQ -LC13  EORTC quality -of-life questionnaire; lung cancer supplement  
ESMO  European Society of Medical Oncology  
EQ-5D-5L EuroQol 5 dimension health status questionnaire (5 level)  
EU European Union  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
G-CSF Granulocyte Colony Stimulating Factor  
HR  Hazard ratio  
IASLC  International Association for the Study of Lung Cancer  
IB Investigator’s Brochure  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624230]  
IRT Interactive Response Technology System  
ITT Intent to treat  
IV Intravenous  
LV Leucovorin  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  Magnetic resonance imaging  
Nal-IRI Irinotecan liposome injection; Liposomal irinotecan  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
ORR  Objective response rate  
OS Overall survival  
PD Progressive disease or disease progression  
PFS Progression free survival  
PGI-C Patient Global Impression of Change  
PGI-S Patient Global Impression of Severity  
PK Pharmacokinetic(s)  
PRO  Patient reported outcome  
QoL Quality of life  
QTcF  QT interval, Fridericia correction  
RANO -BM Response assessment in neuro -oncology brain metastases  
RBC  Red blood cell  
RECIST  Response evaluation criteria in solid tumors  
RNA  Ribonucleic acid  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SCLC  Small cell lung cancer  
SmPC  Summary of medical product characteristics  
SRC  Safety Review Committee  
TEAE  Treatment emergent adverse event  
TOP1  Topoisomerase -[ADDRESS_624231]  Upper limit of normal  
UGT  Uridine diphosphate glucuronosyl transferase  
UGT1A1  Uridine diphosphate glucuronosyl transferase 1A1  
UGT1A1*28  UGT1A1 pharmacogenetic variant *28  
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopeia  
USPI  [INVESTIGATOR_485925] -398-01-03-04 
VERSION 8.0 – [ADDRESS_624232] OBER 2021  
 
Proprietary and Confidential  Page 11  
 SYNOPSIS  
Sponsor:  IPSEN Bioscience, Inc  
[ADDRESS_624233],  
Cambridge MA [ZIP_CODE] - [LOCATION_003]  
Protocol 
Title:  RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome 
Injection (ONIVYDE®) versus  Topotecan in Patients with Small Cell Lung 
Cancer Who Have Progressed on or after Platinum -based First -Line Therapy  
Protocol 
Number:  MM-398-01-03-04 
Phase of 
Development:  3 
Trial 
Locations:  Worldwide  
Number of 
sites:  Approximately 137 sites will participate in the study.   
Patient 
Population:  Patients with small cell lung cancer who have progressed on or after 
platinum -based first line therapy.  
Estimated 
Number of 
Patients:  In Part 1 of the study, approximately 24 to  36 patients will be enrolled and in 
Part 2 of the study approximately 450 patients will be enrolled.  
Objectives  
Part 1  
 Part 1 (single -arm; dose -ranging) Objectives:  
Primary Objectives:  
• Describe the safety and tolerability of irinotecan liposome inject ion 
monotherapy administered every 2 weeks  
• To determine the irinotecan liposome injection monotherapy dose 
(85 mg/m2 or 70 mg/m2 administered every 2 weeks) for Part  2 of this 
study.  
(Note: all doses of irinotecan liposome injection refer to free base unless 
otherwise stated)  
Secondary Objectives:  
To assess the preliminary efficacy of irinotecan liposome injection (at either  the 
85 mg/m2 dose level or the 70 mg/m2 dose level) as determined by:   
• Objective response rate (ORR)  
• Progression free survival (PFS)  
• Overall survival (OS).  
Exploratory Objectives:  
• To describe QTcF following treatment with irinotecan liposome injection.  
• To explore the biomarkers associated with toxicity and efficacy following 
treatment with irinotecan liposome injection in this pat ient population.  
• To describe the association between UGT1A1*28 and other UGT1A1 
genotypes, SN -38 concentration and safety.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624234] OBER 2021  
 
Proprietary and Confidential  Page 12  
 • To evaluate the pharmacokinetics (PK) and the relationship between PK 
exposure and efficacy and safety following irinotecan liposome injection in 
this patient population.  
• To explore patient -reported outcomes (PROs) using the European 
Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC -QLQ -C30) and European Organization for 
Research and Treatmen t of Cancer Quality of Life Questionnaire Lung 
Cancer  13 (EORTC -QLQ -LC13), Patient Global Impression of Severity 
(PGI -S), Patient Global Impression of Change (PGI -C), and 
EuroQol  5- dimension health status questionnaire (5  level) (EQ -5D-5L). 
Objectives  
Part 2  Part 2 (two -arm randomized) Objectives:  
Primary Objective:  
To compare overall survival (OS) following treatment with irinotecan liposome 
injection with OS following treatment with IV topotecan.  
Secondary Objectives:  
To compare the following between  the treatment arms:  
• Progression free survival (PFS)  
• Objective response rate (ORR)  
• Patient Reported Outcomes (PRO)  
• Safety profile.  
Exploratory Objectives:  
• To explore the biomarkers associated with toxicity and efficacy following 
treatment with irinotecan liposome injection in this patient population.  
• To describe the association between UGT1A1*28 and other UGT1A1 
genotypes, SN -38 concentration (irinotecan liposome injection treated 
patients only) and safety.  
• To evaluate the pharmacokinetics and the relation ship between 
pharmacokinetic exposure and efficacy and safety following irinotecan 
liposome injection in this patient population.  
• To compare the rate of development/time to development of central nervous 
system (CNS) progression and development of new CNS  metastases 
between treatment arms.  
• To compare time to treatment failure between treatment arms.  
• To assess the proportion of patients with improvement in symptoms as 
measured by [CONTACT_26740] -C30/LC13 dyspnea scale.  
• To assess the proportion of patients with im provement in symptoms as 
measured by [CONTACT_20368] -LC13.  
• To compare the effect of irinotecan liposome injection versus. topotecan on 
symptoms (other than dyspnea and cough), functioning and global health 
status as measured by [CONTACT_152853] -QLQ -C30, EORTC -QLQ -LC13 and 
EQ-5D-5L. 
Study Design:  This study will be conducted in two parts: an open -label, single -arm, safety run -in 
period (Part  1) followed by a randomized period (Part 2) assessing  irinotecan 

IPSEN GROUP PROTOCOL MM -398-01-03-04
VERSION 8.0 –[ADDRESS_624235] OBER 2021
Proprietary and Confidential Page 13liposome injection versus IV topotecan in patients with small cell lung cancer 
(SCLC) who have progressed on or after platinum-based first line therapy. 
Details of the study design for each part are as follows: 
Note: Onivyde is also known as irinotecan liposome injection, liposomal injection or nal -IRI.  
Each part will consist of three stages: screening stage, treatment/active follow -up 
stage and long -term follow- up stage. Once consented, patients will enter a screening 
stage. Upon first dose of study treatment in Part 1 or randomization (Part 2), patients 
will enter the treatment/active follow -up stage. Once a decision is made to 
permanently discontinue the patient from study treatment, a 30 -day follow -up visit 
will occur and the patient will enter the long -term follow -up stag e. The stages for 
this trial are outlined in the schematic below.
Part 1:
Part 1 is an open -label, single -arm, safety run -in evaluation of irinotecan liposome 
injection administered every 2 weeks intended to confirm the anticipated Part 2 
regimen (85 mg/m2), based on safety and preliminary efficacy. A contingency has 
been included for evaluation of irinotecan liposome injection at a dose level of 
70mg/m2, should the higher dose level of 85 mg/m2result in unacceptable toxicity. 
At either dose level of irinotecan liposome injection up to 24 patients will be 
enrolled.
The safety assessment and the corresponding expansion will be conducted 
according to a “6+6” design followed by [CONTACT_485954] 12 patients (as 
described below). Patients will i nitially be treated with irinotecan liposome 
injection 85 mg/m2every 2 weeks. Dose limiting toxicities (DLTs) will be evaluated 
for the first [ADDRESS_624236] 28 days of treatment (or up to 14 days 
after the second dose of study treatment if there is a treatment delay due to non -
DLT related reasons).
•Among the first 6 patients receiving irinotecan liposome injection 
85mg/m2 (i.e 85 mg/m2cohort), if ≤ 2 patients experience a DLT, another 
6 patients will be enrolled into this cohort. Ot herwise, enrollment into the 
70mg/m2 cohort will be initiated.
•Among the first 12 patients receiving irinotecan liposome injection 
85mg/m2, if ≤ 2 patients experience a DLT, this cohort will be expanded 
by 12 additional patients. Otherwise, the enrollment of the 85 mg/m2 cohort 
will be stopped and the enrollment of the 70 mg/m2 cohort will be initiated. 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624237] OBER 2021  
 
Proprietary and Confidential  Page 14  
  
Note: all doses described are irinotecan liposome injection free base.  
If the 70 mg/m2 cohort is enrolled, the same “6+6” design followed by [CONTACT_485955] 12 patients, and the same DLT guidelines will be used as that for 
the 85  mg/m2 cohort. If ≤ [ADDRESS_624238] 12 patient receiving irinotecan 
liposome injection 70 mg/m2 experience a DLT, then that dose level will be declared 
tolerable and this cohort will be expanded by 12 additional patients. Otherwise, 
additional dose reduction(s) may be considered.  
Note that in either the 85 mg/m2 cohort or the 70 mg/m2 cohort, there will be no 
stoppi[INVESTIGATOR_485926]; however,  DLTs will continue to be 
assessed among the additional [ADDRESS_624239] 
completed DLT evaluation.  
The decision of which dose to use for Part 2 will be made based on the totality of 
data from all patients treated in Pa rt 1. 
If a decision is made to terminate the irinotecan liposome injection 85 mg/m2 dose 
level cohort (and instead initiate enrollment into the 70 mg/m2 cohort) patients who 
are tolerating the 85 mg/m2 dose level will remain at that dose level (unless 
subsequent toxicity requires a dose modification).  
During the DLT evaluation period in either 85 mg/m2 and 70 mg/m2 cohort, the 
following adverse events (AEs) should be considered as DLTs if they occur during 
the first 28  days of treatment (or 14 days after th e second dose of study treatment if 
there is a treatment delay and are deemed related to the study treatment by [CONTACT_1275]:  
• Grade 4 neutropenia or thrombocytopenia that does not resolve within 
7 days despi[INVESTIGATOR_485927],  
• Inability to b egin subsequent treatment course within 14 days of the 
scheduled date, due to drug -related toxicity,  
• Grade 3 -4 neutropenia complicated by [CONTACT_411] ≥ 38.5 °C (i.e. febrile 
neutropenia) and/or by [CONTACT_80601],  
• Any Grade 4 non -hematologic toxicity with the exception of the following:  
o Fatigue/asthenia lasting < 14 days,  
o Nausea and vomiting lasting ≤ 72 hours duration (only considered 
dose limiting if they last > 72 hours after treatment with an optimal 
anti-emetic treatment),  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624240] OBER 2021  
 
Proprietary and Confidential  Page 15  
 o Diarrhea ≤ 72 hours duration (only considered dose limiting if 
diarrhea lasts > 72 hours after treatment with an optimal 
anti-diarrheal regimen),  
• Grade 3 non -hematologic toxicity with the exception of the following:  
o Any gastrointestinal disorder and dehydration (with associated 
signs and symptoms) unless Grade 3 toxicity persists despi[INVESTIGATOR_485928] > 72 hours,  
o Pain unless Grade 3 toxicity persists despi[INVESTIGATOR_115116],  
o Fatigue, fever, flu like symptoms, infections and infestations,  
o Infusion reaction (a nd associated symptoms) unless it occurs 
following steroid premedication,  
o Hepatic and kidney function abnormalities, and electrolyte 
abnormalities unless they persist, despi[INVESTIGATOR_115116].  
The determination of whether an AE is considered a DLT will be made by [CONTACT_317380] (SRC) comprising the Part 1 Investigators and the Medical 
Monitor(s) of the Sponsor. Other AEs, not meeting the DLT criteria above, that are 
deemed related to study treatment can also be considered a DLT even t at the 
discretion of the SRC. Safety review meetings between investigators and sponsor 
will occur regularly during Part [ADDRESS_624241] monthly meetings, or 
more frequently, if required.  
Safety and efficacy results  from Part 1 will determine  if the study proceeds to Part  2. 
The final decision to proceed to Part 2 will be made by [CONTACT_485956], after consideration of all available 
efficacy and safety data from Part 1 of the study.  
All patients in Part 1 will follow the same schedule of assessments as required for 
Part 2 detailed below.  
Part 2:  
Part 2 will be randomized, and assess the efficacy of irinotecan liposome injection 
versus IV topotecan. Approximately 450 eligible patients wi ll be randomized in a 
1:1 ratio between the experimental arm (Arm A: based on the findings of Part  1 
[i.e. likely to be either 85  mg/m2 or 70 mg/m2 of irinotecan liposome injection]) and 
the control arm (Arm  B: topotecan).  Note that following assessment of  the available 
safety and efficacy data from Part 1 the 70 mg/m2 dose was chosen for Arm A . 
Patients will be randomized to the treatment arms using an Interactive Response 
Technology System (IRT) at a central location. Randomization will be stratified, 
based on the following factors:  
• Region (North America vs. Asia vs. Other)  
• Platinum sensitivity (sensitive vs. resistant)  
• Performance status (ECOG 0 vs. 1)  
• Prior immunotherapy (yes vs. no)  
(Note:  for platinum sensitivity, progression within [ADDRESS_624242]-line platinum therapy is considered “platinum resistant” and the others 
“platinum sensitive”. Prior immunotherapy sensitivity should not be confused with 
platinum sensitivity).  
Only region (North America vs. Asia vs. Other) and platinum  sensitivity (sensitive 
vs. resistant) will be used for the stratified efficacy analysis.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624243] OBER 2021  
 
Proprietary and Confidential  Page 16  
 It is intended that all patients in Parts 1 and 2 will be treated until progressive disease 
or unacceptable toxicity (see Section  4.3.1 ). Patients may take a treatment holiday 
and resume study treatment under certain instances. Detailed rule for pausing and 
resuming study treatment can be found in Section 6.2.[ADDRESS_624244] be evaluated at the same f requency as during active treatment. 
Cross -over between treatment arms is not permitted.  
Upon permanent discontinuation of study treatment (defined as patients with 
progressive disease whilst receiving study treatment and/or those assessed by [CONTACT_485957]), patients will return to the study site for a [ADDRESS_624245]. 
Tumor assessments will be performed every 6 weeks (± 1 week), using the 
Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version  1.1) 
(Parts  1 and  2) and Res ponse Assessment in Neuro -oncology  Brain Metastases 
(RANO -BM) criteria for CNS lesions (Part 2). Tumor assessment at screening and 
for all subsequent visits will be computed tomography (CT) with contrast 
(chest/abdomen required and pelvis [or other areas] if clinically indicated) and brain 
magnetic resonance imaging (MRI) with contrast. For patients who are allergic to 
IV contrast or cannot tolerate IV contrast due to impaired renal function or other 
issues, a non -enhanced CT or MRI is acceptable. Each foll ow-up tumor assessment 
should use the same assessment method as performed at screening, unless medically 
contraindicated. Patients who discontinue study treatment, for reasons other than 
disease progression, should continue to be followed -up until radiolog ical 
documentation of progressive disease with the same schedule of tumor assessments 
(every 6  weeks ±  1 week) until radiological documentation of progressive disease 
or until the start of new anti -neoplastic therapy. The Sponsor will collect and store 
all tumor assessment images on all patients throughout the study. Progressive 
disease will be determined by [CONTACT_485958]/or investigator 
assessment. An independent central review of the scans will be performed at the 
discretion of the Sponsor  to support potential early filing to regulatory authorities . 
All patients will be followed at least monthly for survival status until death, loss to 
follow -up or study closure, whichever comes first.  
A quality of life assessment will be performed using the E ORTC -QLQ -C30, 
EORTC -QLQ -LC13, PGI -S, PGI -C and EQ -5D-5L questionnaires. Although the 
PGI-C and PGI -S are not specified as exploratory objectives in Part  2 they will serve 
as anchors deriving a within -patient meaningful change threshold in Part  2. All PRO 
instruments are required to be completed at screening, prior to dosing at 6 -week 
intervals (and prior to any other assessment procedures) following start of treatment, 
at treatment discontinuation, at the 30 -day follow -up visit.  Patients who discontinue 
study treatment, for reasons other than disease progression, should continue to 
complete all QoL assessments every 6 weeks until radiological documentation of 
progressive disease or until the start of  new anti -neoplastic therapy. The PGI -C is  
not included i n the screening assessment. Adverse events will be evaluated 
according to the National Cancer Institute’s (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version  5.0. For summary of AEs, events will be 
coded using the latest Medical Dictionary  for Regulatory Activities (MedDRA) 
dictionary (Version 21.0 or later) at the start of the study.  
The primary analysis is planned when at least [ADDRESS_624246] occurred in 
Part 2. An interim analysis for OS futility is planned at approximately the 29% 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624247] patient has been 
randomized based on the ITT Population. At the timepoints of the interim analysis 
and supplemental interim analysis, ORR by [CONTACT_19375] 
(BICR) tumor assessments will be analyzed descriptively:  
• by [CONTACT_485959] 200 patients randomized in Part  2 of 
the study  
• for the full ITT population in the supplemental interim analysis.  
Details of BICR tumor assessment process and approach will be described in the 
imaging charter document. Details of the study -level  type I error control are 
provided in the section on stati stical methods and in the Statistical Analysis Plan  
(SAP) .  
An independent DMC will be established to monitor data in Part  [ADDRESS_624248]. The 
timing and details of subsequent data reviews will be detailed in the DMC charter . 
Items reviewed will include (but not limited to) s afety events, results of interim 
analysis, any available results of PK testing and UGT1A1*28 genotype. Attention 
will be paid to determining whether any study procedure needs to be modified for 
patients who are homozygous for UGT1A1*28.  
Pharmacokinetics  
Sparse plasma samples for PK will be collected from all patients receiving 
irinotecan liposome injection (Part 1 and Part 2).  
Biobanking  
The exploratory endpoint comprises biobanking of samples for further analysis 
among patients who consent. Patient partic ipation to consent to biobanking samples 
is optional. Analysis from the biobank samples will be performed outside the scope 
of the main study and reported separately.  
Estimated 
Number of 
Patients  In Part 1 of the study, approximately 24 to 36 evaluable patients will be enrolled 
and in the Part 2 of the study approximately 450 patients will be enrolled.  
Inclusion 
Criteria:  To participate in the study patients must meet the following inclusion criteria, and 
none of the exclusion criteria:  
General Inclusion Criteria  
1. At least 18 years of age.  
2. Able to understand and provide the study informed consent.  
3. ECOG performance status of 0 or 1.  
4. Life expectancy >12 weeks.  
 

I P S E N G R O U P  P R O T O C O L M M -3 9 8 -0 1 -03-0 4  
V E R SI O N 8. 0 – [ADDRESS_624249] u d y of L u n g Ca ncer (I A S L C) 
hist o pat h ol o gical classificati o n. Mi xe d or c o m bi ne d s u bt y pes acc or di n g t o t he 
I A S L C are n ot all o we d.  
6.  E val ua ble disease as defi ne d b y R E CI S T Ver si o n 1. 1 g ui deli nes ( patie nts wit h 
n o n -meas ura ble lesi o ns are eli gi ble).  
7.  Ra di ol o gicall y c o nfir me d pr o gressi o n o n or after first -li ne plati n u m base d 
c he m ot hera p y (car b o plati n or cis plati n), or c he m o -ra diati o n i ncl u di n g 
plati n u m -base d c he m ot hera p y f or treat m e nt of li mite d or e xte nsi ve sta ge 
S C L C. I n a d diti o n t o plati n u m -base d re gi me n,  o ne li ne of i m m u n ot hera p y as 
m o n ot hera p y or i n c o m bi nati o n i n first or i n sec o n d li ne setti n g is all o we d.  
8.  Rec o vere d fr o m t he effects of a n y pri or c he m ot hera p y, s ur ger y, ra di ot he ra p y or 
ot her a nti -ne o plastic t hera p y (rec o vere d t o Gra de  1 or better, wit h t he e xce pti o n 
of al o pecia, peri p heral ne ur o pat h y, or ot ot o xicit y).  
He m at ol o gic, Bi oc he mic al a n d Or g a n F u ncti o n I ncl usi o n Criteri a  
9.  D uri n g t he Scree ni n g peri o d, a de q uate b o ne marr o w reser ves as e vi de nce d b y:  
a.  A bs ol ute ne utr o p hil c o u nt > 1, 5 0 0 cells/ µ L ( 1. 5 x 1 0 9/ L) wit h o ut 
t he use of he mat o p oietic gr o wt h fact ors wit hi n t he i m me diatel y 
prece di n g 1 4  da ys;  
b.  Platelet c o u nt > 1 0 0, 0 0 0 cells/ µ L ( 1 0 0 x 1 0 9/ L);  
c.  He m o gl o bi n > 9 g/ d L; tra nsf usi o ns ar e all o we d.  
1 0.  A de q uate he patic f u ncti o n as e vi de nce d b y:  
a.  Ser u m t otal bilir u bi n wit hi n n or mal ra n ge f or t he i nstit uti o n;  
b.  As partate a mi n otra nsferase a n d ala ni ne a mi n otra nsferase 
≤ 2. 5  x u p per li mit of n or mal ( U L N) ( ≤ 5 x U L N is acce pta ble if 
li ver metastases is prese nt);  
c.  Ser u m al b u mi n ≥ 3. 0 g/ d L ( ≥ 3 0 g/ L).  
1 1.  A de q uate re nal f u ncti o n as e vi de nce d b y a ser u m creati ni ne ≤ 1. 5 x U L N a n d 
creati ni ne  cleara nce ≥ 4 0 m L/ mi n.  Act ual b o d y wei g ht s h o ul d be use d f or 
calc ulati n g  creati ni ne cleara nce usi n g t he C oc kcr oft -Ga ult E q uati o n (e xce pt f or 
patie nts wit h b o d y mass i n de x > 3 0 k g/ m 2 w he n lea n b o d y wei g ht s h o ul d be 
use d i nstea d):  
 
 
 
 
w here Se x = 1 f or male a n d 0. 8 5 f or fe males  
 
1 2.  Electr ocar di o gra m wit h o ut a n y cli nicall y si g nifica nt fi n di n gs at scree ni n g, as 
per i n vesti gat or’s assess me nt.  
 
 ( 1 4 0 – A ge ( years)) × ( Wei g ht ( k g))  
7 2 × Ser u m Creati ni ne ( m g/ d L)  
 
 × Se x  Ser u m Creati ni ne ( m g/ mi n) =  
IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624250] OBER 2021  
 
Proprietary and Confidential  Page 19  
 Additional Disease Specific Inclusion Criteria  
13a Patients with certain types of asymptomatic CNS metastases that meet ALL the 
following criteria are eligible.  
a. Patients with asymptomatic CNS metastases prior to enrollment  
b. Prior radiation for CNS metastatic disease is completed ≥[ADDRESS_624251] discontinued corticosteroids or are on stable l ow-
dose steroids (prednisone or equivalent 10  mg daily or less) for at 
least 1  week after completion of radiation for CNS lesion prior to 
enrollment.  
Exclusion 
Criteria:  Patients must meet all the inclusion criteria listed above and none of the following 
exclusion criteria:  
General Exclusion Criteria  
1. Any medical or social condition deemed by [CONTACT_485960] a patient’s ability to sign informed consent, cooperate and 
participate in the study, or interfere with the i nterpretation of the results.  
2. Pregnant or breast feeding; females of child -bearing potential must test negative 
for pregnancy at the time of enrollment based on a serum pregnancy test. 
Females of childbearing potential are defined as fertile, following menarche and 
until becoming postmenopausal unless permanently sterile. Postmenopausal 
women are defined as those that have an absence of menstruation for at least 
2 years. If necessary, follicle stimulating hormone results >50 IU/L at screening 
are confirm atory in the absence of a clear postmenopausal history. Permanent 
sterilization methods include hysterectomy, bilateral salpi[INVESTIGATOR_96802].  
Male patients must agree to use condoms during the study and for [ADDRESS_624252] received any of the following treatments:  
a. Prior treatment regimens with irinotecan, topotecan or any other 
topoisomerase I inhibitor including investigational topoisomerase  I 
inhibitors;  
b. Retreatment with pl atinum -based regimen after relapse of first -line 
platinum -containing therapy;  
c. Any antibody -drug conjugates or molecular targeted agents (e.g. poly 
ADP -ribose polymerase inhibitors), either alone or in combination with 
other treatments;  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624253] OBER 2021  
 
Proprietary and Confidential  Page 20  
 d. More than one line o f prior immunotherapy;  
e. Any other additional regimen of prior cytotoxic chemotherapy, not 
described above.  
5. Patients with a history (any grade) of immunotherapy induced colitis or 
pneumonitis, based on clinical assessment and/or confirmed by [CONTACT_9256].  
6. Patient s with any of the following CNS metastases:  
a. Patients who have developed new or progressive brain metastasis 
within three months following prophylactic and/or therapeutic cranial 
radiation (whole brain or stereotactic radiation) as defined by [CONTACT_9661];  
b. Patients with symptomatic CNS metastases;  
c. Patients with carcinomatous meningitis.  
7. Unable to discontinue the use of strong CYP3A4 or UGT1A1 inhibitors at least 
[ADDRESS_624254] in primary 
(non-pulmonary) site or histology, except carcinoma in situ, treated basal cell 
carcinoma, superficial bladder tumors (Ta and Tis [carcinoma in situ]) or any 
previous can cer curatively treated with last specific treatment  >[ADDRESS_624255] 5  half-lives (whichever is less)  of the investigational agent  
prior to the first scheduled day of dosing in this study.  
Hematologic, Biochemical and Organ Function Exclusion Criteria  
10. Severe cardiovascular and pulmonary disease (e.g. myocardial infarction, 
unstable angina pectoris, coronary angioplasty or stenting, d eep vein 
thrombosis, stroke, pulmonary fibrosis, active uncontrolled bleeding, or a 
known bleeding diathesis) less than 6 months before inclusion.  
11. [LOCATION_001] Heart Association Class III or IV congestive heart failure, ventricular 
arrhythmias or uncontrolled blood pressure.  
12. Active infection (e.g. acute bacterial infection, tuberculosis, active hepatitis B/C 
or active human immunodeficiency virus) which in the Investigator’s opi[INVESTIGATOR_485929]’s participation in the trial or affect the study 
outcome.  
13. Known hypersensitivity to any of the components of irinotecan liposome 
injection, other liposomal products, or topotecan.  
14. Clinically significant  gastrointestinal disorder including hepatic disorders, 
bleeding, inflammation, occlusion, or diarrhea > Grade  1. 
Additional Disease Specific Exclusion Criterion (only applicable in [LOCATION_009], per 
request of French Regulatory Authorities)  
15. Patients who, per investigator assessment, are suitable for a second line 
platinum -based regimen following relapse after first-line platinum -based 
therapy.  
Length of 
Study:  The study will end when all patients are off study drug treatment and at least 
[ADDRESS_624256] occurred  in Part 2  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624257] OBER 2021  
 
Proprietary and Confidential  Page 21  
 Study 
Assessments:  See Schedule of Assessments  
Study 
Treatment  Irinotecan liposome injection:  
Part 1: (single -arm, dose -ranging)  
• Irinotecan liposome injection 85 mg/m2 (strength expressed as irinotecan 
free base; approximately equivalent to 100 mg/m2 of the hydrochloric 
trihydrate salt) IV over 90 minutes, every 2 weeks in a 6 -week cycle  
OR 
• Irinotecan liposome injection 70 mg/m2 (strength expressed as irinotecan 
free base; approximately equivalent to 80 mg/m2 of the hydrochloric 
trihydrate salt) IV over 90 minutes, every 2 weeks in a 6 -week cycle.  
Part 2 (two -arm, randomized):  
• Irinotecan liposome injection 85 mg/m2 (strength expressed as irinotecan 
free base; approximately equivalent to 100 mg/m2 of the hydrochloric 
trihydrate salt) IV over 90 minutes, every 2 weeks in a 6 -week cycle (unless 
deemed unacceptable in Part 1, in which case the  70 mg/ m2 dose level 
[strength expressed based on irinotecan free base; approximately equivalent 
to 80  mg/m2 of the hydrochloric trihydrate salt] will be utilized IV over 
90 minutes, every 2  weeks in a 6 -week cycle). Note that following 
assessment of the a vailable safety and efficacy data from Part 1 the 70  mg/m2 
dose level will be utilized for Part 2.  
• Topotecan 1.5 mg/m2: IV over [ADDRESS_624258] : Irinotecan liposome injection (also known as liposomal irinotecan, nal -IRI, 
MM-398, PEP02, BAX2398 and ONIVYDE®) is a sterile, white to slightly yellow 
opaque isotonic liposomal dispersi on. Each 10  mL single -dose vial contains 43  mg 
irinotecan free base at a concentration of 4.3 mg/mL. The liposome is a unilamellar 
lipid bilayer vesicle, approximately 110  nm in diameter, which encapsulates an 
aqueous space containing irinotecan in a gelat ed or precipi[INVESTIGATOR_485930]. It will be supplied as sterile, single -use vials containing 43  mg 
irinotecan free base at a concentration of 4.3 mg/mL.  
Irinotecan liposome injection must be stored refrigerated (2 to 8°C, 36 to 46°F) with 
protection from light. Do not freeze.  
Sample Size  Part 1:  
Up to 36 patients will be evaluated in Part 1. Up to 12 patients per dose level of 
irinotecan liposome injection may be treated at either 85 mg/m2 or 70 mg/m2 and 
one of these two dose levels will subsequently be expanded to a total of [ADDRESS_624259] an 
acceptable toxicity profile if there are ≤[ADDRESS_624260] 12 patients evaluated.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624261] OBER 2021  
 
Proprietary and Confidential  Page 22  
 A total of 24 patients (at the eventually selected dose level of irinotecan liposome 
injection) is considered sufficient to provide a preliminary assessment of efficacy 
endpoints, for the purposes of determining whether to proceed to Part  2. 
 
Part 2:  
The prima ry endpoint is OS.  
A total of 450 patients will be randomized in a 1:[ADDRESS_624262] 87% power to detect a true hazard ratio of HR ≤ 0.7 14 (median 
OS: 7.5 vs 10.5 months) using a stratified log -rank test (stratified by [CONTACT_11338] 
(North  America vs. Asia vs. Other) and platinum sensitivity (sensitive vs. resistant)) 
with overall 1 -sided significance level of 0.025 (adjusted for the interim anal ysis).  
Assuming enrollment over [ADDRESS_624263] -to-follow -up rate of 5% across both treatment arms, the timing 
of the primary analysis is expected to be at 37  months.  
An interim OS analysis for futil ity will be conducted when approximately 29% of 
the planned final number of OS events (i.e., approximately 100 of 350  OS events) 
has been observed in the ITT population.  
At the timepoint of the interim analysis, ORR by [CONTACT_485961] [ADDRESS_624264] 
patient has been randomized based on the ITT population to fulfill FDA 
recommendation.  At this timepoint, OS and ORR (supported by [CONTACT_109957]) will be 
summarized descriptively . 
Note: detailed methodology is further described in the SAP.  
Statistical 
Considerations 
and Data 
Reporting : General:  
Categorical variables will be summarized by [CONTACT_119395] (number and 
percentages of patients) and continuous variables will be summarized by [CONTACT_84814] (mean, standard deviation, median, minimum, maximum).  
Part 1 : 
The efficacy and safety of irinotecan liposome injection in Part [ADDRESS_624265] one dose of irinotecan liposome injection 
will comprise the Part 1 safety and efficacy population.  
Part 2 : 
Patients randomized in Part 2 will comprise the ITT population. This will be the 
population used to evaluate the efficacy (OS, PFS, ORR)  of the experimental arm. 
In the ITT analyses of efficacy, each patient will be considered according to the 
randomized treatment assignment. Patients who received any part of any study drug 
will define the Part 2 safety population.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624266] OBER 2021  
 
Proprietary and Confidential  Page 23  
 For stratified analyses,  stratification factors will be the randomization stratification 
factors of region (North America, Asia, Other) and platinum sensitivity (sensitive, 
resistant).  
 
Primary Efficacy Analysis (Part 2):  
Overall Survival  
Overall survival is defined as the number of months from randomization in Part [ADDRESS_624267] (stratified by 
[CONTACT_485962]) comparing the OS difference between two 
treatment arms with level of significance controlled at the one -sided 0.025 level. 
Kaplan -Meier methods will be used to estimate median OS (with 95% co nfidence 
intervals (CI)) and to display OS time graphically. A stratified Cox proportional 
hazards model will be used to estimate hazard ratio and its corresponding 95%  CI. 
Sensitivity analyses for OS will be described in the SAP.   
An interim analysis of O S for futility (at approximately 29% of planned OS events) 
is planned. To control type  I and type  II errors, the planned interim analysis will 
utilize an alpha and (non -binding) beta spending function approach with Hwang -
Shih-Decani spending and  γ paramete r equal to -4.5 for each type I error and γ = -1 
for type  II error ( Hwang,  1990 ). 
A supplemental interim analysis is planned on data collected [ADDRESS_624268] 
patient has been randomized based on the ITT population to  fulfill FDA 
recommendation. At this timepoint, OS  and ORR (supported by  [CONTACT_109957] ) will be 
summarized descriptively.  
 
Key Secondary Efficacy Analyses (Part 2):  
Key secondary endpoints are PFS, ORR and  change from baseline in patient 
reported symptoms (dyspnea and cough).  
Key secondary endpoints will be tested no more than once. To control the overall 
Type I error rate for the comparison between irinotecan liposome injection and 
topotecan for the primary and secondary endpoints, a hierarchical approach will be 
applied to the statistical testing of the secondary endpoints. The statistical inference 
for the first secondary endpoint of PFS (by [CONTACT_19377]) will only be performed if the 
primary endpoint (OS), is statistically significant. The second secondary endpoint 
of OR R (by [CONTACT_19377]) will only be tested if PFS is statistically significant. Similarly, 
the PRO endpoints will only be tested if ORR is statistically significant. Any 
parameter which is not statistically significant will be regarded as descriptive and 
exploratory.  
Progression -free survival:  
Progression -free survival is the time from randomization in Part  [ADDRESS_624269] 
documented objective disease progression (PD) using RECIST Version  1.1 (or 
RANO -BM criteria for CNS lesions) or death due to any cause, whichever oc curs 
first. Determination of PFS will be based on BICR tumor assessment , with PFS 
based on investigator tumor assessments as a sensitivity analysis . If neither death 
nor progression is observed, data will be censored on the date of the last observed 
tumor assessment date. Patients without a valid tumor response evaluation at 
enrollment/randomization will be censored on the date of 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624270] OBER 2021  
 
Proprietary and Confidential  Page 24  
 enrollment/randomization. Patients starting a new anti -cancer treatment prior to 
documented PD will be censored at the date of t he last observed tumor assessment 
prior to start of the new treatment. Patients with documented PD or death after an 
unacceptable long interval (i.e. 2 or more missed or indeterminate scheduled 
assessments) will be censored at the time of the last observed  non-PD tumor 
assessment date prior to progression or death. Details of data handling for censoring 
of PFS will be provided in the SAP.  
The difference in PFS between treatments will be evaluated using a stratified log -
rank test (stratified by [CONTACT_201049] p latinum sensitivity). Kaplan -Meier methods will 
be used to estimate median PFS (with 95% CI) and to display PFS time graphically. 
A stratified Cox proportional hazards model will be used to estimate the PFS hazard 
ratio and its corresponding 95% CI. Sensit ivity analyses for PFS will be described 
in the SAP.  
Objective Response:  
Objective response rate is the proportion of patients who achieve partial response  
(PR) or complete response (CR) according to RECIST Version 1.1 guidelines (or 
RANO -BM criteria for CNS lesions, Part 2). An estimate of the ORR and its 95% 
CI will be calculated. The  difference in ORR between treatment groups will be 
compared using Cochran -Mantel -Haenszel method, stratified by [CONTACT_485963].  
In addition to investigator  assessment, a BICR review of the tumor assessment 
images will be performed for all patients included in the study, and more 
specifically at the time of:  
• the interim analysis , for the descriptive analysis of ORR based on the first 
200 patients randomized i n both arms (i.e. approximately 100 patients from 
each arm) as well as for the patients included in Part 1 and treated with the 
selected dose for Part  2. 
• the supplemental analysis, for tumor images for all randomized patients 
collected [ADDRESS_624271] on secondary endpoint ORR will be based on BICR tumor 
assessment , with ORR based on investigator tumor assessments as a sensitivity 
analysis . 
Patient Reported Outcomes:  
The secondary endpoints below are  included in the testing hierarchy:  
• Change from baseline to Week  12 in EORTC QLQ -C30/LC13 dyspnea 
scale  
• Change from baseline to Week  12 in EORTC QLQ -LC13 cough scale  
 
Safety Analysis:  
Safety analyses (AEs and laboratory analyses) will be performed using the safety 
population, defined as all patients receiving any study drug. Treatment assignment 
will be according to actual treatment received. Adverse events will be coded using 
MedDRA (Version  21.0 or later). Severity will be graded according to the NCI 
CTCAE Version  5.0. 
Treatment -emergent adverse events (TEAEs) are defined as any AEs reported from 
the date of first study drug exposure to [ADDRESS_624272] date of study drug 
exposure. Frequency and percentages of patients will be summarized for: any g rade 
TEAE, Grade 3 or higher TEAE, study -drug related TEAE, serious TEAE, TEAE 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624273] OBER 2021  
 
Proprietary and Confidential  Page 25  
  leading to dose modification, TEAE leading to study drug discontinuation, death 
and TEAE leading to death. Adverse events will be summarized by [CONTACT_59134]. All AE data will be listed by [CONTACT_4676].   
Laboratory data will be summarized according to parameter type. Where applicable, 
toxicity grading for laboratory safety parameters will be assigned based on NCI 
CTCAE Version  5.0 criteria.  
QTcF Analyses:  
The potential of QTcF prolongation with irinotecan liposome injection treatment 
will be evaluated in patients receiving irinotecan liposome injection in Part [ADDRESS_624274] modeling. 
Sensitivity analyses will be conducted by [CONTACT_485964].  
Pharmacokinetics and Pharmacodynamics Analysis:  
Pharmacokinetics of total irinotecan and SN -[ADDRESS_624275] modeling. The 
initial PK analysis will use the empi[INVESTIGATOR_485931], however, additional 
covariate analyses will be performed to evaluate alternative bas eline factors specific 
to SCLC. The resulting PK estimates will be used to evaluate the association 
between PK and pharmacodynamics (efficacy and safety endpoints).  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624276] OBER 2021  
 
Proprietary and Confidential  Page 26  
 1 BACKGROUND INFORMATION AND RATIONALE  
1.1 Small Cell Lung Cancer  
Lung cancer is the leading cause of cancer deaths worldwide. Small cell lung cancer (SCLC) 
accounts for about 15% of lung cancers overall and is a particularly aggressive neoplasm with 
a 5-year survival of <10%. Little progress has been made in improving o utcome for this 
malignancy over the last 30 years.  
Small cell lung cancer is classified into limited and extensive stage disease based on the extent 
of the disease. Approximately 30% of patients with SCLC are diagnosed with limited stage 
disease, and are typi[INVESTIGATOR_24164] a combination of radiation and chemotherapy 
(Morabito   2014 ). With current treatments only ~20% of patients with limited stage disease 
have potential to be cured ( Dowell, 1999 ). Extensive stage disease remains incurable with an 
expected median survival of 7  to 9 months ( Morabito, 2014 ). Extensive stage disease is 
typi[INVESTIGATOR_485932] a combination of a platinum (carboplatin or cisplati n) plus etoposide 
in the US and EU ( NCCN guidelines;  Früh et al, 2013 ) or irinotecan plus cisplatin in Japan 
(NCC Japan Annual  Report, 2013 ). About 50 -90% of patie nts with extensive stage disease 
respond to initial treatment ( Morabito, 2014 ); however, patients rapi[INVESTIGATOR_485933]. Those that have progressed within [ADDRESS_624277] -line platinum 
therapy are considered “platinum resistant” and the others “platinum sensitive” (prior 
immunotherapy sensitivity should not be confused with platinum sensitivity). Because most 
patients experience relapse or disease progression after initial response to chem otherapy, 
subsequent therapy is often required with the hope of symptom palliation or prolongation of 
survival. For patients who progress >[ADDRESS_624278] -line therapy, 
re-challenge with the same drugs used as the initial treatment ha s been reported to result in 
potential benefit. Although both the European Society for Medical Oncology (ESMO) 
guidelines ( Früh  et al, 2013 ) and the [ADDRESS_624279] 
line regimen when relapse occurs after 6  months, the level of evidence for this recommendation 
is based on studies conducted in the 1980s ( Postmus, 1987 ; Giaccone, 1987 ) with small  
numbers of patients (level  V evidence in the ESMO guideline, e.g. studies without control 
group, case reports, experts’ opi[INVESTIGATOR_1649]). Additionally, a recent study by [CONTACT_485965] (2015)  showed 
that relapsed patients re -challenged with  the first line regimen had similar outcomes to those 
receiving single -agent chemotherapy. This platinum re -challenge approach is utilized mainly 
due to very limited treatment options for recurrent SCLC.  
The topoisomerase I (TOP 1) inhibitor topotecan is t he only agent approved for second -line 
therapy in the [LOCATION_002] (US) and Europe. A study by [CONTACT_485966] (1999)  compared 
intravenous topotecan with a regimen of cyclophosphamide, doxorubicin, and vincristine 
(CAV) for patien ts with recurrent SCLC. Topotecan treatment reduced symptoms to a greater 
degree than CAV and was associated with less hematologic toxicity, although it failed to 
provide a survival benefit. The combination of oral topotecan plus best supportive care has 
shown both survival and quality -of-life benefits compared with best supportive care alone in 
patients with relapsed SCLC ( O’Brien, 2006 ). In Japan, in addition to topotecan, amrubicin is 
also approved but it failed to gain app roval elsewhere, following its failure to demonstrate 
superior efficacy in a large phase III study conducted in Western patients ( von Pawel, 2014 ). 
Irinotecan is also an active and useful agent in SCLC. Superior overall survival (OS) for 
irinotecan plus cisplatin over cisplatin plus etoposide was noted in a Phase [ADDRESS_624280] line extensive stage patients in Japanese patients ( Noda, 2002 ). Irinotecan is not 
approved for SCLC ou tside of Japan because a study in Western patients failed to replicate the 
superior efficacy seen in Japanese patients ( Hanna, 2006 ). However, three additional phase  III 
studies of irinotecan plus a platinum versus etoposide plus a platinum in the first line setting 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624281] shown a trend of increased OS for patients receiving irinotecan combinations including 
one study that met statistical significance ( Zatloukal, 2010 ; Lara, 2009 ; Hermes,  2008 ). In the 
second line setting, single agent irinotecan has been evaluated in a few small studies with 
reported objective response rate (ORR), time to treatment progression, and OS in the range of 
0-47%, 1.7 -2.6 months and 4.6  months, respectively, ( Pallis, 2009 ; Masuda,  1992 ; 
Sevinc,  2011 ) with similar outcomes to that of topotecan (von Pawel, 2014). Based on these 
and other studies, irinotecan is included in major treatment guidelines for the treatment of 
patients with SCLC. Irinotecan plus either cisplatin or carboplatin is listed as possible first line 
regimen as well as irinotecan monotherapy in second line  in the National Comprehensive 
Cancer Network (NCCN) guidelines ( 2020 NCCN guidelines ). ESMO guidelines list irinotecan 
plus cisplatin as an alternative first line regimen for those patients for whom etoposide is 
contraindica ted (Früh, 2013 ). 
1.2 Study Rationale  
1.2.1 Rationale for Evaluating Irinotecan Liposome Injection in SCLC  
The rationale for testing irinotecan liposome injection (also known as liposomal irinotecan, 
nal-IRI, MM -398, PEP02, BAX2398, and ONIVYDE®) in patients with SCLC is based on 
targeting a validated drug target (TOP1), supportive non -clinical data, the concordance between 
SCLC biology and the proposed irinotecan liposome injection mechanism of action and prior 
clinical data for non -liposomal irinotecan in other indications. Based on these factors it is 
hypothesized that irinotecan liposome injection has the potential to improve upon the clinical 
activity of both topotecan and non -liposomal irinotecan.  
Topoisomerase I  is a validated d rug target in SCLC and is the target of topotecan, an approved 
agent in SCLC . SN-38, the active metabolite of irinotecan (and irinotecan liposome injection), 
is also known to target TOP1. Deoxyribonucleic acid (DNA) topoisomerases are a class of 
enzymes in volved in the regulation of DNA supercoiling. Type I topoisomerases change the 
degree of supercoiling of DNA by [CONTACT_325504] -strand breaks and re -ligation. Inhibition of 
TOP1 stabilizes the complex between TOP1 and DNA which collides with moving DNA 
replication forks, eventually leading to double stranded DNA damage and ultimately cell death. 
It is well established that increased cytotoxicity of TOP1 inhibitors is associated with sustained 
exposure. Liposomal delivery of irinotecan, a prodrug of SN -38, pr ovide a mechanism for 
sustained inhibition of TOP1.  
Nonclinical data support the use of irinotecan liposome injection in SCLC, as described in 
Section 1.2.4 . The biology of SCLC is well -matched with the irinotecan liposome injection 
proposed mechanism of action, which involves liposomal deposition in tumor tissue through 
leaky vasculature, followed by [CONTACT_485967] -38. Irinotecan liposome 
injection deposits in and delivers irinotecan to tumors in SCLC models to a similar or greater 
extent than other tumor types and results in therapeutically relevant levels of tumor SN -38. 
Irinotecan liposome injection demonstrated anti -tumor activity in multiple xenograft models of 
SCLC at clinically -relevant dose levels and, importantly, demonstrated greater anti -tumor 
activity than irinotecan and topotecan.  Finally, irinotecan liposome injection demonstrated 
greater anti -tumor activity than irinotecan and topotecan in a model of second line SCLC in 
which tumor has previously progressed on prior carboplatin plus etoposide.  
Irinotecan liposome injection has no t yet been evaluated in clinical trials in patients with SCLC. 
However , the availability of clinical efficacy data for non -liposomal irinotecan monotherapy in 
this indication (described in Section 1.1), the overlappi[INVESTIGATOR_485934] 
(non-liposomal) irinotecan and irinotecan liposome injection [mediated through the same active 
SN-38) metabolite] and the anticipated predictable safety profile o f irinotecan liposome 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624282] that extrapolation from previous experience with non -liposomal 
irinotecan is an appropriate means of identifying a suitable starting dose level of irinotecan 
liposome injection in the context of SCLC. Ba sed on these considerations, the current study 
comprises an initial non -randomized portion (safety run -in) where patients will be treated with 
irinotecan liposome injection at a dose level of 85mg/m2 every 2 weeks in Part 1 in order to 
ensure that the safe ty of the proposed regimen (85 mg/m2) is acceptable prior to proceeding to 
the randomized Part 2 of the study. Additional data (discussed in Section 1.2.2 ) derived from 
clinical experience of irinotecan liposome injection in malignant indications other than SCLC, 
at dose levels comparable to, or in excess of those included within the current study, further 
support the proposed dose level of 85mg/m2.  
However, a contingency has been included for subsequent safety evaluation of a lower dose 
level of irinotecan liposome injection (70 mg/m2 every 2 weeks) should the 85 mg/m2 level 
prove to have unacceptable toxicity. Additionally, preliminary efficacy will  be defined in a total 
of [ADDRESS_624283] been incorporated into Part  2 
through a futility  analysis for OS combined with a prospective program of safety review by [CONTACT_26756] (DMC). Therefore, the study design facilitates rapid 
progression to a registration directed trial phase in this difficult to treat disease, wh ilst retaining 
sequential ongoing risk -benefit assessment during the conduct of the study, thus protecting 
patient safety and preserving the scientific integrity of the study.  
1.2.2 Rationale for Evaluating 85 mg/m2 Every 2 Weeks Monotherapy Dose of Irinotecan 
Liposome Injection  
The rationale for evaluating 85 mg/m2 free base dose every 2 weeks is supported by [CONTACT_485968] -liposomal irinotecan HCl, the clinical pharmacology of irinotecan liposome 
injection and data from clinical studies of irinotecan liposome injection.  
In early clinical studies of non -liposomal irinotecan HCl there is convincing evidence of a 
dose-response relationship ( Van Cutsem, 2005 ). In phase I studies of non -liposomal irinotecan 
HCl, increased tumo r responses were seen at higher doses ( Merrouche, 1997 ; Abigerges, 1995 ) 
and the dose -efficacy relationship has been further supported by [CONTACT_485969] (PK) analyses ( Chabot, 1995 ). 
The clinical pharmacology of irinotecan liposome injection indicates a dose -efficacy 
relationship supporting the evaluation of a higher than currently approved biweekly dose of 
70 mg/m2 (approved in combination with 5 -fluorouracil (5 -FU) and leucovorin (LV)). In 
metastatic pancreatic cancer, patients in the NAPOLI -1 study treated with irinotecan liposome 
injection 70  mg/m2 + 5-FU/LV, a higher exposure of unencapsulated SN -38 (uSN38; in the 
form of time above effe ctive concentration and average concentration) was found to have 
association with better efficacy in terms of OS, PFS, and ORR therefore, a higher dose of 
irinotecan liposome injection has the potential for further improved efficacy. In the irinotecan 
liposome injection arm of the randomized phase II PEP0206 study, 44 patients with metastatic 
gastric cancer were treated with irinotecan liposome injection monotherapy dosed at 100  mg/m2 
free base every 3  weeks. The ORR in the intent to treat (ITT) population in the irinotecan 
liposome injection arm was 13.6%. Intra -patient dose escalation was permitted for patients who 
tolerated 100 mg/m2 irinotecan liposome injection (every 3 weeks) without Grade 2 or above 
toxicity. Five patients received 130 mg/m2 free base  dose after first receiving the 100 mg/m2 
dose. Three out of the five patients exhibited confirmed partial response and two had stable 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624284] OBER 2021  
 
Proprietary and Confidential  Page 29  
 disease. These results are suggestive of dose -efficacy relationship and provide further support 
for evaluation of an 85  mg/m2 every 2 weeks regimen of irinotecan liposome injection in this 
trial in patients with SCLC.  
Clinical studies of irinotecan liposome injection and clinical pharmacology support the 
potential safety of the 85 mg/m2 dose of irinotecan liposome injection administered every two 
weeks. In a phase I study (PI[CONTACT_177020] -CRC -01), in patients with advanced refractory colorectal 
carcinoma, a dose of irinotecan liposome injection monotherapy of 86 mg/m2 every 2 weeks 
was well tolerated and active. In a cohort of 6 patient s treated at this dose level, there was 1  dose 
limiting toxicity (DLT) (Grade  3 diarrhea) and 1 partial response noted (see Section 1.3.2 ). 
1.2.[ADDRESS_624285] -line chemotherapy and in the 
European Union (EU) for patients with relapsed SCLC for whom re -treatment with the first -line 
regimen is not considered appropriate, and its widespread clinical use in this  disease setting. In 
patients with relapsed or refractory SCLC, the administration of second line single agent 
chemotherapy, including topotecan, is recommended by [CONTACT_94497] ( 2020 NCCN guidelines ) 
and by [CONTACT_485970] o f Clinical Oncology guidelines ( Rudin, 2016 ). The European 
Society of Medical Oncology guidelines ( Früh, 2013 ) recommend oral or intravenous topotecan 
for patients who have platinum -resistant or  sensitive relapsed SCLC. Intravenous topotecan is 
approved in the US for patients with SCLC that are platinum -sensitive and have progressed on 
first-line therapy ( Topotecan USPI ), and in the EU for patients with relapsed SCL C for whom 
re-treatment with the first -line regimen is not considered appropriate ( Topotecan SmPC ).  
It is worth noting that the use of intravenous topotecan for platinum -sensitive patients is 
potentially controversial due to  guidelines suggesting re -challenge with the first line regimen. 
Although both the ESMO guidelines ( Fruh et al, 2013 ) and the [ADDRESS_624286] line regi men when relapse occurs after 6 months, the level of 
evidence for this recommendation is based on studies conducted in the 1980s ( Postmus, 1987 ; 
Giaccone, 1987 ) with small numbers of patients (l evel V evidence in the ESMO guideline, 
e.g. studies without control group, case reports, experts’ opi[INVESTIGATOR_1649]). Additionally, a recent study 
by [CONTACT_485965], et al (2015)  showed that relapsed patients re -challenged with the first line regimen 
had similar outcomes to those receiving monotherapy chemotherapy. Finally, intravenous 
topotecan has been used as a control arm in recently completed phase II and phase III studies 
in second -line SCLC (cabazitaxel vs. intravenous topotecan ( Evans, 2015 ) and amrubicin vs. 
intravenous topotecan ( von Pawel, 2014 )) indicating both its acceptability to the clinical 
community and the feasibility of enrolling a study with this control arm.  
Oral topotecan will not be allowed in the control arm, as intravenous topotecan is the 
predominantly prescribed topotecan formulation (>90%) in US clinical practice 
(Intercontinental Marketing Services claims data) and appears to be the preferred topotecan 
formulation in clinical practice outside of the US as well, as indicated to the Sponsor by [CONTACT_485971]. Finally, intravenous topotecan will result in greater control over 
compliance than oral administration and will further minimize heterogen eity in the control arm.  
1.2.4 Nonclinical Data Supporting Evaluation of Irinotecan Liposome Injection in Small 
Cell Lung Cancer  
The mechanism of action of irinotecan liposome injection comprises extended plasma 
circulation (as compared to non -liposomal irinotec an HCl), deposition into tumor tissue via the 
vasculature, uptake by [CONTACT_485972], release of drug and conversion of irinotecan to its active 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624287] OBER 2021  
 
Proprietary and Confidential  Page 30  
 metabolite SN -38. Sustained tumor -derived SN -38 delivery by [CONTACT_485973] T OP1 inhibition, resulting in subsequent DNA damage and tumor cell death 
(Kalra, 2014 ).  
The following in vitro  and in vivo  data highlight aspects of the proposed mechanism of action 
of irinotecan liposome injection and illustrate the potential activity of irinotecan liposome 
injection in comparison to non -liposomal irinotecan and topotecan in models of SCLC.   
[IP_ADDRESS]  Extended Exposur e of SN -[ADDRESS_624288] various SCLC cell lines was investigated 
using in vitr o growth and viability assays. Figure 1 shows that treatment with SN -38 decreased 
cell viability by >  90% in SCLC cell lines (DMS114, NCI -H1048). Effec tive cell growth 
inhibition was observed between 1 -10 nM, with increased cell killing with increased time of 
exposure. The concentration range of SN -38 in which cell killing begins to occur coincides with 
the amount of SN -38 measured from tumor biopsies ta ken from patients with various solid 
tumors 72 hours after administration of irinotecan liposome injection (range:  3 - 163 nM; 
Ramanathan, 2014 ), which is depi[INVESTIGATOR_6517] [ADDRESS_624289] 
that the prolonged duration of SN -38 TOPO1 inhibition in tumors due to irinotecan liposome 
injection pharmacological characteristics would be likely to res ult in activity in patients with 
SCLC.  
Figure 1: Increased SN -38 Exposure Leads to Increased Cell Death In Vitro  
1 0-31 0-21 0-11 001 011 021 [PHONE_10142] 55 07 51 0 01 2 5 D M S -1 1 4  (S C L C )
C o n c e n tra tio n  (n M )C e ll N u m b e r (% )
1 0-31 0-21 0-11 001 011 021 [PHONE_10142] 55 07 51 0 01 2 5 N C I-H 1 0 4 8  (S C L C )
C o n c e n tra tio n  (n M )C e ll N u m b e r (% )[ADDRESS_624290] time points. 
Range of SN -38 detected in tumor biopsies (grey box) from a previous clinical study ( Ramanathan, 2014 ) in 
patients with various solid tumors is overlaid on the time -dependent SN -38 growth inhibition curves. Cell 
growth inhibition kinetics of SN -38 in 2 SCLC cell lines (DMS -114 and NCI -H1048) using an IncuCyte® 
ZOOM System over a time -course of up to 88 hours.  
[IP_ADDRESS]  Irinotecan Liposome Injection Effectively Delivers Irinotecan and SN -38 to SCLC 
Tumors In Vivo  
Liposo mes require leaky vasculature to gain entry into tumor tissue. Greater than 80% of SCLC 
tumor lesions express detectable levels of vascular endothelial growth factor (VEGF) 
(Dowell,  2004 ). VEGF expression is involved in angio genesis and vessel permeability that may 
indicate the ability to achieve effective liposome delivery into SCLC tumors. Macrophages are 
the primary cell type believed to phagocytose irinotecan liposome injection within the tumor 
tissue. While little data on  macrophages in SCLC are available, macrophages have been 
detected in SCLC biopsy samples and ranged from few cells to heavy infiltration of the tissues 
(Hedbrant,  2015 ). Macrophages express high levels of carboxylesterase  2, which is one of the 
enzymes needed to convert irinotecan to its active metabolite, SN -38. 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624291] OBER 2021  
 
Proprietary and Confidential  Page 31  
 The ability of irinotecan liposome injection to deliver irinotecan and SN -38 into tumors was 
evaluated in SCLC cell -line derived xenograft (CDX) models (NCI -H1048, D MS-114, H841) 
in comparison to CDX and patient -derived xenograft models of other tumor types. Irinotecan 
liposome injection was administered intravenously to xenograft tumor bearing mice. At 
[ADDRESS_624292] administration, mice were sacrificed and tumors wer e harvested. Irinotecan and 
SN-38 levels in tumors were measured by [CONTACT_116141] (HPLC). 
Figure [ADDRESS_624293] similar or higher levels 
of irinotecan liposome injection deposition, as assessed by [CONTACT_485974], than other tumor 
types. Furthermore, analysis of SN -38 levels indicates that increased irinotecan delivery was 
associat ed with increased levels of SN -38. These findings are consistent with a proposed 
mechanism of liposome deposition and local conversion of irinotecan to SN -38 within the 
tumor.  
Figure 2: Irinotecan Liposome Injection -mediated Tumor Delivery of Irinotecan and SN -38 In Vivo  
H 1 0 4 8
D M S - 5 3
H 8 4 1
C T G - 0 1 5 8
A 5 4 9
H 1 5 7
L o V o
H T - 2 9
C T G - 0 0 6 2
C T G - 0 0 7 9
A s P C - 1
C T G - 0 2 8 3 C T G - 0 2 8 8
A 2 7 8 0
C T G - 0 2 5 2
M D A - M B - 2 3 1
H C C 3 8
S K - E S - 10 . 0 10 . 111 01 0 0T u m o r  I r i n o t e c a n  @  2 4  h  ( % I D / g )B r e a s t
S C L C C o l o r e c t a lP a n c r e a t i c
O v a r i a n E w i n g sN S C L C
1 0 0 0 1 0 0 0 0 1 0 0 0 0 011 01 0 01 0 0 01 0 0 0 0
T u m o r  I r i n o t e c a n   @  2 4  h   ( n g / g )T u m o r  S N - 3 8  @  2 4  h  ( n g / g )H 8 4 1
H 1 0 4 8
D M S - 5 3A B
 
(a) Irinotecan delivered by [CONTACT_485975] [ADDRESS_624294] administration 
in various mouse xenograft models, as shown. Data were normalized to injected dose per tumor weight. 
Shown here includes data obtained from SCLC CDX models. (B) Tumor irinotecan and tumor SN -[ADDRESS_624295] administration for 
three SCLC xenograft models. Increased level s of SN -38 were associated with increased levels of tumor 
irinotecan delivered by [CONTACT_485976].  
[IP_ADDRESS]  Irinotecan Liposome Injection Has Improved Anti -Tumor Activity as Compared to 
Non-liposomal Irinotecan HCl and Topotecan In Vivo  
The activity o f irinotecan liposome injection, non -liposomal irinotecan and topotecan were 
directly compared at clinically relevant doses in two CDX models. Clinically relevant doses 
were  calculated by [CONTACT_485977] (NCI) guidelines. Figure 3 presents tumor growth kinetics of mice bearing SCLC 
xenograft tumors that were treated weekly with irinot ecan liposome injection, non -liposomal 
irinotecan or topotecan. In both the DMS -114 and NCI -H1048 models, irinotecan liposome 
injection displayed significantly greater anti -tumor activity than both non -liposomal irinotecan 
and topotecan. Furthermore, 10 ou t of 10 mice treated in NCI -H1048 model treated with 
irinotecan liposome injection experienced complete regressions of their tumors as compared to 
0 out of 10 mice treated with topotecan.  

IPSEN GROUP PROTOCOL MM -398-01-03-04
VERSION 8.0 –[ADDRESS_624296] OBER 2021
Proprietary and Confidential Page 32Figure 3:Anti -tumor Activity of Irinotecan Liposome Injection, Non -liposomal Irinotecan and 
Topotecan at Clinically Relevant Doses in DMS -114 and NCI -H1048 SCLC Xenograft Models
A B
NOD/SCID mice with (A) DMS -114 or (B) NCI -H1048 SCLC xenograft tumors were treated with IV irinotecan 
liposome injection, IV irinotecan, IP topotecan or vehicle control. Vertical dotted lines indicate start of weekly 
dosing. Irinotecan liposome injection dose is shown on irinotecan HCl basis. Following treatment, irinotecan 
liposome injection displayed significant anti-tumor activity compared to topotecan (p <0.0001 for DMS -114 on 
day 52 and p <0.0001 for NCI -H1048 on day 59; non -parametric t -test) and irinotecan (p <0.0001 for DMS -114 
on day 65 and p<0.0001 for NCI -H1048 on day 84; non -parametric t -test).
Note: nal -IRI = irinotecan liposome injection or liposomal irinotecan
Finally, the activity of irinotecan liposome injection, non -liposomal irinotecan and topotecan 
were directly compared in a second line setting of SCLC. Mice bearing NCI -H1048 SCLC 
tumors were tre ated with a carboplatin plus etoposide, a first line regimen in SCLC. Once the 
tumors escaped growth control by [CONTACT_485978], mice were randomized to either 
continue treatment with carboplatin plus etoposide or switch to second line treatment with either 
irinotecan liposome injection, non -liposomal irinotecan or topotecan. As shown in Figure 4, 
irinotecan liposome injection had anti -tumor a ctivity in the second line setting and, furthermore, 
had significantly greater anti -tumor activity than both non -liposomal and topotecan.
Figure 4:Anti -tumor Activity of Irinotecan Liposome Injection, Non -Liposomal Irinotecan and 
Topotecan in a Preclinical Model of Second Line SCLC
[ADDRESS_624297] im p la n ta tio nTum or  Vol um e ( m m3)
1L Cont r ol
1L Car bopl at i n + Et oposi de
2L Cont r ol
2L Car bopl at i n + Et oposi de
2 L  N a l-IR I (1 6  m g /k g /w k , d 1 )
2L I ri not ecan ( 33 m g/kg/w k,  d1)
2L Topot ecan ( 1. 66 m g/kg/w k,  d1- 2)
NOD/SCID mice with NCIH1048 SCLC xenograft tumors were treated weekly with the combination of 
30mg/kg carboplatin plus 25 mg/kg etoposide. When tumor reached approximately 12 00 mm3, mice were 
randomized to receive weekly treatment with topotecan (1.66 mg/kg/wk administered IP in equal fractions on 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624298] OBER 2021  
 
Proprietary and Confidential  Page 33  
 days 1 and 2), non -liposomal irinotecan (33 mg/kg/wk administered IV on day 1) irinotecan liposome injection 
(16 mg/kg/wk administe red IV on day 1), continue treatment with carboplatin plus etoposide or vehicle control. 
Vertical dotted lines indicate start of weekly dosing. Irinotecan liposome injection dose is shown on irinotecan 
HCl basis. After tumors progressed on first -line treat ment with carboplatin plus etoposide, irinotecan liposome 
injection displayed significant anti -tumor activity compared to topotecan and irinotecan (p=0.0002 on day  70 
and p=0.0002 on day 84 for topotecan and irinotecan, respectively).  
Note: nal -IRI = irino tecan liposome injection or liposomal irinotecan  
1.3 Irinotecan Liposome Injection Clinical Experience  
Irinotecan liposome injection has been studied in patients with solid tumors, including cervical 
cancer, gastric cancer, pancreatic cancer, and colorectal cancer. Irinotecan liposome injection 
under the tradename [CONTACT_486027]®, was approved in the [LOCATION_002] and Taiwan in [ADDRESS_624299] cancer and several pediatric 
solid tumors, including Ewing's sarcoma, rhabdomyosarcoma, neuroblastoma, and 
osteosarcoma. Details of completed and ongoing studies are presented in the Investigator's 
Brochure (IB).  
1.3.1 United  States Food and Drug Administration Approval of ONIVYDE® and 
Determination of Irinotecan Liposome Injection Strength  
ONIVYDE® (irinotecan liposome injection, liposomal irinotecan, or nal -IRI) is formulated with 
irinotecan hydrochloride trihydrate into a liposomal dispersion for intravenous use.    
ONIVYDE® in combination with 5 -FU/LV was approved by [CONTACT_48354] (FDA) in October 2015 for the treatment of patients with metastatic 
adenocarcinoma of the pancreas after disease progressio n following gemcitabine -based 
therapy. Prior to FDA approval of ONIVYDE®, the compound was identified as MM -398 (or 
PEP02),  and MM -[ADDRESS_624300] ied the USP Salt Policy; therefore, the 
drug strength of ONIVYDE® in the [LOCATION_002] is now expressed in terms of the active moiety 
rather than the salt.  
Converting ONIVYDE® dose from irinotecan hydrochloride trihydrate salt base (as 
traditionally has b een described for MM -398 until the US approval) to a dose based on 
irinotecan free base is accomplished by [CONTACT_485979] (677.19  g/mole) with the molecular weight of irinotecan free base 
(586.68 g/ mole), which results in a conversion factor of 0.866. Therefore, the 80 mg/m2 based 
on irinotecan hydrochloride trihydrate salt is equivalent to a 69.3 mg/m2 based on irinotecan 
free base. This value was rounded to 70  mg/m2 in the [LOCATION_002] Product Inf ormation to 
minimize any potential dosing errors.  
ONIVYDE® was approved by [CONTACT_3558] (EMA) in October 2016 for the 
treatment of metastatic adenocarcinoma of the pancreas, in combination with 5 -FU/LV, in adult 
patients who have progresse d following gemcitabine based therapy. As approved in the EU, 
ONIVYDE® dosing strength is expressed on the basis of irinotecan hydrochloride trihydrate 
salt. Therefore, the dose of ONIVYDE® described in the Summary of Product Characteristics 
(SmPC) is 80 m g/m2 based on irinotecan hydrochloride trihydrate salt (versus 70 mg/m2 when 
expressed on irinotecan free base).  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624301] OBER 2021  
 
Proprietary and Confidential  Page 34  
 For the purpose of this protocol, all applicable ONIVYDE® (irinotecan liposome injection or 
liposomal irinotecan or nal -IRI) dose regimens, des criptions and modifications are based on the 
irinotecan free base.  
1.3.2 Clinical Pharmacology  
[IP_ADDRESS]  Association Between Exposure and Efficacy with Irinotecan Liposome Injection  
Population PK analysis of data from the irinotecan liposome injection + 5 -FU/LV arm in th e 
NAPOLI -1 trial (patients with advanced metastatic pancreatic cancer) ( Adiwijaya et al, 2016 ) 
was suggestive of a relationship between exposure and efficacy. In the irinotecan liposome 
injection+5 -FU/LV arm of NAPOLI -1, long er OS and PFS were associated with longer time of 
exposure of un -encapsulated SN -38, the active metabolite of irinotecan, above a threshold 
(>0.03  ng/mL) and with higher AUC of un -encapsulated SN -38. Longer duration of exposure 
of un -encapsulated SN -38 abo ve 0.03  ng/mL was associated with a higher probability of 
achieving an objective response in the irinotecan liposome injection+5 -FU/LV arm.  
[IP_ADDRESS]  Association between Exposure and Safety with Irinotecan Liposome Injection  
The exposure -safety relationship for irin otecan liposome injection is based on population PK 
analysis of data from 353 patients ( Adiwijaya et al, 2016 ). Higher total irinotecan maximum 
serum concentration (C max) was associated with higher probability of observing Grade  3 or 
higher diarrhea. Higher C max of un -encapsulated SN -38 was associated with higher probability 
of both incidence and severity of neutropenia treatment -emergent adverse events (TEAEs), with 
different probabilities of observing Grade 3 or higher neutropenia with and without 
co-administration with 5 -FU/LV.  
1.3.3 Clinical Data Supporting Evaluation of Dose  
[IP_ADDRESS]  Clinical Data Supporting Evaluation of 85 mg/m2 Every 2 Weeks  
The maximum tolerated dose of irinotecan liposome injection in a Phase 1 study was established 
to be 104 mg/m2 (dose ex pressed as free base) administered every three weeks.  
The safety of irinotecan liposome injection monotherapy given every 2 weeks was evaluated in 
an open -label phase I dose finding study conducted in Taiwanese patients with colorectal cancer 
“Phase I and  Pharmacokinetic Study of Biweekly PEP02 (Liposome Irinotecan) in Patients with 
Metastatic Colorectal Cancer Refractory to First -line Oxaliplatin -based Chemotherapy 
(PI[CONTACT_177020] -CRC -01)”.  
The starting dose level was 69 mg/m2 and escalated to 77 and then to 86 mg /m2 (doses expressed 
as irinotecan free base).  
Eighteen patients were enrolled at the dose levels of 69, 77 and 86 mg/m2 of irinotecan liposome 
injection (doses expressed as irinotecan free base) with 6 patients at each dose level. Of the 
total of 18 patie nts, the average age was 58.6 years old; 9 (50%) patients were female and 
9 (50%) patients were male. The average weight at screening was 61.8 kg. Twelve (66.7%) and 
6 (33.3%) patients had an ECOG 0 and 1 performance status, respectively. All patients had 
received prior oxaliplatin -based treatment for their metastatic colorectal cancer. All patients 
were Chinese.  
A total of 109 cycles of treatment (2 weeks per cycle in this study) were administered, with a 
mean of 6 cycles per patient (range 2 -18, median 4 cycles/patient). There was 1  DLT at each 
dose level (Grade 3 neutropenia with infection and Grade 3 diarrhea).   
The most commonly reported TEAEs occurring in >20% of patients were diarrhea, decreased 
appetite, and alopecia (each in 16 patients, 88.9%); anemia and nausea (each in 14 patients, 
77.8%); vomiting (13 patients, 72.2%); mucosal inflammation (12 patients,  66.7%); 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624302] OBER 2021  
 
Proprietary and Confidential  Page 35  
 leukopenia, constipation (each in 11 patients, 61.1%); neutropenia (10  patients, 55.6%), fatigue 
(9 patients, 50.0%); alkaline phosphatase increased, hypokalemia (each in 8 patients, 44.4%); 
dizziness (7 patients, 38.9%); abdominal distension, pai n (each in 6  patients, 33.3%); 
abdominal pain, urinary tract infection, gamma -glutamyl transferase increased, insomnia, skin 
hyperpi[INVESTIGATOR_371] (each in 5 patients, 27.8%); abdominal pain upper, influenza like illness, 
aspartate aminotransferase (AST) incre ased, weight decreased, cholinergic syndrome, cough 
(each in 4 patients, 22.2%). Overall, 13 patients (72.2%) experienced at least one (TEAE) of 
Grade [ADDRESS_624303] common Grade 3 or TEAEs were vomiting (5  patients, 
27.8%) and diarrhea and  nausea (each in 3 patients, 16.7%).  
In terms of efficacy, there were 4 partial responses (22%), two in the 69 mg/m2 (dose expressed 
as irinotecan free base) cohort, and 1 in each of the other two cohorts.  
In conclusion, irinotecan liposome injection 69 – 86 mg/m2 (doses expressed as irinotecan free 
base, corresponding to 80 -100 mg/m2 irinotecan liposome injection strength expressed as 
irinotecan hydrochloride) given every two weeks appeared generally well tolerated and active 
when administered as a single agent in patients with advanced colorectal carcinoma refractory 
to first line oxaliplatin -based regimens.  
[IP_ADDRESS]  Clinical Data to Justify 70 mg/m2 Every 2 Weeks in Part 2  
Based on the safety and tolerability of irinotecan liposome injection monotherapy observed at 
the two different dose levels of 85 mg/m2 and 70 mg/m2 (free base equivalent) in Part  1, the 
recommended dose was determined to be 70  mg/m2 administered every two weeks.  
The assessment of the available safety and efficacy data from Part 1 is presented in detail in the 
IB. Thirty patients were treated for more than 12  weeks in Part  1.  
Five patients received irinotecan liposome injection at 85  mg/m2 on a bi -weekly basis. This 
dose was deemed not tolerable due to DLT (defined in Section  3.1.1 ). Once the first two DLT 
events were reported in two patients in the 85  mg/m2 treatment group, enrollment at 85  mg/m2 
dose level was stopped and dose reduction to  70 mg/m2 was recommended for patients who 
continued to receive treatment in the 85  mg/m2 treatment group, (total of five patients), and the 
70 mg/m2  treatment group was initiated.  
As presented in the IB at an interim data cut -off of 08 May 2019, 25 patients received irinotecan 
liposome injection at 70  mg/m2 on a biweekly basis. The 70 mg/m2 dose was deemed tolerable: 
40% of patients at the 70  mg/m2 dose level experienced Grade [ADDRESS_624304] common gastroin testinal adverse event.  
Preliminary efficacy at 70  mg/m2 dose level identified 11 patients with partial responses 
(ORR  44%). Best overall response BOR (partial response +stable disease) was 72%.  
Part 1 demonstrated encouraging anti -tumor activity of irinot ecan liposome injection at 
70 mg/m2 in patients with SCLC (ORR: 44%, BOR: 72%). Irinotecan liposome injection at 
70 mg/m2 was generally well tolerated.  
1.3.4 Clinical Data in UGT1A1*28 Homozygous Patients  
Human uridine diphosphate glucuronosyl transferase (UGT) 1A1 is the enzyme that detoxifies 
neurotoxic bilirubin by [CONTACT_485980] a critical role in the 
detoxification and excretion of endogenous and exogenous lipophilic compounds mainly in the 
liver and gastrointestinal tract. UGT 1A1 is responsible for the glucuronidation of SN -38 to 
SN-38G as part of the mechanism of SN -38 clearance. UGT1A1*28 7/7 homozygosity results 
in reduced UGT enzymatic activity and may result in elevated SN -38 levels and thereby 
[CONTACT_485981] -38 mediated toxicity following treatment with Camptosar® 
(non-liposomal irinotecan) ( Camptosar® USPI 2019 ). 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624305] evaluated the association between UGT1A1*[ADDRESS_624306] the 
associations are dose and inter -patient variability dependent. Higher increase in SN -38 
concentrations were observed for UGT1A1 *1/*28 (6/7) (heterozygous) and UGT1A1 *28/*28 
(7/7) (homozygous) ge notypes compared to UGT1A1 *1/*1 (6/6) (wild type) genotype when 
non-liposomal irinotecan was administered at a high dose of 300 mg/m2 (Iyer 2002 ) than when 
it was administered at a low dose of 20 mg/m2 (Stewart 2007 ). Although absolute neutrophil 
count (ANC) nadirs significantly correlated with SN -38 exposure at the higher dose of 
300 mg/m2 of non -liposomal irinotecan, the difference between the severe grades of 
neutropenia (Grade 3 higher or ab ove) were not found to be statistically significant amongst the 
three genotypes ( Iyer 2002 ). Evaluation of lower dosing regimens of non -liposomal irinotecan 
(15 to 75  mg/m2 daily for 5  days for 2  weeks) found that despi[INVESTIGATOR_485935] -38 
concentrations observed, UGT1A1 genotype was not a significant single predictor for 
irinotecan toxicity. In a study of 66  patients who received single -agent non -liposomal irinotecan 
(350 mg/m2 every 3 weeks), the incidence of Grade 4 neutropenia in patients heterozygous for 
UGT1A1*28 (6/7) and homozygous (7/7) for the UGT1A1*28 was 12.5% and up to 50% 
respectively ( Camptosar® USPI  2019 ). In a subsequent study, ass ociation between 
UGT1A1*28 homozygosity and hematological toxicity was observed only in patients treated 
with >150  mg/m2 non-liposomal irinotecan. By [CONTACT_22242], at lower dose of non -liposomal 
irinotecan (100 to 125  mg/m2 every week) similar hematological to xicities were observed for 
both UGT1A1*28/*28 and those with a UGT1A1*1/*28 or UGT1A1*1/*1 ( Hoskins  2007 ). 
Publications from prospective trials of 250 metastatic colorectal cancer patients studying the 
FOLFIRI regimen (irinot ecan dose of 180 mg/m2) and the role of UGT1A1*28 polymorphism 
in toxicity and efficacy did not support a dose reduction in patients with UGT1A1*[ADDRESS_624307] that the data are insufficient for recommending specific dose 
adjustments b ased on the UGT1A1 genotype ( Toffoli 2006 ). More recently, a study in 
2982  patients with colorectal cancer from trial PETACC -3, found that a complex set of risk 
factors is involved in the development of toxicity, including UG T1A1. However, other 
parameters that are readily available in clinical practice, notably sex, age and performance 
score, were stronger predictors than the UGT1A1*28 genotype ( Tejpar 2018 ). 
In patients treated with irinotecan liposome injection, the association between UGT1A1*28 
(7/7) homozygosity, SN -38, and hematologic toxicity is primarily obtained from the NAPOLI -1 
study, where UGT1A1*28 homozygous patients were treated at a reduced dose (50  mg/m2 
versus 70  mg/m2 (FBE) ever y 2 weeks in combination with 5 -FU/LV, or 70  mg/m2 versus 
100 mg/m2 (FBE) every 3 weeks monotherapy). The NAPOLI -1 study Population PK results 
concluded that no significant association was observed between UGT1A1*28 homozygosity 
and SN -38 exposure. In addi tion, the UGT1A1*[ADDRESS_624308] an approximately 2% higher incidence of neutropenia Grade  3 or higher 
TEAEs compared to nonhomozygous Caucasian patients. An additional pooled Population PK 
study showed that overall exposure to SN‑38 was deemed similar between Japanese and 
non-Japanese populations with unrecognisable influence of UGT1A1 genotype. Based on these 
data, patients homozygous for UGT1A1*28, administered with the same dose of irinotecan 
liposome injection ad ministration as non -homozygous patients, do not appear to be at 
significant clinical risk of increased Grade 3 or higher neutropenia.  
Mechanistically, these data indicate that the association of UGT1A1*28 polymorphism to 
SN-38 concentration and to hematolo gical toxicity appear to depend on the incoming load of 
SN-38 to be metabolized by [CONTACT_325507]. The dose -dependent association of UGT1A1*28 
and SN -38 or neutropenia observed with Camptosar® administration is consistent with this 
hypothesis. Furthermore, li posomal encapsulation appears to spread out the incoming load of 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624309] OBER 2021  
 
Proprietary and Confidential  Page 37  
 SN-38 by [CONTACT_325508]. This is supported by a study in patients with 
advanced gastric cancer in which 100  mg/m2 irinotecan liposome injection administration 
resulted in five times lower plasma SN -38 C max as compared to 300  mg/m2 non-liposomal 
irinotecan (PEP0206) ( Roy, 2013 ). Reduced load of SN -38 may allow for  metabolism by 
[CONTACT_485982] (for example, UGT1A1*28 
homozygous patients).  
Despi[INVESTIGATOR_325442]1A1*28 homozygosity, safety, and PK, the 
irinotecan liposome injection US package inser t followed the NAPOLI -1 protocol that started 
homozygous patients at a lower dose due to the comparatively small number of patients with 
UGT1A1*28 homozygous treated with irinotecan liposome injection. Therefore, the absence 
of a relationship between UGT1A 1*[ADDRESS_624310] arting dose of irinotecan liposome injection will be the same regardless of 
UGT1A1*28 genotype. UGT1A1*28 genotype will be collected on all patients as a safety 
biomarker to further analyze the association between UGT1A1*28 homozygosity, SN -38 
concentration and toxicity. Irinotecan liposome injection dose reduction will follow the same 
dose reduction  rules for all patients regardless of UGT1A1*28 genotype. Patients with 
UGT1A1*28 homozygosity will be closely monitored for safety in comparison to the safety in 
patients with UGT1A1*28 non -homozygous status by [CONTACT_485983].  
2 OBJECTIVES  
This study will be conducted in two parts: an open -label, single -arm, safety run -in (Part  1) to 
confirm the Part 2 dose of irinotecan liposome injection, followed by a randomized, open -label 
comparison of irinotecan liposome injection an d topotecan in patients with SCLC.  
2.1 Part 1  
2.1.1 Primary Objectives  
The primary objectives of Part 1 are:  
• Describe the safety and tolerability of irinotecan liposome injection monotherapy 
administered every 2 weeks  
• To determine the irinotecan liposome injection m onotherapy dose (85 mg/m2 or 
70 mg/m2 administered every 2 weeks) for Part 2 of this study.  
2.1.2 Secondary Objectives  
The secondary objectives of Part 1 are to assess the preliminary efficacy of irinotecan liposome 
injection (at either  the 85 mg/m2 dose level or the 70 mg/m2 dose level) as determined by:  
• Objective response rate (ORR)  
• Progression free survival (PFS)  
• Overall survival (OS).  
2.1.3 Exploratory Objectives  
• To describe QTcF following treatment with irinotecan liposome injection.  
• To explore the biomarkers associated with toxicity and efficacy following treatment with 
irinotecan liposome injection in this patient population.  
• To describe the association between UGT1A1*28 and other UGT1A1 genotypes, 
SN-38 concentration and safety.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624311] OBER 2021  
 
Proprietary and Confidential  Page 38  
 • To evaluate the pharmacokinet ics and the relationship between pharmacokinetic 
exposure and efficacy and safety following irinotecan liposome injection in this patient 
population.  
• To explore patient -reported outcomes (PROs) using European Organization for Research 
and Treatment of Canc er Quality of Life Questionnaire Core 30 (EORTC -QLQ -C30) 
and European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Lung Cancer 13 (EORTC -QLQ -LC13), Patient Global Impression of 
Severity (PGI -S), Patient Global Impression of Change (PGI -C), and EuroQol 
5-dimension health status questionnaire (5 level) (EQ -5D-5L). 
2.2 Part 2  
2.2.1 Primary Objective  
The primary objective of Part 2 is to compare overall survival following treatment with 
irinotecan liposome injection with overall surviva l following treatment with intravenous  (IV) 
topotecan.  
2.2.2 Secondary Objectives  
The secondary objectives of Part 2 are to compare the following between the treatment arms:  
• Progression free survival (PFS)  
• Overall response rate (ORR)   
• Patient reported outcomes ( PRO)  
• Safety profile.  
2.2.3 Exploratory Objectives  
The exploratory objectives include:  
• To explore the biomarkers associated with toxicity and efficacy following treatment with 
irinotecan liposome injection in this patient population.  
• To describe the association between UGT1A1*28 and other UGT1A1 genotypes, SN -38 
concentration (irinotecan liposome injection treated patients only) and safety.  
• To evaluate the pharmacokinetics and the relationship between pharmacokinetic 
exposure and efficacy and safety following iri notecan liposome injection in this patient 
population.  
• To compare the rate of development/time to development of central nervous system 
(CNS) progression and development of new CNS metastases.  
• To compare time to treatment failure (TTF) between treatment arms.  
• To assess the proportion of patients with improvement in symptoms as measured by 
[CONTACT_26740] -C30/LC13 dyspnea scale  
• To assess the proportion of patients with improvement in symptoms as measured by [CONTACT_120372] -LC13 cough scale  
• To compare the effect of  irinotecan liposome injection vs. topotecan on symptoms (other 
than dyspnea and cough), functioning and global health status as measured by [CONTACT_54656] -C30, EORTC QLQ -LC13 and EQ -5D-5L. 
3 STUDY DESIGN  
3.1 Overview of Study Design  
This study will be conducted in two parts: an open -label, single -arm, safety run -in period 
(Part  1) followed by a randomized period (Part 2) assessing irinotecan liposome injection versus 

IPSEN GROUP PROTOCOL MM -398-01-03-04
VERSION 8.0 –[ADDRESS_624312] line 
therapy (see Figure 5). 
Part 1 is an open -label, single -arm, safety run -in evaluation of irinotecan liposome injection 
admin istered every 2 weeks, intended to confirm the anticipated Part 2 regimen (85 mg/m2), 
based on safety and preliminary efficacy. A contingency has been included for evaluation of 
irinotecan liposome injection at a dose level of 70 mg/m2, should the higher d ose level of 
85mg/m2 result in unacceptable toxicity.
Part 2 will be randomized, and assess the efficacy of irinotecan liposome injection versus 
IVtopotecan.
Figure 5:Study Schema
Note: ONIVYDE is also known as irinotecan liposome injection, liposomal irinotecan or nal -IRI.
Each part will consist of three stages: screening stage, treatment/active follow -up stage and 
long-term follow -up stage. Once consented, patients will enter a screening stage. Upon first 
dose of study t reatment in Part 1 or randomization (Part 2), patients will enter the 
treatment/active follow -up stage. Once a decision is made to permanently discontinue the 
patient from study treatment, a 30 -day follow -up visit will occur and the patient will enter the 
long-term follow -up stage. The stages for this trial are outlined in the schematic below.
Figure 6:Description of Treatment Stages
It is intended that all patients in Parts 1 and 2 will be treated until progressive disease or 
unacceptable toxicity. Patients may take a treatment holiday and resume study treatment under 
certain instances. Detailed rule for pausing and resuming study treatment can be found in 
Section 6.2.1 . Cross -over between treatment arms is not permitted.
Upon permanent discontinuation of study treatment (defined as patients with progressive 
disease whilst receiving study treatment and/or those assessed by [CONTACT_485984]), patients will return to the 
study site for a [ADDRESS_624313].
3.1.1 Part 1
Part 1 is an open -label, single -arm, safety run -in evaluation of irinotecan liposome injection 
administered every 2 weeks, intended to confirm the anticip ated Part 2 regimen (85 mg/m2), 
based on safety and preliminary efficacy. A contingency has been included for evaluation of 

I P S E N G R O U P  P R O T O C O L M M -3 9 8 -0 1 -03-0 4  
V E R SI O N 8. 0 – 0 7 O C T O B E R 2 0 2 1  
 
Pr o prietar y a n d C o nfi de ntial  P a ge 4 0   
 iri n oteca n li p os o me i njecti o n at a d os e le vel of 7 0 m g/ m 2, s h o ul d t he hi g her d ose l e vel of 
8 5  m g/ m 2 res ult i n u nacce pta ble t o xicit y. At eit her d ose le vel of iri n oteca n li p os o me i njecti o n 
u p t o 2 4 patie nts will be e nr olle d.  
A q ualit y of life assess me nt will be perf or me d usi n g t h e E O R T C -Q L Q -C 3 0, 
E O R T C -Q L Q -L C 1 3, P GI -S, P GI -C a n d t he E Q -5 D -5 L i n Part 1. All  patie nt -re p ort i nstr u me nts 
will be a d mi nistere d at scree ni n g a n d pri or t o d osi n g at 6 -w ee k i nter vals ( pri or t o a n y ot her 
assess me nt pr oce d ure) f oll o wi n g start of treat me nt, at treat me nt disc o nti n uati o n a n d at t he 
3 0 -da y f oll o w -u p visit. T he P GI -C is n ot i ncl u de d i n t he scree ni n g assess me nt.  
T he safet y assess me nt a n d t he c orres p o n di n g r ule of e x pa nsi o n will be c o n d ucte d acc or di n g t o 
a “ 6 + 6 ” desi g n f oll o we d b y e nr oll me nt of a n a d diti o nal 1 2 patie nts (as descri be d bel o w). 
Patie nts will i nitiall y be treate d wi t h iri n oteca n li p os o me i njecti o n 8 5 m g/ m [ADDRESS_624314] 2 8  da ys 
of treat me nt ( or u p t o [ADDRESS_624315] u d y treat me nt if t here is a tr eat me nt 
dela y d ue t o n o n -D L T rel ate d reas o ns).  
 
• A m o n g t h e first 6 p atie nts recei vi n g iri n ot eca n li p os o me i njecti o n 8 5  m g/ m 2, 
(i.e.  8 5  m g/ m 2 c o h ort) if ≤ 2  patie nts e x perie n ce a D L T, a n ot her 6  p atie nts will be 
e nr olle d. Ot her wise, e nr oll me nt i nt o t he 7 0 m g/ m 2 c o h ort  will be i nitiate d.  
• A m o n g t he first 1 2 patie nts recei vi n g iri n oteca n li p os o me i njecti o n 8 5  m g/ m 2, if 
≤2 patie nts e x perie nce a D L T, t his c o h ort will be e x pa n de d b y 1 2 a d diti o nal patie nts. 
Ot her wise, t he e nr oll me nt of t he 8 5 m g/ m [ADDRESS_624316] o p pe d a n d t he e nr oll me nt of 
t he 7 0 m g/ m 2 c o h ort will be i nitiate d.  
  
Fi g ure  7: Tre at me nt C o h orts: S afet y R u n -i n  
 
 
If t he 7 0 m g/ m 2 c o h ort is e nr olle d, t he sa me “ 6 + 6” desi g n f oll o w e d b y e nr oll me nt of a n 
a d diti o nal 1 2 patie nts, a n d t he sa me D L T g ui deli nes will be use d as t hat f or t he 8 5  m g/ m 2 
c o h ort. If ≤ [ADDRESS_624317] 1 2 p atie nt recei vi n g iri n oteca n li p os o me i njecti o n 
7 0  m g/ m 2 e x perie nce a D L T, t he n t hat d ose le vel will be dec lare d t olera ble a n d t his c o h ort will 
be e x pa n de d b y 1 2 a d diti o nal patie nts. Ot her wise, a d diti o nal d ose re d ucti o n(s) ma y be 
c o nsi dere d.  
IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624318] OBER 2021  
 
Proprietary and Confidential  Page 41  
 NOTE  that in either the 85 mg/m2 cohort or the 70 mg/m2 cohort, there will be no stoppi[INVESTIGATOR_485936]; however, DLTs will continue to be assessed among the 
additional [ADDRESS_624319] completed DLT evaluation.  
The decision of which dose to use for Part 2 will be made based on the totality of data from all 
patients treated in Part 1.  
If a decision is made to terminate the irinotecan liposome injection 85 mg/m2 dose level cohort 
(and instead initiate enrollment into the 70 mg/m2 cohort) patients who are tolerating the 
85 mg/m2 dose level will remain at that dose leve l (unless subsequent toxicity requires a dose 
modification).  
During the DLT evaluation period in either the 85 mg/m2 or 70 mg/m2 cohort,  the following 
adverse events (AEs) should be considered as DLTs if they occur during the first 28  days of 
treatment (or  14 days after the 2nd dose of study treatment if there is a treatment delay according 
to Section  6.2) and are deemed related to the study treatmen t by [CONTACT_737]:  
• Grade 4 neutropenia or thrombocytopenia that does not resolve within 7 days despi[INVESTIGATOR_485937]  
• Inability to resume subsequent treatment within 14 days of the scheduled date, due to 
drug-related toxicity  
• Grade 3 -4 neutropenia complicated by [CONTACT_411] ≥ 38.5 °C (i.e. febrile neutropenia) and/or 
by [CONTACT_80601]  
• Any Grade 4 non -hematologic toxicity with the exception of the following:  
- Fatigue/asthenia lasting < 14 days  
- Nausea and vomiting lasting ≤ 72 hours duration (only co nsidered dose limiting if 
they last > 72 hours after treatment with an optimal anti -emetic treatment)  
- Diarrhea ≤ 72 hours duration (only considered dose limiting if diarrhea lasts 
> 72 hours after treatment with an optimal anti -diarrheal regimen)  
• Grade 3 n on-hematologic toxicity with the exception of the following:  
- Any gastrointestinal disorder and dehydration (with associated signs and 
symptoms) unless Grade 3 toxicity persists despi[INVESTIGATOR_485938] > 72 hours  
- Pain unless Grade 3 toxicity  persists despi[INVESTIGATOR_3062]  
- Fatigue, fever, flu like symptoms, infections and infestations  
- Infusion reaction (and associated symptoms) unless it occurs following steroid 
premedication  
- Hepatic and kidney function abnormalities, and electr olyte abnormalities unless 
they persist, despi[INVESTIGATOR_3062].  
The determination of whether an AE is considered a DLT will be made by [CONTACT_485985] (i.e. the Part 1 Investigators and the Medical Monitor(s) of the Sponsor). Other  AEs, 
not meeting the DLT criteria above, that are deemed related to study treatment can also be 
considered a DLT event at the discretion of the safety review committee. Safety review 
meetings between investigators and sponsor will occur regularly during P art [ADDRESS_624320] monthly meetings, or more frequently, if required.  
The decision on Part 2 dose level, as per Part 1 outcome, will be communicated to all 
participating investigators prior to initiating Part 2 recruitment.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624321] OBER 2021  
 
Proprietary and Confidential  Page 42  
 3.1.2 Part 2  
Approximate ly 450 eligible patients will be randomized in a 1:1 ratio between the experimental 
arm (Arm A: based on the findings of Part 1 [either 85 mg/m2 or 70 mg/m2 of irinotecan 
liposome injection]) and the control arm (Arm B: IV topotecan). Note that following a ssessment 
of the available safety and efficacy data from Part 1 the 70 mg/m2 dose was chosen for Arm A 
(see Section  [IP_ADDRESS] ). Patients will be randomi zed to the treatment arms using an Interactive 
Response Technology System (IRT) at a central location. Randomization will be stratified, 
based on the following factors:  
• Region (North America vs. Asia vs Other)  
• Platinum sensitivity (sensitive vs. resistant)  
• Performance status (ECOG 0 vs. 1)  
• Prior immunotherapy (yes vs. no)  
(Note: for platinum sensitivity, progression within [ADDRESS_624322] -line 
platinum therapy is considered “platinum resistant” and the others “platinum sensitive”. Prior  
immunotherapy sensitivity should not be confused with platinum sensitivity).  
Only region (North America vs. Asia vs. Other) and platinum sensitive vs. resistant will be used 
for the stratified efficacy analysis.  
Tumor assessments will be performed every 6  weeks (± 1 week), using the Response Evaluation 
Criteria in Solid Tumors (RECIST) guidelines Version 1.1 (Parts  1 and  2) and Response 
Assessment in Neuro -oncology Brain Metastases (RANO -BM) criteria for CNS lesions 
(Part  2). Tumor assessment at screening  and for all subsequent visits will be computed 
tomography (CT) with contrast (chest/abdomen required and pelvis [or other areas] if clinically 
indicated) and brain magnetic resonance imaging (MRI) with contrast. For patients who are 
allergic to IV contrast  or cannot tolerate IV contrast due to impaired renal function or other 
issues, a non -enhanced CT or MRI is acceptable. Each follow -up tumor assessment should use 
the same assessment method as performed at screening , unless medically contraindicated. All 
patients will have imaging of the brain at screening  and at each assessment.  Patients who 
discontinue study treatment, for reasons other than disease progression per RECIST Version  1.1 
or RANO -BM criteria (for CNS lesions, Part 2) should continue to be foll owed with the same 
schedule of tumor assessments (every 6  weeks ± 1 week) until radiological documentation of 
progressive disease.  
Progressive disease will be determined by [CONTACT_485958]/or by [CONTACT_69804], to ensure optimal and ti mely medical management. The Sponsor will collect and 
store all tumor assessment images on all patients throughout the study. An independent central 
review of the scans will be performed at the discretion of the Sponsor to support potential early 
filing to  regulatory authorities. All patients will be followed at least monthly for survival status 
until death, loss to follow -up or study closure, whichever comes first.  
A quality of life assessment will be performed using the EORTC -QLQ -C30, 
EORTC -QLQ -LC13, PGI -C, PGI -S, and the EQ -5D-5L in Part 2. Although the PGI -C and 
PGI-S are not specified as exploratory objectives in Part 2, they will serve as anchors for 
deriving a within -patient meaningful change threshold in Part 2. All patient -reported outcome 
(PRO) ins truments will be administered at screening and prior to dosing at 6 -week intervals 
(and prior to any other assessment procedures) following start of treatment, at treatment 
discontinuation and at the 30 -day follow -up visit. Patients who discontinue study t reatment, for 
reasons other than disease progression, should continue to complete all QoL assessments every 
6 weeks until radiological documentation of progressive disease or until the start of alternative 
anti-neoplastic therapy. The PGI -C is not included  in the screening assessment. Adverse events 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624323] OBER 2021  
 
Proprietary and Confidential  Page 43  
 will be evaluated according to the NCI Common Terminology Criteria for Adverse Events 
(CTCAE) Version  5.0. For summary of AEs, events will be coded using the latest Medical 
Dictionary for Regulatory Activities ( MedDRA) dictionary (Version 21.0 or later) at the start 
of the study.  
The primary analysis is planned when at least [ADDRESS_624324] occurred in Part  2. An interim 
analysis of OS for futility is planned at approximately 29% information time, after at lea st 
[ADDRESS_624325] occurred. At the time of the interim analysis, ORR by [CONTACT_485986] (BICR) tumor assessments will be analyzed descriptively by [CONTACT_485987] 200 patients randomized in Part 2 of the study (i.e.  approximately 100 patients 
from each arm). The independent DMC will notify the Sponsor if pre -specified criteria for ORR 
are met, as detailed in the DMC charter. A supplemental interim analysis is planned on data 
collected [ADDRESS_624326] patient has been randomized based on  the ITT Population.  
Details of the ORR by [CONTACT_485988]  (SAP) .  
Pharmacokinetics  
Sparse plasma samples for PK of irinotecan liposome injection and SN -38 will be collected 
from all patients receiving irinotecan liposome injection (Part 1 and Part 2).  
Biomarker Exploratory Endpoint and Evaluation  
The exploratory endpoint comprises biobanking of samples for future analyses, among patients 
who consent for optional exploratory biomarker analysis. Analysis of biobank samples will be 
performed outside the scope of the main study and will be reported separately. Biobank samples 
may be stored for up to 15 years.  
Archival tumor tissue samples wil l be collected at baseline (C1D1), if available.  
Blood and stool samples will be collected as follows in both the ONIVYDE® and Topotecan 
arms:  
• At baseline (C1D1)  
• At week 6 (C2D1)  
• Treatment pause or Week 12 (C3D1) or end of treatment (whichever occurs first ). 
3.2 Study Duration and Study Closure  
Upon completion of screening (up to 28 days) all patients in Parts 1 and 2 will be treated until 
progressive disease or unacceptable toxicity. Each patient’s participation in the study treatment 
phase will end at the tim e of their [ADDRESS_624327] 
occurred in randomized patients.  
3.3 Safety Review Committee and Independent Data Monitoring Committee  
Safety Review Committee  
A Safety Review Committee (SRC) (comprising the Part 1 Investigators and the Medical 
Monitor(s) of the Sponsor) will be responsible for supervising review of DLT and other safety 
data during Part 1 and the decision whether or not to implement enrollment into an irinotecan 
liposome injection 70 mg/m2 cohort.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624328] OBER 2021  
 
Proprietary and Confidential  Page 44  
 The final decision to proceed to Part 2 (and the dose level of irinotecan liposome injection), 
will be made by [CONTACT_485989], after 
consideration of all available efficacy and safety data from Part [ADDRESS_624329]. The timing 
and details of subsequ ent data reviews will be detailed in the DMC charter. Items reviewed will 
include (but not limited to) safety events, results of interim analysis, any available results of PK 
testing and UGT1A1*28  genotype. Attention will be paid to determining whether any  study 
procedure needs to be modified for patients who are homozygous for UGT1A1*28.  
[ADDRESS_624330] meet the following inclusion criteria, and none of the 
exclusion criteria:  
General Inclusion Criteria  
(1) At least 18 years of age.  
(2) Able to understand and provide the study informed consent.  
(3) ECOG performance status of 0 or 1.  
(4) Life expectancy >12 weeks.  
Disease Specific Inclusion Criteria  
(5) Histopathologically or cytologically confirm ed small cell lung cancer according to the 
International Association for the Study of Lung Cancer (IASLC) histopathological 
classification. Mixed or combined subtypes according to the IASLC are not allowed.  
(6) Evaluable disease as defined by [CONTACT_150114] 1. 1 guidelines (patients with 
non-measurable lesions are eligible).  
(7) Radiologically confirmed progression on or after first -line platinum based chemotherapy 
(carboplatin or cisplatin), or chemo -radiation including platinum -based chemotherapy 
for treatment of limited or extensive stage SCLC. In addition to platinum -based regimen, 
one line of immunotherapy as monotherapy or in combination, in first or in second line 
setting is allowed.  
(8) Recovered from the effects of any prior chemotherapy, surgery, radiotherapy o r other 
anti-neoplastic therapy (recovered to Grade 1 or better, with the exception of alopecia, 
peripheral neuropathy, or ototoxicity).  
Hematologic, Biochemical and Organ Function Inclusion Criteria  
(9) During the Screening period, adequate bone marrow reserv es as evidenced by:  
(a) Absolute neutrophil count >1,500 cells/µL (1.5 x 109/L) without the use of 
hematopoietic growth factors within the immediately preceding 14  days;  
(b) Platelet count >100,000 cells/µL (100 x 109/L); 
(c) Hemoglobin >9 g/dL; transfusions are allo wed 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624331] OBER 2021  
 
Proprietary and Confidential  Page 45  
 (10) Adequate hepatic function as evidenced by:  
(a) Serum total bilirubin within normal range for the institution  
(b) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
≤2.5 x upper limit of normal (ULN) (≤[ADDRESS_624332] is acceptable if liver metastases  
are present)  
(c) Serum albumin ≥3.0 g/dL (≥30 g/L)  
(11) Adequate renal function as evidenced by a serum creatinine ≤1.[ADDRESS_624333] and creatinine 
clearance ≥40 mL/min. Actual body weight should be used for calculating creatinine 
clearance using the Cockcroft -Gault Equa tion (except for patients with body mass 
index  >30 kg/m2 when lean body weight should be used instead):  
 
(12) Electrocardiogram (ECG) without any clinically significant findings at screening, as per 
investigator’s assessment.  
Additional Disease Specific Inclusion Criteria  
(13a)  Patients with certain types of asymptomatic CNS metastases that meet ALL the following 
criteria are eligible.  
a) Patients with asymptomatic CNS metastases prior to enrollment  
b) Prior radiation for CNS metastatic disease is completed ≥4  weeks prior to 
enrollment  
c) CNS metastases that are stable or have decreased according to the post radiation 
follow -up scan that is conducted at least 4 weeks after completion of radiation 
treatment for CNS lesion.  
d) Patients have discontinued corticosteroid s or are on stable low -dose steroids 
(prednisone or equivalent 10  mg daily or less) for at least [ADDRESS_624334] meet all the inclusion criteria listed above and none  of the following exclusion 
criteria:  
General Exclusion Criteria  
(1) Any medical or social condition deemed by [CONTACT_101367] 
a patient’s ability to sign informed consent, cooperate and participate in the study, or 
interfere wi th the interpretation of the results  
(2) Pregnant or breast feeding; females of child -bearing potential must test negative for 
pregnancy at the time of enrollment based on a serum pregnancy test. Females of 
childbearing potential are defined as fertile, follow ing menarche and until becoming 
postmenopausal unless permanently sterile. Postmenopausal women are defined as those 
that have an absence of menstruation for at least 2 years. If necessary, follicle stimulating 
hormone results >50 IU/L at screening are con firmatory in the absence of a clear 
postmenopausal history. Permanent sterilization methods include hysterectomy, bilateral 
salpi[INVESTIGATOR_15559].  
Male patients must agree to use condoms during the study and for [ADDRESS_624335] agree to use a 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624336] dose of study drug.  
Disease Specific Exclusion Criteria  
(3) Patients with lar ge cell neuroendocrine lung carcinoma.  
(4) Patients who have received any of the following treatments:  
(a) Prior treatment regimens with irinotecan, topotecan or any other TOP  I inhibitor 
including investigational TOP  I inhibitors;  
(b) Retreatment with platinum -based  regimen after relapse of first -line 
platinum -containing therapy;  
(c) Any antibody -drug conjugates or molecular targeted agents (e.g. poly ADP -ribose 
polymerase inhibitors), either alone or in combination with other treatments;  
(d) More than one line of prior immunotherapy;  
(e) Any other additional regimen of prior cytotoxic chemotherapy, not described 
above.  
(5) Patients with a history (any grade) of immunotherapy induced colitis or pneumonitis 
based on clinical assessment and/or confirmed by [CONTACT_9256].  
(6) Patients with any  of the following CNS metastases:  
(a) Patients who have developed new or progressive brain metastasis within 
three  months following prophylactic and/or therapeutic cranial radiation (whole 
brain or stereotactic radiation) as defined by [CONTACT_9661];  
(b) Patients with s ymptomatic CNS metastases;  
(c) Patients with carcinomatous meningitis.  
(7) Unable to discontinue the use of strong CYP3A4 or UGT1A1 inhibitors at least [ADDRESS_624337] dose of irinotecan 
liposome inje ction. (See Section 5.4.[ADDRESS_624338] of prohibited therapi[INVESTIGATOR_014]).  
(8) Have a previous or concurrent cancer that is distinct in primary (non -pulmonary) site or 
histology, except carcinoma in situ, treated basal cell carcinoma, superficial bladder 
tumors (Ta and Tis [carcinoma in situ]) or any previous cancer curatively treated with 
last specific treatment >3  years ago without evidence of recurrence.  
(9) Investigat ional therapy administered within [ADDRESS_624339] 5  half-lives (whichever is less) of the investigational agent prior to the first 
scheduled day of dosing in this study.  
Hematologic, Biochemical and Organ Function Excl usion Criteria  
(10) Severe cardiovascular and pulmonary disease (e.g. myocardial infarction, unstable 
angina pectoris, coronary angioplasty or stenting, deep vein thrombosis, stroke, 
pulmonary fibrosis, active uncontrolled bleeding, or a known bleeding diathesi s) less 
than 6 months before inclusion.  
(11) [LOCATION_001] Heart Association Class III or IV congestive heart failure, ventricular 
arrhythmias, or uncontrolled blood pressure.  
(12) Active infection (e.g. acute bacterial infection, tuberculosis, active hepatitis B or acti ve 
human immunodeficiency virus) which in the Investigator’s opi[INVESTIGATOR_485939]’s participation in the trial or affect the study outcome.  
(13) Known hypersensitivity to any of the components of irinotecan liposome injection, other 
liposomal pr oducts, or topotecan.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624340] OBER 2021  
 
Proprietary and Confidential  Page 47  
 (14) Clinically significant gastrointestinal disorder including hepatic disorders, bleeding, 
inflammation, occlusion, or diarrhea > Grade  1. 
Additional Disease Specific Exclusion Criterion (only applicable in [LOCATION_009], per request of 
French Regulatory Authorities)  
(15) Patients who, per investigator assessment, are suitable for a second line platinum -based 
regimen following relapse after first -line platinum -based therapy.  
4.3 Patient Discontinuation  
4.3.1 Permanent Discontinuation of Study Treatment  
It is i ntended that patients will be treated until radiologically determined progressive disease 
per local radiology review and/or investigator assessment, per RECIST Version 1.1 criteria (or 
RANO -BM for CNS lesions in Part 2) or unacceptable toxicity. However, a  patient may 
permanently discontinue study treatment at any point. Criteria for permanent discontinuation 
of study treatment for patients receiving irinotecan liposome injection (Part 1 and Part 2) and 
those receiving topotecan (Part 2) include:  
• Radiologic ally determined progressive disease local radiology review and/or per 
investigator assessment, per RECIST Version 1.1 (or RANO -BM for CNS lesions in 
Part 2); 
• Clinical deterioration sufficient to prevent further radiological assessment;  
• Unacceptable toxicit y, defined as a study drug related AE, prior to disease progression, 
which:  
- in the opi[INVESTIGATOR_689], precludes ANY further treatment with study 
drug 
- requires treatment with study drug to be withheld for more than [ADDRESS_624341] dose reduction in study drug (in a patient having already 
experienced 2 previous dose reductions) Detailed rule of dose modification can be 
found in Section 5.3. 
• Development of an intercurrent medical condition or need for concomitant therapy that 
precludes ANY further treatment with study dru g; 
• Withdrawal of consent for further treatment;  
• Pregnancy.  
A patient who permanently discontinues study treatment and has not withdrawn from the study 
and must continue with all ongoing protocol requirements, as detailed in Section 4.3.3 . 
4.3.2 Withdrawal from the Study  
A patient may withdraw, or be withdrawn, from the study at any time. Reasons for withdrawal 
from the study include, but are not limited to  the following:  
• Significant noncompliance with the protocol, per investigator assessment;  
• The Investigator removes the patient from the trial in the best interests of the patient;  
• Use of prohibited concomitant medications;  
• Patient is lost to follow -up; 
• Withdrawal of consent for further participation in the study;  
• Death;  
• Study termination by [CONTACT_1034].  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624342] OBER 2021  
 
Proprietary and Confidential  Page 48  
 4.3.3 Procedures following Study Drug Discontinuation or Study Withdrawal  
Following permanent study drug discontinuation all procedures and evaluations require d at the 
30-day (End of Treatment) follow -up visit should be completed. All patients who permanently 
discontinue study medication as a result of an AE must be followed until resolution or 
stabilization of the AE. Patients who permanently discontinue study drug prior to radiologically 
determined disease progression should continue to be assessed radiologically and complete 
QoL assessments every [ADDRESS_624343] Version 1.1 (or RANO -BM for CNS lesions) ha s been documented or until the start 
of new anti -neoplastic therapy. Overall survival follow -up contacts should continue every 
month from the [ADDRESS_624344] to follow -up, the date of death may be captured from public records. 
Since OS is the primary endpoint it is extremely important to capture the date of death.  
If a patient discontinues from the study treatment, the patient will continue to be followed up 
for survival status (including where appropriate through publicly available records). Ongoing 
survival follow -up must be documented in both the source hospi[INVESTIGATOR_485940] (eCRF).  
If a patient wit hdraws consent to participate in the study at any point, a complete final 
evaluation at the time of the patient’s withdrawal should be made with an explanation of the 
reason for withdrawal.  
Patients participating to the optional research biobanking progra m have the right to withdraw 
their consent from the optional research biobanking program at any time and for any reason 
during the study or during the period of sample storage (i.e. the entire 15 years during which 
the sample is kept). If a patient wishes to withdraw consent for biobanking, and the samples are 
still at the Investigator site at that time, the Investigator must inform the Medical Monitor in 
writing of the patient’s decision and destroy the samples. If the samples are in the Sponsor’s 
reposito ry, the Investigator must inform Ipsen directly using the e -mail address, 
, mentioning only the patient ID. Ipsen will ensure the destruction 
of the samples and all corresponding aliquots and issue confirmation of the destruction, which 
will be forwarded to the Investigator. Analyses conducted before withdrawal will not be 
affected.  
4.4 Enrollment of Additional Patients (Patient Replacement)  
For Part 1, if a patient discontinues study treatment before completing two doses of study 
treatment, for reasons other than a DLT, then that patient may be replaced by a new patient at 
the same dose level. For Part 2, there is no patient replacement.  
4.5 Method of Assigning Patients to Treatment Groups  
Part 1:  
Patients will initially be allocated to the  irinotecan liposome injection 85 mg/m2 dose cohorts 
(according to the 6+6 design followed by [CONTACT_485954] 12 patients as described 
in Section 3.1). According to the DLT rules detailed in Section 3.1, patients may subsequently 
be allocated in cohorts to an irinotecan liposome injection dose level of 70 mg/m2, as 
determined by [CONTACT_12217].  
Part 2:  
Part 2 will be initiated upon passing the stoppi[INVESTIGATOR_485941].  
[COMPANY_003]
IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624345] patient reported outcome 
assessment has been completed, eligible patients will b e randomized using a computerized IRT, 
in a 1:1 ratio, to one of the following treatment arms:  
• Arm A (experimental arm): irinotecan liposome injection (70  mg/m2 based on the 
findings of Part 1)  
• Arm B (control arm): IV topotecan.  
Randomization must occur wi thin 7 days of planned dosing when all eligibility criteria are 
confirmed. The randomization will be stratified based on the following factors:  
• Region (North America vs. Asia vs. Other)  
• Platinum sensitivity (sensitive vs. resistant)  
• Performance status (ECO G 0 vs. 1)  
• Prior immunotherapy (yes vs. no).  
Platinum resistant patients are defined as patients with disease that either progressed during 
first-line platinum containing therapy or within [ADDRESS_624346] 
line platinum containing therapy.  
5 INVESTIGATIONAL PRODUCTS  
5.1 Description of Irinotecan Liposome Injection  
Irinotecan liposome injection is a sterile, white to slightly yellow opaque isotonic liposomal 
dispersion. Each 10  mL single -dose vial contains 43 mg irinotecan free base at a concentration 
of 4.3 mg/mL. The liposome is a unilamellar lipid bilayer vesicle, approximately 110 nm in 
diameter, which encapsulates an aqueous spac e containing irinotecan in a gelated or 
precipi[INVESTIGATOR_325449]. It will be supplied as sterile, single -use vials containing 
43 mg irinotecan free base at a concentration of 4.3 mg/mL.  
5.1.[ADDRESS_624347] be stored refrigerated at 2 to 8°C, with protection from light. 
Diluted solution must be protected from light prior to infusion. Irinotecan liposome injection 
must not be frozen. Responsible individuals should inspect v ial contents for particulate matter 
before and after they withdraw the drug product from a vial into a syringe. They must contact 
[CONTACT_485990] a problem with the study drug.  
Irinotecan liposome injection must be diluted prior to administration. Because of the potential 
for microbial contamination during dilution, the solution for infusion should be used 
immediately, but may be stored at room temperature (15° to 30°C) for up to 4 hours prior to the 
start of the infusion. If nece ssary, the solution for infusion may be refrigerated (2° to 8°C) for 
up to [ADDRESS_624348] container, will be labelled in accordance 
with local regulatory requirements.  
5.1.3 Administration of Irinotecan Liposome Injection  
Irinotec an liposome injection will be administered at a dose of 85 mg/m2 (strength expressed 
based on irinotecan free base; approximately equivalent to 100 mg/m2 of the hydrochloric 
trihydrate salt) IV over 90 minutes, every 2 weeks in a 6 -week cycle.  Should the 8 5 mg/m2 dose 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624349] unacceptable toxicity, the 70 mg/m2 will be utilized (strength expressed 
based on irinotecan free base; approximately equivalent to 80 mg/m2 of the hydrochloric 
trihydrate salt) IV over 90 minutes, every 2  weeks in a 6 -week c ycle.  Note that following 
assessment of the available safety and efficacy data from Part 1 the 70 mg/m2 dose was chosen 
for Part 2 (see Section [IP_ADDRESS]).  
Prior to administration, the appropriate dose of irinotecan liposome injection must be diluted in 
5% Dextrose Injection (D5W) or 0.9% Sodium Chloride Injection to a final volume of 500  mL. 
Care should be taken not to use any diluents other than D5W or 0.9% sodium chloride.  
The actual dose of irinotecan liposome injection to be administered will be determin ed by 
[CONTACT_485991]’s body surface area (BSA) prior to each IP administration. Use of BSA 
calculation formula according to institutional standards is allowed. The Du Bois formula, which 
has been shown to be effective for estimating body fat in bo th obese and non -obese patients, is 
widely used in clinical practice, and may be utilized in the study at investigator discretion, if 
different from institutional standard. BSA is represented in  m2, W is weight in  kg, and  H is 
height in  cm, 
 
BSA = 0.007184  × W0.425 × H0.725  
Du Bois D, Du Bois EF (Jun 1916). "A formula to estimate the approximate surface area if height and weight be known". Archives of 
Internal Medicine 17 (6): 863 -71. PMID 2520314. Retrieved 2012 -09-09. 
 
A ±5% variance in the calculated total dose will be allowed for ease of dose administration.  
Caution should be exercised when using irinotecan liposome injection in patients with body 
mass index <18.5  kg/m2. 
Irinotecan liposome injection vials are single -use vials; therefore, site staff m ust not store any 
unused portion of a vial for future use and they must discard unused portions of the product.  
Dose reduction and supportive care measures are described in Sections 5.3 and 5.4.1 , 
respectively.  
[IP_ADDRESS]  Irinotecan Liposome Injection Premedication  
All patients m ust be pre -medicated prior to irinotecan liposome injection infusion with at least 
standard doses of dexamethasone or equivalent other steroids, and a [ADDRESS_624350], and/or 
equivalent other anti -emetics according to standard institutional practices. Use  of 
diphenhydramine hydrochloride and acetaminophen is allowed as per institutional guidelines 
and as clinically indicated. Atropi[INVESTIGATOR_485942]  
[IP_ADDRESS]  Toxicity of Irinotecan Liposome Injection  
The most clinically important adverse reactions of irinotecan liposome injection are 
summarized below. For more detailed description of the additional adverse reactions, the IB 
should be consulted.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624351] signs of onset. Patients may experience late onset diarrhea (after 24  hours 
following chemotherapy) and early onset diarrhea (within 24 hours of chemotherapy, 
sometimes occurring with other symptoms of cholinergic reaction). An individual patient may 
experience both early and late -onset diarrhea. Irinotecan liposome injection is prohibited to be 
administered to patients with bowel obstruction.  
Early onset diarrhea (occurring during or shortly after infusion of irinotecan) is usually 
cholinergic in nature. It may be accompanied by [CONTACT_329638], increased salivation, 
miosis, lacrimation, diaphoresis, flushing, and intestinal hyper -peristalsis that can cause 
abdominal crampi[INVESTIGATOR_007]. Early onset diarrhea of any severity is treated with IV or subcutaneous 
atropi[INVESTIGATOR_050] 0.25 to 1 mg (unless clinically contraindicated).  
Late onset diarrhea (generally occurring more than 24 hours after administration of irinotecan) 
can be life  threatening since it may be prolonged and may lead to dehydration, electrolyte 
imbalance, or sepsis. Late onset diarrhea should be treated promptly with loperamide, and 
octreotide should be considered if diarrhea persists after loperamide. Loss of fluids and 
electrolytes associated with persistent or severe diarrhea can result in life threatening 
dehydration, renal insufficiency, and electrolyte imbalances, and may contribute to 
cardiovascular morbidity. The risk of infectious complications is increased, w hich can lead to 
sepsis in patients with chemotherapy -induced neutropenia. Patients with diarrhea should be 
carefully monitored, given fluid and electrolyte replacement if they become dehydrated, and 
given antibiotic support if they develop ileus, fever, o r severe neutropenia. A Clostridium 
difficile test per institutional guidelines is recommended if clinically indicated.  
Neutropenia  
Irinotecan liposome injection can cause severe or life -threatening neutropenia and fatal 
neutropenic sepsis. In patients wit h metastatic pancreatic cancer in the NAPOLI -1 study 
receiving irinotecan liposome injection/5 -FU/LV, the incidence of Grade 3 or 4 neutropenia 
was higher among Asian patients [18 of 33 (55%)] compared to White patients [13 of 73 
(18%)]. Neutropenic compli cations should be managed promptly with antibiotic support. 
Granulocyte -colony stimulating factor (G -CSF) may be used to manage neutropenia at the 
Investigator’s discretion.  
Hypersensitivity  
Hypersensitivity reactions including severe anaphylactic or anaph ylactoid reactions have been 
observed with irinotecan, however, have not been observed with irinotecan liposome injection 
to date. This could be due to the limited cumulative patient exposure to date of irinotecan 
liposome injection, or the use of appropri ate premedication and early recognition and treatment 
of expected AEs. There is insufficient evidence to know whether these known adverse reactions 
of irinotecan are also associated with irinotecan liposome injection. Suspected drugs should be 
withheld imm ediately and aggressive therapy should be given if hypersensitivity reactions 
occur.  
Interstitial Lung Disease  
Irinotecan HCl can cause severe and fatal interstitial lung disease. This adverse reaction has not 
yet been described with irinotecan liposome in jection. Irinotecan liposome injection should be 
withheld in patients with new or progressive dyspnea, cough, and fever, pending diagnostic 
evaluation. Irinotecan liposome injection should be discontinued in patients with confirmed 
diagnosis of interstitia l lung disease.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624352] OBER 2021  
 
Proprietary and Confidential  Page 52  
 Embryo -Fetal Toxicity  
Based on animal data with irinotecan HCl and the mechanism of action of ONIVYDE®, 
ONIVYDE® can cause fetal harm when administered to a pregnant woman. Embryotoxicity 
and teratogenicity were observed following treatment with irinotecan HCl, at doses resulting in 
irinotecan exposures lower than those achieved with irinotecan liposome injection 70  mg/m2 in 
humans, administered to pregnant rats and rabbits during organogenesis. Pregnant women 
should be advised of the potential risk to a fetus. Females of reproductive potential should use 
a highly effective contraception method during treatment with irinotecan liposome injection 
and for one month following the final dose. Highly effective contraceptive methods include:  
• Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation (e.g. oral, intravaginal , transdermal)  
• Progestogen -only hormonal contraception associated with inhibition of ovulation 
(e.g. oral, implantable, injectable)  
• Intrauterine device  
• Intrauterine hormone -releasing system  
• Bilateral tubal occlusion  
• Male partner has had a vasectomy.  
Total abstinence from intercourse with male partners (periodic abstinence is not acceptable).  
Care of Intravenous Site  
Care should be taken to avoid extravasation, and the infusion site should be monitored for signs 
of inflammation. Should extravasation occur, f lushing the site with sterile saline and 
applications of ice are recommended, or as per institutional standard of care.  
Patients at Particular Risk  
In clinical trials of the weekly schedule of irinotecan, it has been noted that patients with 
modestly eleva ted screening  serum total bilirubin levels (1.0 to 2.0  mg/dL) have had a 
significantly greater likelihood of experiencing first -cycle Grade 3 or 4 neutropenia than those 
with bilirubin levels that were less than 1.0  mg/dL (50.0% [19/38] versus 17.7% [47/22 6]; 
p <0.001). Patients with abnormal glucuronidation of bilirubin, such as those with Gilbert's 
syndrome, may also be at greater risk of myelosuppression when receiving therapy with 
irinotecan.  
The PKs of irinotecan liposome injection have not been studie d in patients with hepatic 
impairment. In a population PK analysis, patients with screening  bilirubin concentrations of 
1-2 mg/dL (N=19) had average steady state concentrations for total SN -38 that were increased 
by 37% compared to patients with screening  bilirubin concentrations of <1 mg/dL (N=329); 
however, there was no effect of elevated ALT/AST concentrations on total SN -38 
concentrations. No data are available in patients with bilirubin >2 mg/dL.  
Acute Infusion Associated Reactions  
Acute infusion -assoc iated reactions characterized by [CONTACT_288881], shortness of breath, facial 
swelling, headache, chills, back pain, tightness of chest or throat, and hypotension have been 
reported in a small number of patients treated with liposome drugs. In most patients, thes e 
reactions generally resolve within [ADDRESS_624353] patients who experienced acute 
infusion reactions to liposome drugs are able to tolerate further i nfusions without complications. 
Infusion reactions, consisting of rash, urticarial, periorbital edema, or pruritus, occurring on the 
day of irinotecan liposome injection administration were reported in 3% of patients receiving 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624354] OBER 2021  
 
Proprietary and Confidential  Page 53  
 irinotecan liposome injection  monotherapy or irinotecan liposome injection/5 -FU/LV 
combination in the NAPOLI -1 study.  
Management of Infusion Reactions  
The guidelines described  in this section can be followed in case of infusion reactions to either 
study treatment given per protocol (i rinotecan liposome injection and topotecan). Infusion 
reactions will be defined according to the NCI CTCAE (Version  5.0) definitions of an allergic 
reaction or anaphylaxis as defined below:  
• Allergic reaction  (i.e., a disorder characterized by [CONTACT_485992]):  
Grade 1:  Transient flushing or rash, drug fever <38 °C (<100.4 °F); intervention not 
indicated  
Grade 2:  Intervention or infusion interruption indicated; responds promptly to 
symptomatic treatment (e.g. , antihistamines, NSAIDS, narcotics); 
prophylactic medications indicated for ≤ 24 hours  
Grade 3:  Prolonged (e.g., not rapi[INVESTIGATOR_14137]/or 
brief interruption of infusion); recurrence of symptoms following initial 
improvement; hospi[INVESTIGATOR_79806] (e.g., renal 
impairment, pulmonary infiltrates)  
Grade 4:  Life-threatening consequences; urgent intervention indicated.  
• Anaphylaxis (i.e., a disorder characterized by [CONTACT_485993] -like substances from mast cells, causing 
hypersensitivity immune response. Clinically, it presents with breathing difficulty, 
dizziness, hypotension, cyanosis and loss of consciousness and may lead t o death):  
Grade 1:  Not applicable  
Grade 2:  Not applicable  
Grade 3:  Symptomatic bronchospasm, with or without urticaria; parenteral 
intervention indicated; allergy -related edema/angioedema; hypotension  
Grade 4:  Life-threatening consequences; urgent interv ention indicated.  
Institutional policies or the following treatment guidelines shall be used for the management of 
infusion reactions.  
Grade 1  
• Slow infusion rate by 50%  
• Monitor patient every 15 minutes for worsening of condition  
• Future infusions may be adm inistered at a reduced rate (e.g. over 120 minutes for 
irinotecan liposome injection), at the discretion of the Investigator.  
Grade 2  
• Stop infusion  
• Administer diphenhydramine hydrochloride 50 mg IV, acetaminophen 650 mg orally, 
and oxygen  
• Resume infusion at 50% of the prior rate once infusion reaction has resolved  
• Monitor patient every 15 minutes for worsening of condition  
• For all subsequent infusions, pre -medicate with diphenhydramine hydrochloride 50  mg 
IV, dexamethasone 10 mg IV, and acetaminophen 500 o r 650 mg orally.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624355] OBER 2021  
 
Proprietary and Confidential  Page 54  
 • Future infusions may be administered at a reduced rate (e.g. over 120 minutes for 
irinotecan liposome injection), at the discretion of the Investigator.  
Grade 3  
• Stop infusion and disconnect infusion tubing from patient  
• Administer diphenhyd ramine hydrochloride 50 mg IV, dexamethasone 10  mg IV, 
bronchodilators for bronchospasm, and other medications or oxygen as medically 
necessary  
• No further treatment will be permitted.  
Grade 4  
• Stop the infusion and disconnect infusion tubing from patient  
• Administer epi[INVESTIGATOR_238], bronchodilators or oxygen as indicated for bronchospasm  
• Administer diphenhydramine hydrochloride 50 mg IV, dexamethasone 10 mg IV and 
other medications as medically necessary  
• Consider hospi[INVESTIGATOR_325452]  
• No further trea tment will be permitted.  
For patients who experience a second Grade 1 infusion reaction, administer dexamethasone 
10 mg IV. All subsequent infusions should be premedicated with diphenhydramine 
hydrochloride 50 mg IV, dexamethasone 10 mg IV, and acetaminoph en 500 or 650 mg orally 
or as per institutional guidelines.  
UGT1A1*28 Monitoring  
UGT1A1*28 genotype will be collected on all patients and assessed centrally. Results will be 
provided to the site and to the Sponsor. Sites will be asked to include the result  from the 
UGT1A1*28 genotypi[INVESTIGATOR_485943].  
All patients treated with irinotecan liposome injection, regardless of the results of the 
UGT1A1*28 genotype, will be treated with the same starting dose of irinotecan liposome 
injection and will follow the same dose reduction rules. During the regular safety monitoring 
of patients during the study, as will be conducted by [CONTACT_37755](s) and by 
[CONTACT_12217] (Part 1) and the DMC (Part 2), the safety and PK of UGT1A1*28 homozygous  patients 
will be compared to those who are non -homozygous for UGT1A1*28 to determine whether any 
different dosing strategy (such as a lower starting dose and/or different dose reduction for 
irinotecan liposome injection) is required for patients who are h omozygous for UGT1A1*28. 
The first safety DMC meeting will occur after the 30th patient completed one cycle of treatment 
or discontinued treatment, whichever occurs first. No association between UGT1A1*28 and 
safety is expected in patients treated with top otecan.  
Other Potential Toxicities  
Irinotecan liposome injection, the liposomal formulation of irinotecan is different from 
irinotecan in unencapsulated formulation, so there is potential for toxicities other than those 
caused by [CONTACT_372338]. All patients s hould be monitored closely for signs and symptoms 
indicative of drug toxicity, particularly during the initial administration of treatment.  
5.2 Description of Topotecan for Injection  
The following information has been obtained from the HYCAMTIN® (topotecan) fo r injection 
US and EU package inserts. In the US, topotecan for injection, as a single agent, is indicated 
for the treatment of patients with SCLC with platinum -sensitive disease who progressed after 
first-line chemotherapy ( Topotecan USPI ). In the EU, IV topotecan is indicated for the 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624356] -line regimen is 
not considered appropriate ( Topotecan SmPC ). 
5.2.1 Storage and Handling of Topotecan  
[IP_ADDRESS]  US package insert/EU SmPC  
Instructions for storage and handling of topotecan are provided in the pharmacy manual and the 
commercial package inserts and SmPCs.  
5.2.[ADDRESS_624357] in accordance with local country requirements.  
5.2.3 Administration of Topotecan  
Topotecan is administer ed at an initial dose of 1.5 mg/m2 IV over [ADDRESS_624358] dos e (both short and long acting growth factor is 
acceptable, based on investigator preference).  
5.3 Rules for Dose Modification of Irinotecan Liposome Injection and Topotecan  
Dose modifications of irinotecan liposome injection and topotecan are allowed as clinically 
indicated (Section 5.3.1  and Section 5.3.2  respectively). If a patient’s dose is reduced during 
the study, it should remain reduced for the duration of the study, dose re -escalation is not 
permitted.  
5.3.[ADDRESS_624359]:  
• Absolute neutrophil count (ANC)  1500/mm3 (1.5x109/L) 
• Platelet count  100,000/mm3 (100x109/L) 
• All local lab results assessed.  
All clinical decisions will be based on local laboratory assessments. Treatment should be 
delayed for recover y from toxicity and upon recovery to at least Grade 1, treatment should be 
administered according to the guidelines in Table [ADDRESS_624360] resolved to 1500/mm3 (1.5x109/L) and the patient must have recovered 
from infection.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624361] OBER 2021  
 
Proprietary and Confidential  Page 56  
 Table 1: Recommended Dosea Modifications for Irinotecan Liposome Injection  
Toxicity NCI CTCAE Gradeb Occurrence  Starting Dose  
70 mg/m2 85 mg/m2 
Hematological toxicities:  
Neutropenia, leukopenia, or 
thrombocytopenia Grade  [ADDRESS_624362] 
occurrence  56 mg/m2 
 (80% of original 
dose)  68 mg/m2 
(80% of original 
dose) 
Second 
occurrence  46 mg/m2 
(65% of original 
dose)  55 mg/m2 
(65% of original 
dose)  
Third 
occurrence  35 mg/m2 
(50% of original 
dose)  43 mg.m2 
(50% of original 
dose)  
• A new dose of treatment should not begin until the absolute neutrophil count is ≥1500/mm3 
(1.5x109/L) 
• A new dose of treatment should not begin until the platelet count is ≥100,000/mm3 
(100x109/L) 
Nonhematological toxicities :  
All nonhematological 
toxicities (except asthenia and 
anorexia): Grade  3 or 4 Withhold irinotecan liposome injection. Upon recovery to 
≤ Grade 1, resume irinotecan liposome injection as below:  
First 
occurrence  56 mg/m2  
(80% of original 
dose)  68 mg/m2 
(80% of original 
dose)  
Second 
occurrence  46 mg/m2 
(65% of original 
dose)  55 mg/m2 
(65% of original 
dose)  
Third 
occurrence  35 mg/m2 
(50% of original 
dose)  43 mg/m2 
(50% of original 
dose)  
• A new dose of treatment should not begin until serum chemistry parameters resolve to 
≤ Grade  1 
• A new dose of treatment should not begin until nonhematological toxicities resolve to 
≤ Grade  1 
• For Grade  ≥ 3 nausea and vomiting, reduce dose only if occur despi[INVESTIGATOR_9025] -emetic 
therapy  
• Asthenia and Grade  [ADDRESS_624363] benefit from the treatment. Dose modifications 
(dose delays, including dose holidays, dose reductions), prophylactic use of myeloid growth 
factors, antibiotic s for high risk patients and all other appropriate supportive care measures 
should be used to ensure that patients receive the highest tolerated dose and duration possible.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624364] OBER 2021  
 
Proprietary and Confidential  Page 57  
 In exceptional circumstances (e.g. long holidays), where administration of the topo tecan IV is 
not possible for [ADDRESS_624365] the dosing regimen based on their clinical judgment to ensure:  
(1) The patient is receiving highest tolerable dose and duration possible, and  
(2) The highest daily dose does not exceed 1.5  mg/m2. 
The recommended dose modifications are described in this section (Section 5.3.2 ) for topotecan 
and the recommended supportive care measures are described in Section 5.4.1 . 
Topotecan should only be started in patients with a screening  neutrophil count of greater than 
or equal to 1,500/mm3 (1.5x109/L) and a platelet count greater than or equal to 100,000/mm3 
(100x109/L). 
In subsequent cycles topotecan should not be administered unless the neutrophil count 
is ≥1x109/L, the platele t count is ≥100 x 109/L, and the hemoglobin level is ≥9 g/dL 
(after  transfusion if necessary). Treatment should be administered according to the guidelines 
in Table 2 below.  
Dose reduction of topotecan is allowed at investigator discretion during the treatment cycle as 
clinically indicated after the starting dose of 1.5 mg/m2 is initiated.  
Dose reduction from dose level 0 to dose level -2 is permitted.  The reduced dose should 
continue to be administered over 5 consecutive days per topotecan prescribing information. 
Prophylactic antibiotics are recommended for patients at high risk of infectious complications.  
Up to two dose reductions of topotecan per p atient are permitted due to toxicities (see Table 2). 
If a third dose reduction is needed to manage a toxicity, topotecan treatment can be adjusted 
per clinical assessment after discussion with the Medical Monitor and documented 
appropriately.  
Table 2: Recommended Topotecan Dose Modification Scheme for Subsequent Cycles  
Dose Level  Dose Modifications  
0 1.5 mg/m2 IV days 1 -5 
-1 1.25 mg/m2 IV days 1 -5 
-2 1.0 mg/m2 IV days 1 -5 
The dose of topotecan in patients should be reduced to 0.75 mg/m2/day for 5 consecutive days 
if the creatinine clearance is between 20 and 39 mL/min.  
Topotecan should be discontinued if a new diagnosis of i nterstitial lung disease is confirmed.  
Please note that for both irinotecan liposome injection and topotecan, all dose 
modifications should be based on worst preceding toxicity and a patient may permanently 
discontinue study treatment if he/she meets any o f the criteria for permanent 
discontinuation of study treatment listed in Section 4.3.1 .  
5.4 Concomitant and Prohibited Therapi[INVESTIGATOR_014]  
5.4.1 Concomitant and Supportive Care Therapi[INVESTIGATOR_014]  
[IP_ADDRESS]  Antiemetic Medications  
Irinotecan Liposome Injection : Dexamethasone and a 5 -HT3 blocker (e.g., ondansetron or 
granisetron) will be administered as premedications to all patients receiving irinotecan liposome 
injection. Antiemetics  may be prescribed as clinically indicated during the study period. An 
NK1 inhibitor, such as rolapi[INVESTIGATOR_053] (with no CYP3A4 interactions), for delayed nausea and 
vomiting for moderately emetogenic chemotherapy may be used in addition to [ADDRESS_624366], as p er institutional standards and as clinically indicated, with consideration of 
potential drug -drug interaction (please refer to list of prohibited medications in Section 5.4.2 ). 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624367] OBER 2021  
 
Proprietary and Confidential  Page 58  
 Topotecan : Antiemetic therapy for topotecan per institutional standard of care, including 5 -HT3 
antagonists and NK -1 inhibitor Rolapi[INVESTIGATOR_053], may be prescribed as clinically indicated during the 
study period.  
[IP_ADDRESS]  Myelosuppression  
Use of G-CSF is permitted. All patients randomized to the topotecan arm are recommended to 
receive prophylactic G -CSF in all cycles starting [ADDRESS_624368] dose (both short 
and long acting growth factor is acceptable, based on investigator prefere nce). For patients 
receiving irinotecan liposome injection the use of prophylactic G -CSF (both short and long 
acting growth factor is acceptable, based on investigator preference) is allowed, based on 
investigator judgment. History of prior abdominal radia tion increases the risk of severe 
neutropenia and febrile neutropenia following irinotecan liposome injection treatment. Close 
monitoring of blood counts is recommended, and the use of myeloid growth factors should be 
considered for patients with a history  of radiation. Caution should be exercised in patients 
receiving concurrent administration of irinotecan liposome injection with irradiation. 
Prophylactic antibiotics are recommended for patients at high risk of infectious complications.  
[IP_ADDRESS]  Therapy for Diarrhea  
Acute diarrhea and abdominal cramps, developi[INVESTIGATOR_485944] [ADDRESS_624369] onset of bowel movements that are more frequent than normal. For both arms, diarrhea 
should be managed according to institutional guidelines, or according to the guide lines 
developed by [CONTACT_485994] -induced diarrhea ( Benson 2004, Ustaris  2015, 
Bossi  2018 ). 
For a detailed algorithm of diarrhea management for chemotherapy -induced diarrhea see 
Appendix  1. 
5.4.2 Prohibited Therapi[INVESTIGATOR_485945], after disease pro gression following gemcitabine -based therapy, the following 
drugs are noted as interacting with irinotecan liposome injection when administered in 
combination with 5 -FU and LV  (including but not limited to):  
• Strong CYP3A4 inducers, e.g., St. John’s Wort, C YP3A4 inducing anticonvulsants 
(phenytoin, phenobarbital, and carbamazepi[INVESTIGATOR_050]), rifampin, rifabutin, rifapentine, 
mitotane, avasimibe, enzalutamide.  
• Strong CYP3A4 inhibitors, e.g. clarithromycin, indinavir, itraconazole, ketoconazole, 
lopi[INVESTIGATOR_054], nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole, 
tipranavir, troleandomycin, danoprevir, mibefradil, pozaconazole, conivaptan, grapefruit 
juice.  
• Weak to moderate CYP3A4 inhibitors, e.g., troleandomycin, erythromycin, diltiazem, 
verapamil, fosap repi[INVESTIGATOR_053].  
• Strong UGT1A1 inhibitors, e.g., atazanavir, gemfibrozil, indinavir, ketoconazole.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624370] with irinotecan or topotecan should be 
avoided wherever possible. Refer to the IB for ONIVYDE® and topoteca n instructions leaflet 
(as prepared and packaged for this study) for any other drug interactions.  
The following therapi[INVESTIGATOR_485946]:  
• Other systematic anti -neoplastic therapy, (e.g. cytotoxics, targeted agents, 
immun otherapy, or antibodies, etc.).  
• Radiotherapy, unless given for palliative reason and with the approval of the Medical 
Monitor. Study treatment must be held during palliative radiation and for 2 weeks after 
completion of radiation.  
• Any other investigational  therapy is not permitted.  
5.[ADDRESS_624371] of all vials of study drug received and 
administered will be maintained on an investigational drug inventory form provided by [CONTACT_429]. The following information will be recorded:  
• Date and quantity of study drug  received  
• Date and quantity of study drug dispensed from the pharmacy per patient  
• Date and quantity of study drug administered to each patient  
• Date and quantity of study drug destroyed (if prepared and dispensed, but not 
administered for any reason, the study drug may not be returned to inventory)  
• Date and quantity of study drug returned to sponsor.  
Each shipment of study drug will contain an invoice describing the amount of drug shipped to 
the investigational site. The information on the invoice will be verified against the actual 
amount of drug received, after which the Investigator or the Investigator’s designee will place 
the invoice in the Investigator’s file.  
During monitoring, the Sponsor’s monitor will reconcile the information on the investigation al 
drug inventory form with the actual amount of study drug remaining at each site. At the end 
study, all used and unused vials can be destroyed on site as per local regulations and 
instructions, or shipped to the Sponsor’s storage facility for destruction . A certificate of 
destruction will be provided by [CONTACT_485995]’s 
file. 
6 STUDY ASSESSMENTS  
See Section 7.1 and Section 7.2 for schedule of assessments.  
6.1 Screening Visit  
The screening phase will begin once the patient signs the informed consent f orm. All procedures 
for screening are outlined in Section 8. For further descriptions of the clinical and laboratory 
assessments required, please r efer to Section 9. Rescreening is only allowed after discussion 
and approval from the Sponsor’s Medical Monitor.  
6.2 Treatment/Active Follow -up Visits  
Patients who are confirmed to meet all inclusion and exclusion criteria will be enrolled in Part  [ADDRESS_624372] dose (Cycle 1 Day 1) must be given within 7  days 
of enrollment/randomization. All study procedures and assessm ents are outlined in Section  8 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624373] OBER 2021  
 
Proprietary and Confidential  Page 60  
 and Section 9. During the treatment period, a window of ±2 days will apply to all visits, unless 
otherwise stated.  
While in the Treatment/Active Follow -up phase, pauses in study drug treatment may be 
allowed, at the discretion of the Investigator. If a pause occurs  in treatment, patients should 
continue to follow the same schedule of assessments, however, once [ADDRESS_624374] study drug administration, visits may be limited to every 3 weeks rather than weekly.  
6.2.1 Pauses in Treatment  
It is intended that a ll patients will be treated until progressive disease or unacceptable toxicity. 
Patients may take a treatment holiday and resume study treatment under one of the following 
instances:  
• Patients with at least stable disease at the end of Cycle 3 may take a tr eatment holiday or 
may continue study treatment at the Investigator discretion as long as the Investigator 
believes that there is clinical benefit from continued study treatment.  
• Patients who discontinue study treatment due to unacceptable toxicity prior t o disease 
progression may resume study treatment if their underlying disease progresses and they 
recovered from the toxicity following discussion with the Investigator and in agreement 
with the Sponsor Medical Monitor.  
• Patients who require palliative radio therapy must withhold study treatment during 
palliative radiation and for [ADDRESS_624375] of the patient in the judgment of the Investigator.  
• In case of suspected or confirmed COVID -[ADDRESS_624376] a patient to be retested before administration of study 
treatment is resumed. (See also Section  10.1.2  for the reporting of COVID -19 infection).  
In exceptional circumstances (e.g. long holidays), where administration of the topotecan IV is 
not possible for [ADDRESS_624377] the dosing regimen based on their clinical judgment to ensure:  
(1) The patient is receiving highest tolerable dose and duration possible, and  
(2) The highest daily dose does not exceed 1.5  mg/m2. 
Please note that the duration of a treatment holiday should NOT be longer than 1 cycle  
(6 weeks).  More than one treatment holiday is allowed as long as the above criteria are satisfied.  
During treatment breaks, QoL assessments and RECIST (or RANO -BM for CNS lesions in 
Part 2) scans should continue to  follow the same frequency (every 6 weeks). All remaining 
assessments only need to be completed when/if the patient comes in to clinic for a scan or QoL 
assessment during this break, with the exception of safety monitoring, complete blood counts 
(CBCs) and  serum chemistry collection. Safety monitoring and labs should be collected at a 
reduced rate of a minimum of every [ADDRESS_624378] clinic visit, or at a higher frequency 
based on investigator judgment. If/when a patient restarts treatment, the cycle 2 and beyond 
schedule should be resumed.  
6.3 30-day Follow -up Visit  
All patients are expected to complete a 30 -day follow -up assessment upon permanent 
discontinuation of study treatment. This assessment should occur approximately 30  days 
(± 1 week) after a decis ion is made to permanently discontinue study treatment (defined as 
patients with progressive disease whilst receiving study treatment  and/or those assessed by 

[CONTACT_485996] -398-01-03-04 
VERSION 8.0 – [ADDRESS_624379] OBER 2021  
 
Proprietary and Confidential  Page 61  
 the Investigator as unable to continue or resume study treatment due to unacceptable toxicity) 
All procedures and assessments are outlined in Section 7. 
6.4 Survival or Long -Term Follow -up 
After the 30 -day follow -up visit, patients should continue to be followed for survival status 
once every month (± 14 days) via clinic visit, telephone, email, or medical record review until 
death, lost to follow -up, withdrawal of consent (to further surviv al follow -up), or study closure, 
whichever occurs first. Additionally, data on subsequent anti -cancer treatments and the date of 
progression associated with subsequent anti -cancer treatment should be collected during these 
contacts and documented in the eC RF. In the case of patients who discontinue protocol 
treatment, for reasons other than progressive disease per RECIST Version 1.1 and/or RANO -
BM criteria, and remain on study, disease evaluations (including imaging studies) and QoL 
assessments should conti nue into the follow -up period, as described in the Section 7. 
If a patient does not respond to attempts to contact [CONTACT_485997] -up, at least three documented 
attempts, including one via certified mail, should be made to contact [CONTACT_485998] 
a patient lost to follow -up. If the patient does not respond to these requests, the date of death 
should be captured from public records if availa ble. 
 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
 VERSION 8.0 – 07 OC TOBER 2021  
Proprietary and Confidential  Page 62  
 7 SCHEDULE OF ASSESSMENTS  
The schedule of assessments for irinotecan liposome injection is shown in Section  7.1 (Table 3) and IV topotecan in Section  7.2 (Table 4). 
If the COVID -[ADDRESS_624380] their study visit assessments performed remotely as judged 
appropriate by [CONTACT_737]. Please also r efer to Appendix  15.4. Of note, as the adapted visit deviates from the regular protocol plan, the changes 
will be recorded as protocol deviations rela ted to COVID -19. 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
 VERSION 8.0 – 07 OC TOBER 2021  
 
Proprietary and Confidential  Page 63  
 7.1 Irinotecan Liposome Injection  
The schedule of assessments shown in Table 3 below, only applies to patients receiving irinotecan liposome injection:  
Table 3: Schedule of Assessments for Patients Receiving Irinotecan Liposome Injection  
Procedure  Screening 
Visit  Treatment/Active Follow -up Visits  30 Day 
Follow -
up10 LTFU 
(q1mo)15 Cycle 1  Cycle 2 and beyond  Treatment 
Pause16 D1 D8 D15 D22 D29 D36 D1 D15 D22 D29 
Informed consent  X1              
Medical history  X1              
Demographics  X1              
Vital signs & weight  X2 X X X X X X X X X X X X  
Physical Exam3 X1 X  X  X  X X  X X X  
ECOG PS Scoring  X2 X X X X X X X X X X X X  
CBC with differential4 X2 X X X X X X X X X X X X  
Serum chemistry4, 5 X2 X X X  X  X X  X X X  
Pregnancy test6 X2 X2      X     X  
UGT1A1*28 genotype  X1              
Tumor assessment7 X1 Every 6 weeks from C1D1  X X  
QoL Questionnaires8, 13 X17 Every 6 weeks from C1D1  X X  
ECG8 X2 X12, 14 X12, 14 X12, 14           
Archived tumor tissue   X             
Concomitant medications  X1 X X X X X X X X X X X X  
Concomitant procedures  X1 X X X X X X X X X X X X  
Randomization (Part 2)  X2              
Biobanking9  X8 Collected at 6 and 12 weeks8    
PK samples11  X X X      X11     
Irinotecan liposome 
injection administration18  X  X  X  X X  X    
Adverse event reporting  X X X X X X X X X X X X X  
Overall survival reporting15              X 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
 VERSION 8.0 – 07 OC TOBER 2021  
 
Proprietary and Confidential  Page 64  
 Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; C=cycle; CBC=cell blood count; D=day; DNA=deoxyribonucleic acid; 
ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase; LTFU=long -term follow -up; PK=pharmacokinetic; PS=performance status; 
QoL=quality of life; RECIST=Res ponse Evaluation Criteria in Solid Tumors; RANO -BM=Response Assessment in Neuro -oncology brain metastases; RBC=red blood cell; RNA=ribonucleic 
acid; WBC=white blood cell  
1 Within 28 days of C1D1.  
2 Within 7 days of C1D1.  
3 Physical Exams should occur on days of dosing prior to study drug administration.  Height should be collected at screening only.  
4 Day 1: within [ADDRESS_624381] document their review of each laboratory report. T he CBC will include the following: hemoglobin, 
hematocrit, platelet count, RBC, WBC with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils and other  cells). Serum chemistry will include electrolytes (sodium, 
potassium, chloride and bicarbonate) , BUN, serum creatinine, glucose, bilirubin, AST, ALT, alkaline phosphatase, LDH, uric acid, total protein, albumin, calcium,  magnesium and phosphate.     
[ADDRESS_624382] be sent to the central lab; local lab results may be used for enrollment and  dosing decisions if central lab results are not available.  
[ADDRESS_624383] every 6 weeks during the follow -up period until objective disease progression or 
commencement of new anti -neoplastic therapy (in accordance with RECIST Version 1.1, ( or RANO -BM for Part 2). Tumor assessment comprises imaging of both peripheral disease and the 
brain at each assessment.  
[ADDRESS_624384] signed the optional biobanking 
informed consent for exploratory biomarkers at baseline (C1D1), as well as 6 and 12 weeks, (end of study. If a patient progre sses prior to 12 weeks, a sample shou ld be taken at time of 
discontinuation.  “X" at D1 in Cycle 2 and beyond to include C3D1.  
10 The 30 -day follow -up visit should occur 30 days after discontinuation of the study treatment ( ± 1 week).  
11 Please refer to Section 9.5 for details on PK sampling. An optional sample may also be provided during Days 2 to 6 (Part 2). Cycle 1 Day 8 sampling may o ccur ±1day.  
12 Replicate ECG readings (Holter monitoring) will be collected on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 1 Day 15 at the sa me time point at PK assessments for patients in Part 1 only 
unless also required for Part 2 at the discretion of the Sponsor.  Plea se refer to Section 8.7 for time points  
13 Quality of life questionnaires (EQ5D and EORTC -QLQ -C30 +LC13, Patient Global Impression of Change, and P atient Global Impression of Severity) are collected in Part [ADDRESS_624385] every 6 weeks during the follow -up period until objective disease progression or commencement of 
new anti -neoplastic therapy. A ±1 -week window is permitted in order to sync assessment with clinic visit. The Patient Global Impression of Change is omitted at the screening assessment.  
14 Part 1 only  
15 Follow -up should occur every 1 month ( ± 2 weeks).  
16 Treatment Pause Modified Schedule: During treatment breaks, Q oL assessments and radiological assessments should continue to follow the same frequency (every 6  weeks).  All 
remaining assessments only need to be completed when/if the patient comes in to clinic for a scan or QoL assessment during th is break with the ex ception of safety monitoring, CBCs and 
serum chemistry collection.  Safety monitoring and labs should be collected at a reduced rate of a minimum of every [ADDRESS_624386] clinic visit, or at a higher frequency based on 
investigator judgment.  If/when a patient restarts treatment, the cycle 2 and beyond schedule should be resumed.  
17 Within 14 days of C1D1.  
18 Between 48 and 72 hours after completion of the irinotecan liposome injection infusion, a safety follow -up phone call will be made by a study nurse . 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
 VERSION 8.0 – 07 OC TOBER 2021  
 
Proprietary and Confidential  Page 65  
 7.2 IV Topotecan  
The schedule of assessments shown in Table 4, below, only applies to patients receiving IV topotecan:  
Table 4: Schedule of Assessments for Patients Receiving IV Topotecan  
Procedure  Screening 
Visit  Treatment/Activ e Follow -up Visits  30 Day 
Follow -
up10 LTFU 
(q1mo)12 Cycle 1  Cycle 2 and beyond  Treatment 
Pause13 D1 D8 D15 D22 D29 D36 D1 D15 D22 D29 
Informed consent  X1              
Medical history  X1              
Demographics  X1              
Vital signs &  weight  X2 X X X X X X X X X X X X  
Physical Exam3 X1 X   X   X  X  X X  
ECOG PS Scoring  X2 X X X X X X X X X X X X  
CBC with differential 4 X2 X X X X X X X X X X X X  
Serum chemistry4, 5 X2 X X  X   X  X  X X  
Pregnancy test6 X2 X2      X     X  
UGT1A1*28 genotype  X1              
Tumor assessment7 X1 Every 6 weeks from C1D1  X X  
QoL Questionnaires8, 11 X14 Every 6 weeks from C1D1  X X  
ECG8 X2              
Archived tumor tissue   X             
Concomitant medications  X1 X X X X X X X X X X X X  
Concomitant procedures  X1 X X X X X X X X X X X X  
Randomization  X2              
Biobanking9  X8 Collected at 6 and 12 weeks8    
Topotecan Administration 
(5 consecutive days)   X   X   X  X     
Adverse event reporting  X X X X X X X X X X X X X  
Overall survival reporting12              X 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
 VERSION 8.0 – 07 OC TOBER 2021  
 
Proprietary and Confidential  Page 66  
 Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; C=cycle; CBC=cell blood  count; D=day; DNA=deoxyribonucleic acid; 
ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase; PK=pharmacokinetic; PS=performance status; QoL=quality of life; RECIST =Response 
Evaluation Criteria in Solid Tumors; RANO -BM=Response Assessment in Neuro -oncology brain metastases; RBC=red blood cell; RNA=ribonucleic acid; WBC=white blood cell  
 
1 Within 28 days of C1D1.  
2 Within 7 days of C1D1.  
3 Physical Exams should occur on days of dosing prior to study drug administration.  Height should be collected at screening only.  
4 Day 1: within  [ADDRESS_624387] document their review of each laboratory report. T he CBC will include the following: hemoglobin, 
hematocrit, platelet count, RBC, WBC with differential (neutrophils, lymphocytes, m onocytes, eosinophils, basophils and other cells). Serum chemistry will include electrolytes (sodium, 
potassium, chloride and bicarbonate), BUN, serum creatinine, glucose, bilirubin, AST, ALT, alkaline phosphatase, LDH, uric ac id, total protein, albumin, c alcium, magnesium and phosphate.     
[ADDRESS_624388] be sent to the central lab; local lab results may be used for enrollment and dosing decisions if ce ntral lab results are not available.  
[ADDRESS_624389] every 6 weeks during the follow -up period until objective disease progression or 
commencement of new anti -neoplastic therapy (in accordance with RECIST Version 1.1 (or RANO -BM) for Part 2). Tumor assessment comprises imaging of both peripheral disease and the 
brain at each assessment.  
[ADDRESS_624390] signed the optional biobanking 
informed consent for exploratory biomarkers at  baseline (C1D1), as well as 6 and 12 weeks, (end of study).  If a patient progress prior to 12 weeks, a sample should be take n at time of 
discontinuation.  "X" at D1 in Cycle 2 and beyond to include C3D1.  
10 The 30 -day follow -up visit should occur 30 days after discontinuation of the study treatment ( ± 1 week).  
11 Quality of life questionnaires (EQ5D and EORTC -QLQ -C30 +LC13, Patient Global Impression of Change, and Patient Global Impression of Severity) are collected in Part [ADDRESS_624391] every 6 weeks during the follow -up period until objective disease progression or 
commencement of new anti -neoplastic therapy. A ± 1 -week window is permitted in order to sync assessment with clinic visit. The Patient Global Impression of Change is omitted at the 
screening assessment.  
12 Follow -up should occur every 1 month ( ± 2 weeks).  
13 Treatment Pause Modified Schedule: During treatment breaks, QoL assessments and radiological assessments should continue t o follow the same frequency (every 6 week s).  All 
remaining assessments only need to be completed when/if the patient comes in to clinic for a scan or QoL assessment during th is break with the exception of safety monitoring, CBCs and 
serum chemistry collection.  Safety monitoring and labs should be collected at a reduced rate of a minimum of every [ADDRESS_624392] clinic visit, or at a higher frequency based on 
investigator judgment.  If/when a patient restarts treatment, the cycle 2 and beyond schedule should be resumed.  
14 Within 14 days of C1 D1. 
 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624393] of care assessments to evaluate for AEs. 
This may include, but is not limited to, verbal reports from the pa tient and/or caregiver, physical 
examination and laboratory findings. Adverse events should be reported throughout the course 
of the study, including during the 30 day follow -up period (or until death or withdrawal of 
consent if they occur before the end o f this period).  
8.3 Physical Exam  
Physical examination will include a careful assessment of all body systems, including the skin; 
central and peripheral nervous system; eyes; ears, nose and throat; respi[INVESTIGATOR_696], musculoskeletal 
and cardiovascular systems; abdomen and extremities. Particular  attention should be paid to 
areas of possible neoplastic involvement.  
8.4 Vital Signs  
Vital signs should include height (screening only), weight, resting blood pressure, pulse, 
respi[INVESTIGATOR_697], and temperature.  
8.5 Performance Status Assessment  
The Eastern Coop erative Oncology Group (ECOG) performance status will be obtained by [CONTACT_74320]/her designee by [CONTACT_16022]. A 
description of the ECOG performance status criteria is summarized in Appendix II.  
8.6 Quality of Life Assessments  
A quality of life assessment will be performed using the EQ -5D-5L and the 
EORTC -QLQ -C30 + LC13), to be collected via an electronic ePRO device. The EORTC 
QLQ -C30 is a questionnaire developed to assess the quality of life of cancer  patients . Patient 
reported symptoms from EORTRC -QLQ are recorded on a 4 -point scale with values ranging 
from 1 (no symptoms experienced at all) to 4 (symptomology experienced is very much). The 
EORTC QLQ -LC13 is a lung cancer specific module to be used in  conjunction with the EORTC 
QLQ -C30. The LC13 covers typi[INVESTIGATOR_485947], such as cough, pain, 
dyspnea, sore mouth, peripheral neuropathy, hair loss ( Koller, 2015 ) with 13 questions . The 
EORTC -QLQ -C30 + LC13 has a total of 43 questions.  The EQ -5D-5L consists of the 
EQ-5D-5L descriptive system and the EQ visual analogue scale. The descriptive system 
comprises 5 dimensions: mobility, self -care, usual activities, pain/discomfort, and 
anxiety/depression).  Each dimension has 5 levels: no problems, slight problems, moderate 
problems, severe problems, and extreme problems.  
Two additional single item patient -reported outcomes assessments, the PGI -S and the PGI -C, 
will be administered at each quality of life as sessment. The PGI -C is not included in the 
screening assessment, since the baseline assessment is not applicable for this instrument.  
Patients in Parts 1 and 2 will be required to complete the QoL questionnaires at time points 
outlined in the Schedule of A ssessments (at screening and every 6 weeks thereafter). On days 
that the patient is to receive study drug, assessments should be completed prior to study drug 
administration, and prior to any other assessment procedures . The first collection of quality of 
life assessments must be completed at screening. It is intended that questionnaires be completed 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624394] OBER 2021  
Proprietary and Confidential  Page 68  
 in clinic on days of dosing. A ± one -week window is allowed in order to assist synchronizing 
survey assessment with dosing. The sequence in which these questio nnaires are completed 
should be as follows: the EORTC QLQ -C30 should be administered first, followed by [CONTACT_120372] -LC13, the PGI -C and PGI -S, and the EQ -5D-5L in this order. The QoL 
questionnaires should be completed in a language that is understood by [CONTACT_102]. Only 
validated and approved translations can be used.  
8.7 Electrocardiogram and Pharmacokinetic -Matched Holter Monitoring  
At screening, for Part 1 and 2, a single 12 -lead ECG will be performed to include a description 
of the cardiac rate, rhythm,  interval durations, and an overall impression, to determine 
eligibility. This will be assessed locally by [CONTACT_737].  
Patients enrolled to Part 1 will undergo serial Holter monitoring ECG recordings and 
time-matched PK sampling. Holter monitoring comprises continuous ECG recording, and ECG 
extractions will be made via the vendor at the time points indicated within Table 7. ECG 
recordings will be time -matched with PK samples in order to assess any relationship between 
blood levels of irinotecan liposome injection and its metabolite SN -38 and possible QTcF 
interval changes, as shown in Table 5. Holter monitor ing equipment will be provided, additional 
details regarding ECG collection should be followed in accordance with the central ECG 
manual.  
Based on the results of the Part 1 Holter data analysis, additional Holter data may be collected 
in Part  2 at the disc retion of the Sponsor.  
Table 5: Part 1 PK and ECG Extraction Time Points  
Part 1 PK and ECG Extraction Time Points   
Cycle, 
Day Time point  PK ECG  
(Holter monitoring, 
continuous ECG recording)  ECG 
Recording 
Duration  
C1D1  Pre-dose x x 
30 hours 
continuous  C1D1  End of irinotecan liposome injection 
infusion  x x 
C1D1  2 hours after end of infusion (±1 
hour)  x x 
C1D2  Approximately 24 hours after end of 
irinotecan liposome injection 
infusion  x x 
C1D8  Day of visit  x x 5 hours  
C1D15  Pre-dose x x 5 hours  
PK samples are collected in Part 1 and Part 2, however the PK matched ECG extractions are only 
performed during Part 1.  
C=cycle; D=day; ECG=electrocardiogram; PK=pharmacokinetic   
8.8 Disease Evaluation  
Tumor assessments will be performed at screening and every 6 weeks (± 1 week) from C1D1 
using the RECIST guidelines Version 1.1 (Parts  1 and 2) and the RANO -BM criteria for CNS 
lesions (Part 2). All patients will have imaging of the brain at screening  and at each restaging.   
The tumor assessment at screening are:  
• CT with contrast (chest/abdomen required and pelvis if clinically indicated)  
• Brain MRI with contrast.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624395] of care within 28 days of enrollment are 
acceptable as long they are consistent with protocol requirements, and imaging data is available 
to transmit for central review per IMI ICON specifications.  
The tumor assessment every 6 weeks (± 1 week) from C1D1 are:  
• CT with contrast (chest/abdomen requ ired and pelvis if clinically indicated)  
• Brain MRI with contrast.  
For patients who are allergic to IV contract or cannot tolerate IV contrast due to impaired renal 
function or other issues, a regular CT or MRI is acceptable. Each follow -up tumor assessme nt 
should use the same assessment method as performed at screening, unless medically 
contraindicated. Patients who discontinue study treatment for reasons other than disease 
progression by [CONTACT_393] (or RANO -BM for CNS lesions in Part  2) should continue to be  
followed on the same schedule until radiological documentation of progressive disease (based 
on local radiology review and/or investigator's assessment) or start of another treatment. The 
Sponsor will collect and store all tumor measurement images on all patients throughout the 
study; however, progressive disease will be determined by [CONTACT_485958]/or 
investigator assessment. A review of the scans will be performed by [CONTACT_485999]. Details of BICR tumo r assessment process and approach 
will be described in a separate imaging charter document.  
For Part 2 only, comparison of the rate of development/time to development of CNS 
progression and development of new CNS metastases (exploratory endpoint), tumor r esponses 
in the CNS will assessed using the response criteria developed by [CONTACT_337171] -oncology Brain Metastases (RANO -BM) working group ( Lin 2015 ). See Appendix  III 
for details of the RANO -BM response assessment.  
9 LABORATORY PROCEDURES AND ASSESSMENTS  
9.1 Complete Blood Count  
The CBC will include the following: hemoglobin, hematocrit, platelet count, RBC, WBC with 
differential (neutrophils, lymphocytes, monocytes, eos inophils, basophils and other cells).  
Local laboratory results may be used for enrollment and dosing decisions.  
9.2 Serum Chemistry  
Serum chemistry will include electrolytes (sodium, potassium, chloride and bicarbonate), blood 
urea nitrogen (BUN), serum creati nine, glucose, bilirubin, AST, ALT, alkaline phosphatase, 
lactate dehydrogenase, uric acid, total protein, albumin, calcium, magnesium and phosphate.  
A chemistry sample must be sent to the central laboratory; local laboratory results may be used 
for enroll ment and dosing decisions.  
9.[ADDRESS_624396]  
For women of childbearing potential, (refer to Section 4.2 Exclusion Criterion  (2) for 
definition), pregnancy tests should be performed via se rum β -HCG within [ADDRESS_624397] be confirmed via serum β -HCG.  
9.4 UGT1A1*[ADDRESS_624398] 
for UGT1A1*28 genotype from all pa tients. The result is not needed prior to the initial dose of 
irinotecan liposome injection or topotecan, but the result will be provided to the site. All patients 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624399] OBER 2021  
Proprietary and Confidential  Page 70  
 receiving irinotecan liposome injection will receive the same starting dose regardless of th eir 
UGT1A1*28 genotype.  
9.5 Pharmacokinetic Sampling  
Plasma samples will be collected to determine the levels of irinotecan and SN -38. The PK time 
points are outlined in Table  6. PK samples will be collected during Parts 1 and 2 of the study.  
Table  6: Pharmacokinetic Sampling Plan  
Sample  Timepoint  Window  
 Part 1:  
1 Cycle 1 Day 1 (Pre-Dose): prior to irinotecan liposomal injection  -24 hr  
2 Cycle 1 Day 1 (Post -Dose): at the end of the irinotecan liposomal 
injection infusion.  +15 min  
3 Cycle 1 Day 1 (Post -Dose): at 2 hours after end of the irinotecan 
liposomal injection infusion.  ±1 hr 
4 Cycle 1 Day 1 (Post -Dose): at 24 hours after end of the irinotecan 
liposomal injection infusion.  ±6 hr  
5 Cycle 1 Day 8: at any time of day.  ±1 day  
6 Cycle 1 Day 15 (Pre -Dose): prior to irinotecan liposomal injection 
infusion.  -24 hr  
7 Cycle 2 Day 22: at any time of day.  ±1 day  
8 Early withdrawal visit: at any time of day.   
  Part 2  
1 Cycle 1 Day 1 (Pre -Dose): prior to irinotecan liposomal injection  -24 hr  
2 Cycle 1 Day 1 (Post -Dose): at the end of the irinotecan liposomal 
injection infusion.  +15 min  
3 Cycle 1 Day 1 (Post -Dose): at 2 hours after end of the irinotecan 
liposomal injection infusion.  ±1 hr  
4 Cycle 1 Days 2 to 6 (optional sample*): anytime between 1 and 5 days 
after the start of irinotecan liposomal injection infusion.  ±3 days  
5 Cycle 1 Day 8: at any time of day.  ±1 day  
6 Cycle 1 Day 15 (Pre -Dose): prior to irinotecan liposomal injection 
infusion.  -24 hr  
For Part 2 of the study, PK samples are only expected for patients enrolled to the irinotecan liposome injection arm. 
hr=hour; min=minutes  
*Optional sampling: to be taken if the patient visits or is at the clinic on these days  
Directions for processing and shippi[INVESTIGATOR_485948]. Full details regarding the destruction processes for these 
samples are documented in the PK Sample Management Plan.  
Residual plasma samples used for irinotecan liposome injection and SN -38 analysis may also 
be used for exploratory analysis. This could include using lef tover plasma samples for protein 
binding analysis, metabolite profiling or analysis of excipi[INVESTIGATOR_840]. Plasma samples remaining from 
the analysis may be retained by [CONTACT_486000] (i.e. long -term 
stability, reproducibility and bioana lytical method cross -validation).  
9.[ADDRESS_624400] agreed to it by 
[CONTACT_486001]. Archival tumor 
tissue samples will be collected at baseline (C1D1), if available. Blood and stool samples at 
proposed timepoints will be collected as indicated in schedule of assessments Section  7: 
• Plasma (5 mL, dry tube)  
• Blood for RNA (2.5 mL, Paxgene RNA tube)  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624401] OBER 2021  
Proprietary and Confidential  Page 71  
 • Blood for DNA (2.5 mL, Paxgene DNA tube)  
• Blood for cfDNA (10 mL, Streck tube)  
• Stool sample (outlined in laboratory manual).  
Instructions for collection, processing, handling and shipment of the samples for biobanking 
will be outlined in the laboratory manual. Full details regarding the destruction processes for 
these samples are documented in the Biobanking Sample Management Plan.  
Samples will be archived in a central biorepos itory designated by [CONTACT_486002]/or the EMA and will not carry personal identification (such 
as patient’s social security number or name). The samples will be destroyed no more than 
15 years after the en d of the main study or at the patient’s request.  
Blood samples are biobanked for future analysis of additional circulating markers, including 
proteins, pharmacogenetic and pharmacogenomic biomarkers (including potential genetic 
research).  
Analysis from the  biobank samples will be performed outside the scope of the main study and 
reported separately. Exploratory analysis techniques, including graphical representations, may 
be employed, including graphical representations, appropriate to examine relationships  between 
the study endpoints and observed genotypes.  
Only those designated by [CONTACT_486003]. All information 
collected will be kept strictly confidential and all clinical information will be anonymous. This 
means that no  personally identifiable information will be retained with the results of the 
exploratory analyses, so that no individual or collective results will be linked to the individual 
patient whose sample was taken in the study. No individual genetic results will  be 
communicated to the Investigator or patient unless required by [CONTACT_1295]. The Sponsor 
will comply with all local regulations related to the establishment, management and application 
of a human blood samples biobank.  
[ADDRESS_624402]. 
Worsening of a medical condition of  the underlying disease (e.g. progression of small cell lung 
cancer), for which the efficacy of the study drug is being evaluated will not be considered an 
AE in this study.  
10.1.2  Serious Adverse Events  
A serious adverse event (SAE) is any untoward medical occur rence that at any dose:  
• Results in death.  
• Is life -threatening (an event in which the patient was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it 
were more severe).  
• Requires in -patient hospi[INVESTIGATOR_1081] 
(Exception: hospi[INVESTIGATOR_5187] a pre -existing condition that did not 
worsen during the study is not considered an AE. NOTE: Complications that occur 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624403] OBER 2021  
Proprietary and Confidential  Page 72  
 during hospi[INVESTIGATOR_485949] a complication prolongs hospi[INVESTIGATOR_059], then the 
event is serious).  
• Results in persistent or significant disability/incapacity.  
• Is a congenital anomaly or birth defect.  
• Other important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_485950]. Examples of such events are intensive 
treatment in an emergency room for allergic bronchospasm; blood dysc rasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug dependency or 
drug abuse.  
In addition to the above criteria, the following is considered a medically important event and 
must be reported to the Sponsor under the SAE repor ting rules in Section  10.3 within 24  hours 
of site awareness, irrespective of causality:  
• Thrombo -embolic events, NCI CTCAE Grade 1 to 5.  
While the term “severe” is often used to describe the intensity (severity) of an event, the event 
itself may be of rela tively minor significance (such as a severe headache). This is not the same 
as “serious”, which is based on a patient/event outcome or action criteria usually associated 
with events that pose a risk to a patient’s life or functioning.  
Any additional AE tha t the Sponsor or Investigator considers serious should be immediately 
reported to the Sponsor and included in the corporate SAEs database system. This includes any 
suspected or confirmed coronavirus COVID -19 (SARS -CoV -2) infection (seriousness criteria 
should be “other medically significant” if no other seriousness criteria are present (e.g. 
hospi[INVESTIGATOR_11956])).  
10.[ADDRESS_624404] of care assessments to evaluate 
for toxicity and symptoms of drug -induced AEs. This may include, but is not limited to, verbal 
reports from the patient and/or caregiver, physical examination and laboratory f indings.  
All AEs, whether serious or not, will be described in the source documents and the AE page of 
the case report form. All new events, as well as those that worsen in intensity or frequency 
relative to screening, which occur after signing of informed  consent and during the [ADDRESS_624405] be reported any time the Investigator becomes aware of such an event, 
even if this occurrence is after the 3 0 day follow -up period. All AEs should be followed until 
resolution, until death or withdrawal of consent.  
Laboratory, vital signs or ECG abnormalities are to be recorded as AEs only if they are 
medically relevant, e.g. symptomatic, requiring corrective tr eatment, leading to discontinuation 
and/or fulfilling a seriousness criterion.  
Information to be reported in the description of each AE includes:  
• A medical diagnosis of the event (if a medical diagnosis cannot be determined, a 
description of each sign or s ymptom characterizing the event should be recorded)  
• The date of onset of the event  
• The date of resolution of the event  
• A determination of whether the event is serious or not  
• A determination of relatedness to the study drug  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624406] OBER 2021  
Proprietary and Confidential  Page 73  
 • Action taken: none; change in the  study drug administration (e.g., temporary interruption 
in dosing); drug treatment required; non -drug treatment required; diagnostic or 
concomitant procedure performed; patient discontinued from the study treatment 
(complete Treatment Termination case rep ort form)  
• Outcome: resolved without sequelae; resolved with sequelae; event ongoing; subject died 
(notify the Sponsor immediately, and complete the SAE page and the Subject Death 
page).  
10.[ADDRESS_624407] 
Research Organizations (CRO’s) medical team by [CONTACT_16062] e -mail. Within [ADDRESS_624408] to the event should be included 
with the SAE form. Care should be taken to ensure that the patient’s identity is protected and 
the patient’s identifiers (as assigned at the time of study enro llment) are properly mentioned on 
any copy of source document provided to the Sponsor. For laboratory results, include the 
laboratory normal ranges.  
In case of accidental or intentional overdose of study drug (irinotecan liposome injection or 
topotecan), e ven if asymptomatic or not fulfilling a seriousness criterion, the overdose is to be 
reported to the Sponsor immediately (within 24 hours) using the AE and SAE forms.  
All other SAEs and any medically important events (Section  10.1.2 ) must be reported to the 
Sponsor within [ADDRESS_624409] 
information shall be maintained at the site within the regulatory binder.  
All SAEs will be evaluated by [CONTACT_1689]. If meeting the requirements for expedited 
reporting, the Sponsor will report the SAE to  all regulatory authorities with jurisdiction over 
ongoing trials with the study drug, to the EC and to all other investigators involved in clinical 
trials with the study drug. The Investigator is responsible for reporting all SAEs to the 
appropriate IRB/E C, if appropriate according to local requirements.  
10.4 Determining the Severity and Relatedness of an Event  
10.4.1  Grading the Severity of an Adverse Event  
Each AE will be graded according to the NCI CTCAE Version  5.0, which may be found at 
http://ctep.cancer.gov/rep orting/ctc.html. For events not listed in the CTCAE, severity will be 
designated as mild, moderate, severe, or life -threatening, or fatal which correspond to 
Grades  1, 2, 3, 4, and 5, respectively on the NCI CTCAE, with the following definitions:  
Mild : an event not resulting in disability or incapacity and which resolves without 
intervention;  
Moderate : an event not resulting in disability or incapacity but which requires 
intervention;  
Severe : an event resulting in temporary disability or incapacity and whic h requires 
intervention;  
[COMPANY_003]
[COMPANY_003]
IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624410] OBER 2021  
Proprietary and Confidential  Page 74  
 Life-threatening : an event in which the patient was at risk of death at the time of the 
event;  
Fatal : an event that results in the death of the patient.  
10.4.[ADDRESS_624411] all female patients to inform them immediately should they 
become pregnant during the study. The Investigator should counsel the patient, discuss the risks 
of continuing with the pregnancy and the possible effects on the fetus. Monitoring of the patient 
should continue until conclusion of t he pregnancy. If the Investigator becomes aware of a 
pregnancy occurring in the partner of a male patient participating in the study, this should be 
reported to the Sponsor. Monitoring of the partner pregnancy should continue until conclusion 
of the pregna ncy. 
11 STATISTICAL METHODS  
Detailed methodology for summary and statistical analyses of the data collected in this study 
will be documented in a SAP, which will be dated and completed prior to database lock. The 
SAP may modify the plans outlined in the proto col; however, any major modifications of the 
primary endpoint and/or its analysis will also be reflected in a protocol amendment.  
11.1 General Considerations  
Categorical variables will be summarized by [CONTACT_119395] (number and percentages 
of patients ) and continuous variables will be summarized by [CONTACT_9086] (mean, 
standard deviation, median, minimum, maximum).  
The efficacy and safety of irinotecan liposome injection in Part [ADDRESS_624412] whether OS is increased in 
patients treated with irinotecan liposome injection.  
A total of 450 patients will be randomized in a 1:[ADDRESS_624413] 87% power to detect a true hazard ratio of HR ≤0.714 (median OS: 
7.5 versus 10.5  months) using a stratified logrank test (stratified by [CONTACT_486004]) with overall 1 -sided significance level of 0.025 (adjusted for interim analyses).  
Assuming enrollment over [ADDRESS_624414] -to-follow -up rate of 5% acros s both treatment arms, the timing of the primary analysis 
is expected to be at 37  months.  
An interim OS analysis for futility will be conducted when approximately 29% of the planned 
final number of OS events (i.e., approximately 100 of 350 OS events) has b een observed in the 
ITT population. To control type I and type II errors, the planned interim analyses for OS will 
utilize an alpha and (non -binding) beta spending function approach with Hwang -Shih-Decani 
spending and γ  parameter equal to -4.5 and -1 for e ach error type, respectively ( Hwang, 1990 ). 
Non-binding for the futility indicates that the boundary will be constructed in such a way that 
it can be overruled if desired without inflating the type I or II error. Nominal a lpha of 0.0001 
will be spent at the supplemental interim analysis requested by [CONTACT_8415]. Since the boundary is 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624415] the nominal α spent at the supplemental 
interim analysis. P -boundary will be used as the criteria for the formal statistical inference.  
The interim analysis specifications per the plan are provided in Table 7. 
Table 7: Type I (α) and Type II (β) Error Spending for the Planned OS Analyses  
  Futility  Effica cy 
Analysis  D Zboundary  pboundary  Cum β 
spend  HR crit Zboundary  pboundary  Cum α 
spend  HR crit 
Interim  100 0.276  0.609  0.025  1.057  -3.181  0.001  0.001  0.529  
Final  350 -1.967  0.025  0.13 0.810  -1.967  0.025  0.025  0.810  
D = # of OS events at analysis. Z boundary  is the critical test statistic value at which futility (< Z) or efficacy (> Z) would be 
concluded. p bounday is the critical one -sided p -value threshold for the comparison (>p for futility, <p for efficacy). HR crit is 
the observed hazard ratio thre shold (> HR for futility, < HR for efficacy).  
 
The DMC will be responsible for evaluating the futility OS analysis and making a 
recommendation about early termination due to observed study results. At the time of the 
interim analysis, ORR by [CONTACT_486005] a ssessments will be analyzed descriptively by [CONTACT_486006] 200 patients randomized in Part 2 of the study (i.e. approximately 
100 patients from each arm). The independent DMC will notify the Sponsor if pre -specified 
criteria for ORR are  met. A supplemental interim analysis is planned on data collected [ADDRESS_624416] patient has been randomized based on the ITT population to fulfill FDA 
recommendation. At this timepoint, OS  and ORR (supported by  [CONTACT_109955] ( DOR )) 
will b e summarized descriptively. Further detail on statistical analysis is provided in SAP. A 
Data Integrity Management Plan will also be created and finalized prior to the descriptive 
analysis of ORR at the time of the interim analys is to clearly describe the data handling 
approach and the data transfer and review pathway.  
Key secondary endpoints are PFS, ORR, and change from baseline in patient -reported 
symptoms (dyspnea and cough).  
Key secondary endpoints will be tested no more than once. To control the overa ll Type I error 
rate for the comparison between irinotecan liposome injection and topotecan for the primary 
and secondary endpoints, a hierarchical approach will be applied to the statistical testing of the 
secondary endpoints. The statistical inference fo r the first secondary endpoint of PFS (by [CONTACT_19377]) 
will only be performed if the primary endpoint, OS, is statistically significant. The second 
secondary endpoint of ORR (by [CONTACT_19377]) will only be tested if PFS is statistically significant. 
Similarly, the PRO end points will only be tested if ORR is statistically significant. Any 
parameter which is not statistically significant will be regarded as descriptive and exploratory. 
Further information on alpha control methods will be provided in the SAP.  
Where treatment comparisons are by [CONTACT_486007], stratification factors will be region and 
platinum sensitivity with classification according to the randomization designation.  
Any additional data collected after primary and secondary analyses have been completed ma y 
be used in post -hoc analysis as deemed appropriate.  
11.[ADDRESS_624417] one dose of irinotecan liposome injection will 
comprise the Part 1 safety and efficacy populations. The safety and efficacy of these patients 
will be presented descriptively.  
Patients randomized in Part 2 will comprise the ITT population. This will be the population that 
is evaluated in comparison to evaluate the efficacy (OS, PFS, ORR) of the experimental arm. 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624418] OBER 2021  
Proprietary and Confidential  Page 76  
 In the ITT analyses of ef ficacy, each patient will be considered according to the randomized 
treatment assignment. Patients who received any dose of any study drug will define the Part  2 
safety population.  
Patient reported outcome (PRO) endpoints will be evaluated on the ITT.  
The PK population will include all irinotecan liposome injection treated patients which received 
at least one dose, and who had at least one plasma concentration and no major protocol 
deviations affecting PK variables.  
11.4 Disposition, Demographics, and Baseline Characteristics  
Disposition of patients will be summarized, including those screened, randomized, treated, 
discontinued from treatment, and discontinued from study. Reasons for discontinuation will be 
tabulated. Demographic and baseline characteristics wil l be summarized. Medical history and 
prior medications will be tabulated.  
11.5 Efficacy Analysis  
11.5.1  Primary Efficacy Analysis (Part 2)  
Overall survival is defined as the number of months from randomization in Part [ADDRESS_624419] (stratified by [CONTACT_485963] ) comparing the OS difference b etween two treatment arms with level of 
significance controlled at the one -sided 0.025 level. Kaplan -Meier methods will be used to 
estimate median OS (with 95% CI) and to display OS time graphically. A stratified Cox 
proportional hazards model will be used  to estimate hazard ratio and its corresponding 95%  CI. 
Sensitivity analyses for OS will be described in the SAP and will include subgroup analyses 
(according to levels of each stratification factor and other potential prognostic variables).  
11.5.2  Key Secondary Analyses (Part 2)  
Key secondary endpoints are PFS, ORR, and change from baseline in patient -reported 
symptoms (dyspnea and cough). Key secondary endpoints will be tested no more than once.  
[IP_ADDRESS]  Progression -free Survival  
Progression -free survival is the time fro m randomization in Part [ADDRESS_624420] documented 
objective disease progression (PD) using RECIST Version 1.1 (or RANO -BM criteria for CNS 
lesions) or death due to any cause, whichever occurs first. Determination of PFS will be based 
on BICR tumor assessme nt, with PFS based on investigator tumor assessments as a sensitivity 
analysis.  If neither death nor progression is observed, data will be censored on the date of the 
last observed tumor assessment date. Patients without a valid tumor response evaluation a t 
enrollment/randomization will be censored on the date of enrollment/randomization. Patients 
starting a new anti -cancer treatment prior to documented PD will be censored at the date of the 
last observed tumor assessment prior to start of the new treatment . Patients with documented 
PD or death after an unacceptable long interval (i.e., 2 or more missed or indeterminate 
scheduled assessments) will be censored at the time of the last observed non -PD tumor 
assessment date prior to progression or death. Details  of data handling for censoring of PFS 
will be provided in the SAP.  
The difference in PFS between treatments will be evaluated using a stratified log -rank test 
(stratified by [CONTACT_485962] ). Kaplan -Meier methods will be used to estimate 
median PFS (with 95% CI) and to display PFS time graphically. A stratified Cox proportional 
hazards model will be used to estimate the PFS hazard ratio and its corresponding 95%  CI. 
Sensitivity analyses for PFS will be described in the SAP.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624421] OBER 2021  
Proprietary and Confidential  Page 77  
 [IP_ADDRESS]  Objective Respon se 
Objective response rate is the proportion of patients who achieve partial response (PR) or 
complete response (CR) according to RECIST Version 1.1 guidelines (or RANO -BM criteria 
for CNS lesions in Part  2). An estimate of the ORR and its 95% CI will be c alculated. The 
difference in ORR between treatment groups will be compared using Cochran -Mantel -Haenszel 
method, incorporating analysis stratification factors (region and platinum sensitivity).  
In addition to investigator assessment, a BICR review of the t umor assessment images will be 
performed for all patients included in the study, and more specifically at the time of:  
• the interim analysis for the descriptive analysis of ORR based on the first 200  patients 
randomized in both arms (i.e. approximately 100  patients from each arm), as well as for 
the patients included in Part 1 and treated with the selected dose for Part  2. 
• the supplemental interim analysis, for tumor images for all randomized patients collected 
[ADDRESS_624422] on secondary endpoint ORR will be based on BICR tumor assessment , with 
ORR based on investigator tumor assessments as a sensitivity analysis . 
[IP_ADDRESS]  Change From Baseline in Dyspnea and Cough Symptoms  
The efficacy of irinotecan liposome injection compared to topotecan on dyspnea and will be 
evaluated considering the response to treatment in terms of:  
• Change from baseline to Week  12 in patient’s perceived dyspnea, as measured by 
[CONTACT_26740] -C30/LC13  
• Change from baseline to Week  12 in patien t’s perceived cough, as measured by [CONTACT_54656] -LC13  
Change from baseline defined as post -baseline value minus baseline value will be calculated 
for each assessment.  
Change from baseline at Week  12 in dyspnea/cough will be analysed using an ANCOVA model 
with covariates treatment group, stratification factors (region, platinum sensitivity, performance 
status, prior immunotherapy), and PRO score at baseline. Patients having missing baseline, 
Week  6, or Week  12 dyspnea/cough score will have their missing dys pnea score imputed under 
the Missing at Random (MAR) assumption using the multiple imputation (MI) methodology in 
the primary analysis, and under the missing not at random (MNAR) assumption in the 
sensitivity analysis. Detailed analysis methods for PRO end points will be discussed in the SAP.  
11.5.3  Exploratory Objectives Analyses  
[IP_ADDRESS]  Time to treatment failure  
Time to treatment failure (TTF) is the time from randomization to the occurrence of 
discontinuation of treatment for any reason, including disease progression, t reatment toxicity, 
and death. The treatment -failure date for patients who discontinue for reasons other than 
RECIST Version 1.1 (or RANO -BM criteria for CNS lesions in Part 2) progression will be the 
date of the last study drug administration. Patients who  have not discontinued treatment prior 
to the data cut -off date will be censored at the date of last tumor assessment documenting no 
objective progression. TTF will be described by [CONTACT_5263] -Meier methods and treatments will be 
compared using stratified log -rank test.  
[IP_ADDRESS]  EORTC -QLQ outcomes  
Analysis of the EORTC -QLQ -C30 questionnaires will be performed in accordance with the 
EORTC guidelines ( Fayers, 2001 ). The subscales of the EORTC QLQ -C30 and the QLQ -LC13 
will be scored based on t he EORTC scoring manual. Scores will be standardized such that 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624423] OBER 2021  
Proprietary and Confidential  Page 78  
 higher scores on the EORTC QLQ -C30 or the QLQ -LC13 will represent higher (“better”) levels 
of functioning and/or a higher (“worse”) level of symptoms.  
EORTC QLQ -C30 and QLQ -LC13 scale scores wi ll be summarized by [CONTACT_145423] (mean, standard deviation, minimum, maximum and median) on ITT. An 
ANOVA model will be used to analyze the change in the EORTC QLQ -C30 and QLQ -LC13 
scale scores from baseline to post -baseline  visits.  
For each QLQ -C30 and QLQ -LC13 subscale, the proportion of patients with improvement will 
be tabulated by [CONTACT_486008] a logistic 
regression model adjusting for the randomization stratification  factors (region and platinum 
sensitivity).  
Additional EORTC QLQ analyses will be performed and details are provided in a standalone 
PRO SAP.  
[IP_ADDRESS]  Patient Global Impression of Change and Severity  
The PGI -C and PGI -S will be used as anchors in analyses designed to compute a responder 
definition of the EORTC QLQ scales. This responder definition will be used in analysis of the 
specified EORTC QLQ -C30 and QLQ -LC13 scales as secondary endpoints.  
[IP_ADDRESS]  EQ-5D-5L 
EQ-5D-5L visual analog scale (VAS) will be descriptively repor ted as a total score. Utility 
score and change from baseline over time will be reported. Mean change scores will be 
compared between treatment groups descriptively and may be explored via longitudinal 
modeling (i.e., covariate analysis and repeated measure s modeling).  
[IP_ADDRESS]  Time to CNS Progression  
The time to CNS progression is defined as the time from randomization to the development of 
CNS progression as defined by [CONTACT_342786] -BM working group ( Lin, 2015 ). Time to CNS 
progression  (by [CONTACT_486009])  will be described by [CONTACT_5263] -Meier 
methods and treatments will be compared using stratified log -rank test.  
[IP_ADDRESS]  Biomarkers  
The biobanked samples may be used to identify prognostic markers, as well as predictive 
markers (i.e,  other variants of drug metabolizing enzymes such as UGT1A1, p53 mutations) 
that may correlate with the PKs, efficacy and safety of irinotecan liposome injection.  
11.6 Safety Analysis  
Safety analyses (AEs and laboratory analyses) will be performed using the safety population, 
defined as all patients receiving any study drug. Treatment assignment will be according to 
actual treatment received. Adverse events will be coded using MedDRA (Version 21.0 or later). 
Severity will be graded according to the NCI CTCAE Version  5.0. 
Treatment -emergent adverse events are defined as any AEs reported from the date of first study 
drug exposure to [ADDRESS_624424] date of study drug exposure. Frequency and percentages 
of patients will be summarized for: any grade TEAE, G rade 3 or higher TEAE, study -drug 
related TEAE, serious TEAE, TEAE leading to dose modification, TEAE leading to study drug 
discontinuation, death and TEAE leading to death. Adverse events will be summarized by 
[CONTACT_6657]. All AE  data will be listed by [CONTACT_4676]. Based on 
accumulated data a subgroup analysis of safety by [CONTACT_15924]1A1*28 allele status may be performed.  
Laboratory data will be summarized according to parameter type. Where applicable, toxicity 
grading for laboratory safety p arameters will be assigned based on NCI CTCAE Version  5.0 
criteria.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624425] OBER 2021  
Proprietary and Confidential  Page 79  
 11.7 Pharmacokinetic Analysis  
11.7.1  Listings and Summary Statistics of Concentrations  
Individual plasma concentrations for total irinotecan and SN -38 will be listed and summarized 
by [CONTACT_486010], for both Part 1 and for Part 2, using descriptive statistics for 
continuous variables (number of available observations, number of below the limit of 
quantification  (BLQ), mean, SD, %CV, geometric mean and %CV geomean , median, minimum, 
maximum).  
11.7.[ADDRESS_624426] modeling. The population PK model previously 
developed on historical data will be applie d to this SCLC study by [CONTACT_486011]. 
A full description of this Population PK analysis of the concentration data will be captured 
separately in a data  analysis plan, and results will be reported in a standalone report.  
11.7.3  Pharmacokinetics/Pharmacodynamics Relationship  
Graphical exploration will be performed to investigate any relationship between PK and 
pharmacodynamic endpoints (efficacy, safety). If a trend is shown, PK/PD modelling will be 
performed, and this will be described in a separate Data Analysis Plan and reported in a 
standalone report.  
12 STUDY ADMINISTRATION  
12.1 Pre-Study Documentation  
Prior to initiating the trial, the Investigator will provide th e Sponsor or designee required 
documents according to ICH GCP, and at a minimum:  
• A signed FDA Form 1572 or equivalent  
• A current (i.e. updated no more than 12 months prior) curriculum vitae for the Principal 
Investigator [INVESTIGATOR_53477] -investigator listed on the FDA Form 1572 or equivalent that is 
signed and dated. A copy of the current medical license for the Investigator and each 
sub-investigator  
• A letter from the IRB/EC stipulating approval of the protocol, the informed consent 
document, and any other mater ial provided to potential trial participants with information 
about the trial (e.g. advertisements)  
• The current IRB/EC membership list for the reviewing IRB/EC  
• A signed Investigator Protocol Agreement  
• A completed financial disclosure form for the Investiga tor and all sub -investigators  
• A current laboratory certification for the local reference laboratory and curriculum vitae 
of the laboratory director  
• A list of current laboratory normal values for the reference laboratory.  
12.[ADDRESS_624427] the da te on which the 
patient signed informed consent prior to the patient’s participation in the trial. Source 
documents must completely reflect the nature and extent of the patient’s medical care, and must 
be available for source document verification against entries in the case report forms when the 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624428] OBER 2021  
Proprietary and Confidential  Page 80  
 Sponsor’s monitor visits the investigational site. Source documents regarding procedures such 
as scans and laboratory evaluations performed as part of the standard of care prior to enrollment 
in the study can be us ed to fulfill certain screening and baseline assessments. Source data must 
be attributable, legible, contemporaneous, original, accurate and complete. All information 
obtained from source documents will be kept in strict confidentiality. Source data sent t o the 
Sponsor or the Sponsor’s representative as supporting documentation for SAEs will be 
de-identified to preserve confidentiality.  
12.3 Trial Ethics  
The study will be performed according to the principles of the Declaration of Helsinki, the 
International Council on Harmonization guidance (ICH) on Good Clinical Practice and the 
requirements of the US FDA and/or local regulatory authorities regarding the conduct of human 
clinical trials  
12.4 Patient Informed Consent  
No study related procedures will be performed u ntil a patient or a patient’s legal representative 
has given written informed consent. The Sponsor will provide to the Investigator a sample 
informed consent document that includes all the requirements for informed consent according 
the ICH GCP, and all re quired local regulatory guidelines including applicable privacy laws. 
However, it is up to the Investigator to provide a final informed consent that may include 
additional elements required by [CONTACT_737]’s institution. Changes to the Sponsor’s sample  
informed consent should receive approval from the Sponsor or the Sponsor’s representative 
prior to use in the study. The informed consent document must clearly describe the potential 
risks and benefits of the trial, and each prospective participant must b e given adequate time to 
discuss the trial with the Investigator or site staff and to decide whether or not to participate. 
Each patient who agrees to participate in the trial and who signs the informed consent form will 
be given a copy of the signed, date d and witnessed document. The provision of informed 
consent must be documented in the medical record.  
The ICF will contain a separate section that addresses the use of all data and remaining material 
after analysis from mandatory samples and extra samples for optional future research. These 
data and biosamples may only be used for scientific health -related research to find new ways 
to detect, treat, prevent or cure health problems. Patients will be told that they are free to refuse 
to participate and may wi thdraw their consent at any time and for any reason during the study 
and the storage period. A specific consent will be required to document a patient’s agreement 
to allow any data and remaining specimens to be used for future research.  
12.[ADDRESS_624429] (IRB) or Independent Ethics Committee (IEC). The IRB or IEC 
should be duly constituted according to local regulatory requirements. Approval must be in the 
form of a letter signed by [CONTACT_59563]/IEC or the Chairperson’s designe e, must 
be on IRB/IEC stationary and must include the protocol by [CONTACT_59564]/or by [CONTACT_486012]. 
If an investigator is a member of the IRB/IEC, the approval letter must stipulate that the 
Investigator did not participate in the final vote, although the Investigator may participate in the 
discussion of the trial. The Investigator will also inform the IRB/IEC of any SAE that the 
Sponsor reports to regulatory authorities, will report on the progress of the trial at least yearly 
(or more frequently if requir ed by [CONTACT_486013]) and will provide to the IRB/IEC 
a final summary of the results of the trial at the conclusion of the trial.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624430] OBER 2021  
Proprietary and Confidential  Page 81  
 This study has the option for patients to consent to the collection of samples for biobanking for 
future explora tory analysis, and storage for up to 15 years (where local regulations allow). A 
specific informed consent is required for the collection of these samples and will be explained 
after the patient has given written informed consent for the main study. Patien ts must receive 
an explanation that they are completely free to refuse to enter the exploratory part of the study 
and may withdraw from it at any time and for any reason up to 15 years after the end of the 
study and will still be allowed to take part in th e main study.  
12.6 Monitoring  
Overall study monitoring will be conducted through a combination of on -site visit and 
centralized monitoring. Details regarding the monitoring will be described in the monitoring 
plan. A clinical monitor will make regularly schedul ed trips to the investigational site to review 
the progress of the trial, study data and site processes. At each visit, the monitor will review 
various aspects of the trial including, but not limited to: screening and enrollment logs; 
compliance with the p rotocol and study manual and with the principles of Good Clinical 
Practice; completion of case report forms; source data verification; study drug accountability 
and storage; facilities and staff.  
The actual frequency of monitoring trips will depend on the enrollment rate and performance 
at each site. The Investigator will allow the Sponsor, and/or its representatives or designees, 
access to all pertinent medical records, as required by [CONTACT_2091], in order to allow for 
the verification of data gat hered in the CRFs and for the review of the data collection process.  
During scheduled monitoring visits, the Investigator and the investigational site staff must be 
available to meet with the study monitor in order to discuss the progress of the trial, mak e 
necessary corrections to case report form entries, respond to data clarification requests and 
respond to any other trial -related inquiries of the monitor. In addition to on -site monitoring 
visits, the Sponsor and/or representatives will also be routinely  reviewing data. Any queries 
identified through this review will be managed within the systems established for query 
resolution and tracking. Inquiries related to study conduct which require further information or 
action will be discussed within the study team for appropriate and documented escalation plans. 
It is expected that response to data clarification requests and other trial -related inquiries will 
occur throughout the course of the study through regular communication with the site monitor, 
the Spons or or representatives, and review/entry of data into the electronic study database.  
At any time during the course of the study, representatives of the FDA and/or local regulatory 
agencies may review the conduct or results of the study at the investigationa l site. The 
Investigator must promptly inform the Sponsor of any audit requests by [CONTACT_21652], and 
will provide the Sponsor with the results of any such audits and with copi[INVESTIGATOR_485951].  
In accordance with l ocal regulations, such as the Health Insurance Portability and 
Accountability Act in the US and associated privacy regulations, a patient’s authorization to 
use personal identifiable health information may be required from each patient before 
commencement of research activities. This authorization document must clearly specify what 
parties will have access to a patient’s personal health information, for what purpose and for 
what duration.  
12.[ADDRESS_624431] combination. It is declared 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624432] 
successfully undergone software application training prior to entering data into the eCRF.  
Data management will be conducted by a service provider under the responsibility of the 
Sponsor’s Data Management Department. All data manageme nt procedures will be completed 
in accordance with the Sponsor’s and the CRO’s Standard Operating Procedures.  
The Sponsor will ensure that an appropriate eCRF is developed to capture the data accurately, 
and suitable queries are raised to resolve any missi ng or inconsistent data. The Investigator will 
receive their data, from the clinical study, in an electronic format (PDF files) which will be an 
exact copy of the eCRF, and will include the full audit trail for the study, for archiving purposes 
and future reference.  
Any queries generated during the data management process will be raised within the EDC 
system. It is the monitor’s responsibility to ensure that all queries are resolved by [CONTACT_486014].  
The Sponsor will also ensure that SAE data collect ed in the eCRF are consistent with 
information provided to the Sponsor’s Pharmacovigilance department (and vice versa).  
The coding of an AE, medical history and concomitant medication terms will be performed by 
[CONTACT_361537]. Concomitant medications  will be coded using the World Health 
Organisation Drug Dictionary and AEs/medical history terms will be coded using MedDRA.  
12.[ADDRESS_624433] never contain the name [CONTACT_4007] a trial patient. 
All patients in the trial will be identified by a unique identifier which will be use d on all CRF’s 
and any other material submitted to the Sponsor. All case report forms and any identifying 
information must be kept in a secure location with access limited to the study staff directly 
participating in the trial.  
12.9 Protocol Amendments  
The prot ocol will only be amended with the consent of the Sponsor and the IRB/EC. Changes 
to the protocol must be in the form of a written amendment; changes other than those of a simple 
administrative nature (e.g., a new telephone number for a medical monitor) mu st be submitted 
by [CONTACT_300341]/EC and such amendments will only be implemented after 
approval of the requisite IRB/EC. All amendments will also be submitted to the FDA and/or 
local regulatory authorities by [CONTACT_1034].  
Protocol chang es to eliminate an immediate hazard to a trial patient may be implemented by 
[CONTACT_201433]. The Investigator must then immediately inform their IRB/EC and 
the Sponsor will immediately notify applicable regulatory authorities.  
12.10  Publication  
The Sponsor encourages acknowledgement of all individuals/organisations involved in the 
funding or conduct of the study, including medical writers or statisticians subject to the consent 
of each individual and entity concerned, including acknowledgement of th e Sponsor.  
The results of this study may be published or communicated to scientific meetings by [CONTACT_486015]. For multi -centre studies, a plan for scientific publication 
and presentation of the results may be agreed and implement ed by [CONTACT_486016] a 
Steering Committee. The Sponsor requires that reasonable opportunity be given to review the 
content and conclusions of any abstract, presentation, or paper before the material is submitted 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624434] OBER 2021  
Proprietary and Confidential  Page 83  
 for publication or communicated.  This condition also applies to any amendments that are 
subsequently requested by [CONTACT_385093]. The Sponsor will undertake to comment 
on the draft documents within the time period agreed in the contractual arrangements, including 
clinical tr ial agreements, governing the relationship between the Sponsor and authors (or the 
author’s institution). Requested amendments will be incorporated by [CONTACT_347230], provided they 
do not alter the scientific value of the material.  
If patentability would be ad versely affected by [CONTACT_325582], this will be delayed until (i) a patent 
application is filed for the content of the publication in accordance with applicable provisions 
of the clinical trial agreement concerned, (ii) the Sponsor consents to the publicatio n, or (iii) 
the time period as may be agreed in the contractual arrangements, including clinical trial 
agreements, governing the relationship between the Sponsor and authors (or authors’ 
institution) after receipt of the proposed publication by [CONTACT_1034] , whichever of (i), (ii) or 
(iii) occurs first.  
The author undertakes to reasonably consider the Sponsor's request for delay to the proposed 
publication should the Sponsor reasonably deem premature to publish the results obtained at 
the then stage of the s tudy.  
12.11  Records Retention  
The Investigator will retain the records of the clinical trial (including, but not necessarily limited 
to, CRFs, source documents, informed consent forms, drug accountability records, IRB/EC 
correspondence, sponsor correspondence, etc.) for [ADDRESS_624435] be retain ed as per the GCP guidelines and local regulatory requirements, 
including, but not limited to, case report forms, signed informed consents, correspondence with 
the IRB/EC, study drug dispensing and inventory records, source documents (clinic charts, 
medica l records, laboratory results, radiographic reports) and screening/enrollment logs.  
Should the Investigator relocate or retire the responsibility for maintaining the study records 
may be transferred to another investigator. The Sponsor must be notified of the identity of the 
individual assuming responsibility for maintaining the study records and the location of their 
storage. If no other individual at the site is willing to assume this responsibility, the Sponsor 
will assume responsibility for maintaining the study records.  
12.12  Study Termination  
The Sponsor reserves the right to terminate the study at any site and at any time. Reasons for 
study termination may include, but are not limited to, the following:  
• Investigator non -compliance with the protocol, GCP or regulatory requirements  
• Insufficient enrollment  
• Safety concerns  
• Drug supply or manufacturing issues  
• The Sponsor’s decision to modify or discontinue the development of irinotecan liposome 
injection in this indication  
• A request to discontinue the study by [CONTACT_486017]/or local regulatory authorities  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624436] OBER 2021  
Proprietary and Confidential  Page 84  
 The Sponsor will promptly inform all investigators and the FDA and/or local regulatory 
authorities if the study is suspended or terminated for any reason. The Investigator will 
promptly notify the IRB/IEC if the study is suspended or terminated.  
 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624437] this study as outlined herein, including all statements regar ding 
confidentiality. I will make a reasonable effort to complete the study within the time designated. 
I will provide copi[INVESTIGATOR_485952]. I will discuss thi s material with them to ensure that they 
are fully informed about the drug and the study. I will identify study personnel conducting study 
specific procedures and appropriately document their training and/or delegated responsibilities. 
I understand that th e study may be terminated or enrollment suspended at any time by [CONTACT_429], with or without cause, or by [CONTACT_486018].  
I agree to conduct this study in full accordance with all appl icable regulations and Good Clinical 
Practice (GCP).  
 
 
_________________________________    _______________________  
Signature [CONTACT_164968]  
 
 
________________________________       
Print Name [CONTACT_7919]   
    
 
_______________________________    ______________________  
On behalf of the Sponsor      Date  
 
 
 
 Oncology  
Global Drug Development, R&D  
IPSEN   
 
[COMPANY_003]
IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624438] OBER 2021  
Proprietary and Confidential  Page 86  
 14 REFERENCES  
Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D. Phase I and 
pharmaco logic studies of the camptothecin analog irinotecan administered every 3 weeks in 
cancer patients. J Clin Oncol. 1995 Jan;13(1):210 -21. 
Adiwijaya B, Kim J, Lang I, Csõszi T, Cubillo A, Chen J -S, Wong M, Park JO, Kim JS, Rau 
KM, Melichar B, Gallego J, Fitzg erald J, Belanger B, Molnar I, Ma WW. Mechanism -based 
Population Pharmacokinetics and Pharmacodynamics of Liposomal Irinotecan in Patients with 
Cancer. Submitted for publication . 
Benjamini, Y., & Hochberg, Y. (1995). Controlling the False Discovery Rate: A  Practical and 
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society, B, 57, 
289-300. 
Benson AB, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer 
treatment -induced diarrhea. J. Clin. Oncol. 2004;22(1 4):2918 –26. 
Bossi P, Antonuzzo A, Cherny N et al. Diarrhoea in adult cancer patients: ESMO Clinical 
Practice Guidelines. Ann Oncol 2018;29(Suppl4):126 –42. doi:10.1093/annonc/mdy145.  
CAMPTOSAR® injection for intravenous use U.S. Package Insert, 2019.  
Chabot  GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, et al. Population 
pharmacokinetics and pharmacodynamics of irinotecan (CPT -11) and active metabolite SN -38 
during phase I trials. Ann Oncol. 1995 Feb;6(2):141 -51. 
Dowell JE, Amirkhan RH, Lai WS, Frawley WH, Minna JD. Survival in small cell lung cancer 
is independent of tumor expression of VEGF and COX -2. Anticancer Res. 2004 
Jul-Aug;24(4):2367 -73. 
Dowell JE. Small cell lung cancer: are we making progress? Am J Med Sci. 2010 
Jan;339(1):[ADDRESS_624439] -Line Platinum -Based Chemotherapy . J 
Thorac Oncol. 2015 Aug;10(8):1221 -8.  
Fayers, P., Aaronson, N., Bjordal, K., Curran, D., & Groenvald, M. (2001). The EORTC 
QLQ -C30 Scoring Manual (3rd Edition). Brussels: European Organisation for Research and 
Treatment of Cancer.  
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, on behalf of the ESMO. Small -cell 
lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -
up. Annals of Oncology 24 (Supplement 6): vi99 –vi105, 2013.  
Giaccone G, Ferrati P, Donadio M , et al. Reinduction chemotherapy in small cell lung cancer. 
Eur J Cancer Clin Oncol 1987; 23:1697 -1699.  
Glimm E, Maurer,W and Bretz, F. Hierarchical testing of multiple endpoints in group -
sequential trials . Statistics in Medicine. 2010; 29:219 - 228. 
Hanna N, Bunn P a., Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized Phase III Trial 
Comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated 
Estensive -Stage Disease Small -Cell Lung Cancer. JCO 2006; 24:[ADDRESS_624440] properties that influence lung cancer cell progression. Tumor Biol. 2015; 
36(11):8715 -8725.  
Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrø m S, Thaning L, 
Vilsvik J, Aasebø U, Sörenson S. Irinotecan plus carboplatin versus oral etoposide plus 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624441] OBER 2021  
Proprietary and Confidential  Page 87  
 carboplatin in extensive small -cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 
Sep 10; 26(26):4261 -7. 
Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and 
irinotecan -induced neutropenia: dose matters. J Natl Cancer Inst. 2007 Sep 5; 99(17):1290 -5.  
Hwang, I. K., Shih, W. J., and DeCani, J. S. (1990), "Group Sequential Designs Using a Family 
of Type I Error Probab ility Spending Functions," Statistics in Medicine , 9, 1439 –1445.  
Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, 
Ratain MJ. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. 
Pharmacog enomics J. 2002; 2(1):[ADDRESS_624442]; 74(23):7003 –13.  
Koller M, Warncke S, Hjermstad MJ, Arraras J, Pompi[INVESTIGATOR_45769] C, Harle A, Johnson CD, Chie WC, 
Schulz C, Zeman F, van Meerbeeck JP, Kuliś D, Bottomley A. Use of the lung cancer -specific 
Quality of Life Questionnaire EORTC QLQ -LC13 in clinical trials: A systematic review of the 
literature 20 years after its development. Cancer. 2015 Dec 15; 121(24):[ADDRESS_624443]. Phase III trial of irinotecan/cisplatin  compared with 
etoposide/cisplatin in extensive -stage small -cell lung cancer: clinical and pharmacogenomic 
results from SWOG S0124. J Clin Oncol. 2009 May 20; 27(15):[ADDRESS_624444], Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van 
den Bent MJ, Vogelbaum MA, Wen PY; Response Assessment in Neuro -Oncology (RANO) 
group. Response assessment criteria for brain metastases: proposal from the RANO group. 
Lancet Oncol. 2015 Jun; 16(6):270 -8. 
Masuda N, Fukuoka M, Kusunoki Y, Motsui K, Takifuji N, Kudoh S, et al. CPT -11: A new 
derivative of camptothecin for the treatment of  refractory or relapsed small -cell lung cancer. J. 
Clin. Oncol. 1992; 10(8):1225 –1229.  
Merrouche Y, Extra JM, Abigerges D, Bugat R, Catimel G, Suc EP, et al. High dose -intensity 
of irinotecan administered every 3 weeks in advanced cancer patients: a feasib ility study. J Clin 
Oncol. 1997 Mar; 15(3):1080 -6. 
Morabito A, Carillio G, Daniele G, Pi[INVESTIGATOR_485953], Montanino A, Costanzo R, Sandomenico C, 
Giordano P, Normanno N, Perrone F, Rocco G, Di Maio M. Treatment of small cell lung cancer. 
Crit Rev Oncol Hematol.  2014 Sep; 91(3):257 -70.  
National Cancer Center of Japan, Department of Thoracic Oncology Annual Report, 2013. 
http://www.ncc.go.jp/en/publication/2013/ncch/ncch08.html.  
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung 
Cancer, Version 3.0. 2020. © National Comprehensive Cancer Network, 2 May 2020. All rights 
reserved. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf  
Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irin otecan plus 
Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small -Cell Lung Cancer. 
NEJM 2002; 346:85 -91. 
O’Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, Čučeviá B, Juhasz G, et al: Phase III trial 
comparing supportive care alone with support ive care with oral topotecan in patients with 
relapsed small -cell lung cancer. J Clin Oncol 2006; 24:5441 -5447  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624445] OBER 2021  
Proprietary and Confidential  Page 88  
 Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol. 1982; 5:649 -655. 
ONIVYDE® injection for intravenous use U.S. Package Insert, 2017.  
ONIVYDE® European Union summary of product characteristics, 2016.  
Pallis AG, Agelidou A, Agelaki S, Varthalitis I, Pavlakou G, Gerogianni A, Papakotoulas P, 
Rapti A, Chandrinos V, Christophy llakis C, Georgoulias V. A multicenter randomized phase II 
study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously 
treated patients with extensive stage small -cell lung cancer. Lung Cancer. 2009 
Aug;  65(2):187 -91.  
Postmus P E, Berendsen HH, van Zandwijk N et al. Retreatment with the induction regimen in 
small cell lung cnacer relapsing after an initial response to short term chemotherapy. Eur J 
Cancer Clin Oncol 1987; 34:1409 -1411.  
Ramanathan RK, Korn RL, Sachdev JC, Fetterly  GJ, Jameson G, Marceau K, et al. Lesion 
characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation 
with treatment response to MM -398, nanoliposomal irinotecan (Irinotecan liposome injection). 
Eur. J. Cancer 2014 Nov; 50:8 7.  
Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero 
J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study 
of PEP02 (MM -398), irinotecan or docetaxel as a second -line therapy in patients wi th locally 
advanced or metastatic gastric or gastro -oesophageal junction adenocarcinoma. Ann Oncol. 
2013 Jun; 24(6):1567 -73. 
Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, et al. Treatment of small -
cell lung cancer: American society of clini cal oncology endorsement of the American college 
of chest physicians guideline. J. Clin. Oncol. 2015; 33(34):4106 –4111.  
Sevinc A, Kalender ME, Altinbas M, Ozkan M, Dikilitas M, Camci C. Irinotecan as a second -
line monotherapy for small cell lung cancer. As ian Pacific J. Cancer Prev. 2011 Jan; 
12(4):1055 –9.  
Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, Liu T, Billups 
C, Rodriguez -Galindo C, Gajjar A, Furman WL, McGregor LM. UGT1A1 promoter genotype 
correlates with SN -38 pharmacokine tics, but not severe toxicity in patients receiving low -dose 
irinotecan. J Clin Oncol. 2007 Jun 20; 25(18):2594 -600. 
Tejpar S, Yan P, Pi[INVESTIGATOR_223671] H, Dietrich D, et al. Clinical and pharmacogenetic determinants 
of 5-fluorouracyl/leucovorin/irinotecan toxicit y: Results of the PETACC -3 trial. Eur J Cancer 
2018 ;99:66 -77. 
Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, 
Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, 
Boccalon M, Biaso n P, Frustaci S. The role of UGT1A1*28 polymorphism in the 
pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal 
cancer. J Clin Oncol. 2006 Jul 1; 24(19):[ADDRESS_624446] characteristics,  
Ustaris F, MD, Saura C, Di Palma J et al. Effective management and prevention of 
neratinib -induced diarrhea. American journal of hematology/oncology. 2015;11(11):13 -22. 
Van Cutsem E, Dirix L,  Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, et al. 
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624447] OBER 2021  
Proprietary and Confidential  Page 89  
 after 5 -FU failure: results from a multinational, randomised phase II study. Br J Cancer. 2005 
Mar 28; 92(6):[ADDRESS_624448] FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al: 
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent 
small cell lung cancer. J Clin Oncol 1999; 17:[ADDRESS_624449], O’Brien MER, Socinski MA, Mezger J, et al. Randomized 
phase III trial of Amrubicin versus topotecan as second -line treatment for patients with small -
cell lung cancer. J. Clin. Oncol. 2014; 32(35):4012 –4018.  
Wakuda K, Kenmo tsu H, Naito T, Akamatsu H, Ono A, Shukuya T, Nakamura Y, Tsuya A, 
Murakami H, Takahashi T, Endo M, Nakajima T, Yamamoto N. Efficacy of rechallenge 
chemotherapy in patients with sensitive relapsed small cell lung cancer. Am J Clin Oncol. 2015 
Feb; 38(1):28 -32.  
Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria 
JC, Domine M, Thomas M. A multicenter international randomized phase III study comparing 
cisplatin in combination with irinotecan or etoposide in previously untre ated small -cell lung 
cancer patients with extensive disease. Ann Oncol. 2010 Sep;21(9):1810 -6.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624450] OBER 2021  
Proprietary and Confidential  Page 90  
 15 APPENDIX  
15.1 Appendix I: Recommendations for Management of Chemotherapy Induced 
Diarrhea  
Proposed algorithm for the assessment and management of treatment -induced diarrhea is 
provided below in Table  8. These guidelines are adapted from those developed by [CONTACT_486019] (ASCO) panel and ES MO Clinical Practice Guidelines for 
treating chemotherapy -induced diarrhea ( Benson 2004, Ustaris  2015, Bossi  2018 ). Also 
Section  5.[ADDRESS_624451] onset of bowel movements that are more frequent than normal.  
Table  8 Recommendations for Management of Chemotherapy Induced Diarrhea  
Dietetic  
Dietetic Measures (applicable for all grades of diarrhea)  
Stop all lactose -containing products  
Drink [ADDRESS_624452] Line Therapy: loperamide  
Clinical Presentation  Intervention  
If receiving prophylaxis:  Increase loperamide dose to a maximum of 16  mg/day.  Continue until 
diarrhea free for 12  hours. If no improvement within 48 hours 
implement second -line therapy.  
If new -onset diarrhea (i.e. first loose 
stool):  Take loperamide [ADDRESS_624453] bout of diarrhea followed by 2  mg 
every 4 hours or after every unformed stool (maximum 16  mg/day). 
Continue until diarrhea free for 12  hours. If no improvement within 48 
hours implement second -line therapy.  
With recovery to ≤Grade 1:  Take loperamide 4 mg one dose with each subsequent cycle of 
irinotecan liposome injection administration.  
Second Line Therapy  
Grade 1  
If persistent diarrhea on loperamide:  Add diphenoxylate, hydrochloride plus atropi[INVESTIGATOR_325483] (Lotomil®) 
2.5 mg every 6 -8 hours.  
Monitor for trend in decreasing WBC and/or neutropenia.  
Recommend G -CSF if decreasing WBC and/or neutropenia to avoid 
infectious/septic compli cations. See Section  5.4.1 . 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624454] OBER 2021  
Proprietary and Confidential  Page 91  
 Grade 2  
If persistent diarrhea on loperamide:  Add octreotide (short acting) 150  μg subcutaneously tid or after initial 
dose of short acting octreotide, if well tolerated, a single dose of 
octreotide LAR 20  mg intramuscularly.  
Monitor for trend in decreasing WBC and/or neutropenia.  
Recommend G -CSF if decreasing WBC and/or neutropenia to avoid 
infectious/septic complications . See Section  5.4.1 . 
Consider stool cultures to exclude infectious causes (e.g.  Clostridium 
difficile) prior to prophylactic antibiotics, especially i f diarrhea is 
persistent beyond 24 hours or if there is a fever or Grade  3 or 4 
neutropenia  
Grade 3/4  
After intensive loperamide therapy:  Titrate loperamide to keep diarrhea controlled (<4 stools/day).  
Octreotide (100 to 150 μg subcutaneously bid or 25 to 50 μg/hour 
intravenously if dehydration is severe, with dose escalation up to 500μg 
subcutaneously tid).  
Intravenous fluids as appropriate.  
Consider prophylactic antibiotics, especially if diarrhea is persistent 
beyond 24 hours or if there is a fever or  Grade  3 or 4 neutropenia.  
Stool cultures to exclude infectious causes.  
Monitor for trend in decreasing WBC and/or neutropenia.  
Recommend G -CSF if decreasing WBC and/or neutropenia to avoid 
infectious/septic complications. See Section 5.4.1 . 
Consider stool cultures to exclude infectious causes (e.g.  Clostridium 
difficile) prior to prophylactic antibiotics, especially if diarrhea is 
persistent beyond 24  hours or if there is a fever or Grade 3 or 4 
neutropenia  
 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624455] OBER 2021  
Proprietary and Confidential  Page 92  
 15.2 Appendix II: ECOG Performance Status  
Grade  ECOG Performance Statusa  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities; up and 
about more than 50% of waking hours  
3 Capa ble of only limited selfcare; confined to bed or chair more than 50% of waking hours  
4 Completely disabled; cannot carry on any selfcare; totally confined to bed or chair  
5 Dead  
a Published by [CONTACT_325587] M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative 
Oncology Group.Am J Clin Oncol. 1982;5:649 -655. 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624456] OBER 2021  
Proprietary and Confidential  Page 93  
 15.3 Appendix III: Response Criteria for CNS Metastases  
Summary of the response criteria for CNS metastases proposed by [CONTACT_337171] -Oncology Brain Metasta ses (RANO -BM) working group ( Lin, 2015 ) 
 Complete 
Response  Partial Response  Stable Disease  Progressive 
Disease  
Target Lesions  None  ≥30% decrease in 
sum longest 
distance relative to 
baseline  <30% decrease 
relative to baseline  
but <20% increase in 
sum longest distance 
relative to nadir  ≥20% increase in 
sum longest 
diameter relative 
to nadira  
Non-target lesions  None  Stable or improved  Stable or improved  Unequivocal 
progressive 
diseasea  
New lesion(s)b  None  None  None  Presenta  
Corticosteroids  None  Stable or decreased  Stable or decreased  Not applicablec  
Clinical status  Stable or 
improved  Stable or improved  Stable or improved  Worsea  
Requirement for 
response  All All All Anyc  
a Progression occurs when this criterion is met.  
b A new lesion is one that is not present on prior scans and is visible in minimum two projections. If a new 
lesion is equivocal, for example because of its small size, continued therapy can be considered, and follow -up 
assessment will clarify if the new lesio n is new disease. If repeat scans confirm there is definitely a new 
lesion, progression should be declared using the date of the initial scan showing the new lesion. For 
immunotherapy -based approaches, new lesions alone do not define progression.  
c Increas e in corticosteroids alone will not be taken into account in determining progression in the absence of 
persistent clinical deterioration.  

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624457] OBER 2021  
Proprietary and Confidential  Page 94  
 15.4 Appendix IV: Temporary Measures and Procedures Related to COVID -[ADDRESS_624458] for differing periods of time per country/site. Invest igators will 
determine the feasibility of starting or continuing study treatment on a patient by [CONTACT_486020], 
depending on the ability to conduct safety monitoring and providing patients an adequate supply 
of study treatment, in accordance with local req uirements.  
Any temporary measure will be reported as a protocol deviation related to COVID -19. 
This appendix was assembled using suggestions from the TransCelerate publication "Beyond 
COVID -19: Modernizing Clinical Trial Conduct" published by [CONTACT_486021]. 
2020, which was influenced by [CONTACT_486022] -19 pandemic.  
Specific Guidance for Study Visits and Assessments  
Informed Consent (including Re -consent)  
As per guidelin es issued by [CONTACT_325590], the 
use of electronic signatures is authorised to obtain the patient’s informed consent. The Sponsor 
and IRB need to be notified, and approval obtained where applicable, of the us e of electronic 
informed consent signature [CONTACT_486028]. 
This is not meant to replace the important discussion between the patient, Investigator and site 
staff. Such a discussion must still occur and be part of a screening visit (in -person, by 
[CONTACT_144891], or home health visit). A clear, documented process on how patients are contact[CONTACT_486023].  
Dosing visits (Arm A and Arm B)  
Dosing visits m ay be delayed due to COVID -19 (for example temporary closure of the site, 
patient unable to travel etc). Dose delay rules should be followed per protocol (Section  6.2). In 
case of dosing visit delays outside of the protocol these should be discussed between the 
Investigator and the Sponsor. Screening visit and assessments (apart from informed consent as 
described above) must be performed on site.  
Physical Examinations and ECOG Performance Status: Assessment can be done via 
telemedicine (as per the rules below ) and should be done according to l ocal practice.  
Quality of Life Assessments:  
The QoL assessments are routinely captured while the patient is at the site, in real time. The 
site has an electronic tablet containing the questionnaires, in which the patient records his/her 
answers. As some patients are concerned about touching the device, sanitation practices that 
allows for thorough cleaning of the device have been implemented. In cases where study staff 
are not allowed on site or patients unable to attend their visit, interview mode is use d to capture 
e-PRO and electronic clinical outcome assessment (e -COA). The site staff will call the patient, 
ask the questions as per the assessment in exactly the same order and wording (paraphrasing is 
not allowed apart from the VAS scales for the EQ -5D-5L. The clinician should define for the 
patient  the upper  and lower bounds (ie. [ADDRESS_624459])) 
and directly enter the data into the ePRO system on behalf of the patient. Answers to questions 
must not be noted do wn first and then entered into the eCRF as this could impact validation of 

IPSEN GROUP  PROTOCOL MM -398-01-03-04 
VERSION 8.0 – [ADDRESS_624460] OBER 2021  
Proprietary and Confidential  Page 95  
 the ePRO tool. Details of the verification of the patient and the site personnel conducting the 
assessment should be documented.  
The interview mode has been authorized by [CONTACT_486024]/rules provided 
to the sites to conduct these interviews.  
Disease Evaluation: CT/MRI Scans:  This study assessment does not always coincide with a 
dosing day, though it might coincide if the patient has had no dosing delays (e.g. due to toxicity). 
In the case where the assessment does not coincide with a dosing visit, to reduce the risk 
associated with travelling (to a study site), imaging may be performed at a local imaging 
facility. The modality to be used for the imaging is to be do cumented and shared with the local 
imaging facility for consistency to ensure the same imaging modality is used. Documentation 
of the imaging facility is to be collected by [CONTACT_325591]. Scanned images are to be 
shared with the site. The site is r esponsible for submitting scans to the central imaging vendor. 
The RECIST reading is to be done by [CONTACT_737] (as per Section  8.8). 
Sample Colle ction  
Haematology and Biochemistry:  To reduce the risk associated with travel to the site if the 
subject comes in the day prior to dosing for haematology sampling, or to reduce the risk 
associated with time the subject spends at the study site, a local lab oratory may be used to obtain 
and analyse the haematology samples. Results of haematology samples taken need to be shared 
with the investigational site and assessed prior to dosing as per protocol requirements. 
Documentation of the local laboratory (accred itation and reference ranges) are required to be 
collected and shared with the Sponsor. As the subject comes at the site for dosing, effort should 
be made to collect biochemistry samples for central laboratory assessment, as well as all other 
central labor atory samples. If this is not possible, local biochemistry samples are to be collected 
as described above.  
Pregnancy Test:  Pregnancy testing is required on Day [ADDRESS_624461]  need to be shared with the investigational site and assessed prior 
to dosing as per protocol requirements.  
Concomitant Medications and Procedures: Details can be collected by [CONTACT_486025] b elow.  
AE Reporting: Details can be collected by [CONTACT_486026].  
Specific Rules Relating to use of Telemedicine  
The form of telemedicine used (phone call or use of a platform), the legal and privacy protection 
of the subject as well as details of the verification of the identity of the subject and site personnel 
conducting the assessment must be documented at site level and should be available for review 
by [CONTACT_2037].  
Note that further information about specific measures adopted for the COVID -19 situation to 
cover temporary discontinuations and SAE reporting are found in Sections  6.2.1  and 10.1.2 , 
respectively.  
 
